The antibody response as it relates to human immunodeficiency virus type 1 by Roben, Paul
The Antibody Response as it relates to 
Human Immunodeficiency Virus Type 1.
Thesis
Presented for the degree of 
DOCTOR OF PHILOSOPHY 
by
Paul Roben, B.Sc.
Under the Supervision of 
Dr. Richard O’Kennedy
School of Biological Sciences, 
Dublin City University
July, 1993
This thesis is dedicated to my parents.
I declare that all the work reported in this thesis was 
performed by Paul Roben, unless otherwise stated.
PAUL ROBEN
ACKNOWLEDGEMENTS
I would like to thank Dr. Richard O’Kennedy for his continued support, 
both practically and financially throughout the three years it took 
me to complete this Ph.D.
I would also like to thank Dr. Dennis Burton whose guidance on 
practical research matters was invaluable for this project. I learned 
an enormous amount while working in his laboratory in Scripps.
I am especially grateful to my parents whose support and 
encouragment made life a lot easier. They believed in my ability to 
finish this work and helped me at every stage. I can only hope that it 
has lived up to their expectations.
Of course I cannot forget Jackie- someone who really understood the 
problems of being a Ph.D. student. I am also grateful for her 
technical advice, her proof-reading ability and for getting me a 
position in Scripps in the first place.
I am especially grateful to Dr. Tom Collet for all his help in the lab 
and for getting me the computer I wrote this thesis on. Maybe 
someday he will slow down long enough to read this.
I would also like to thank Dr, Richard Lerner for allowing me to work 
in his laboratory and for his support throughout my stay in 
California.
I cannot forget all the other people in the labs in D.C.U., whose 
friendliness, generosity and general slagging ability made life at the 
college a lot more enjoyable. Tenhnical advice from many of these 
people was also much appreciated. I am very happy I had the 
opportunity to work with you all. I am particularly indebted to the 
people working in the same lab as myself: (not in any particular 
order!) Denise, Mary, Liz, Rob, Teresa, Declan and Orla.
There are a number of people in Scripps who I am indebted to, not 
only because I learned a lot from them, but also because they were 
very generous to me and made my stay at Scripps very easy. These 
include all the people in the Lerner lab and in Dennis’ lab, but in 
particular, Terri, Glen, Carlos, Jim Binley, Willi, Doug, Roman, 
Denise, Diane, Angray (especially for Harry) and Lori-Anne.
I am also very grateful for the support given to me by the Irish- 
American Partnership and the Research and Postgraduate Studies 
Committee, D.C.U, throughout the three years.
Last, but not least, Thank God l,m finished I!
ABSTRACT
The humoral immune system responds to antigenic challenge by 
producing a d iversity of antibodies specific  for antigenic 
determinants being presented by the foreign body, as is the case 
when a human becomes infected with the HIV virus. A large diversity 
of antibodies is produced against two primary epitopes of the HIV 
surface antigen, gp120, namely the V3 loop and the CD4-binding site. 
A better understanding of this, and other similar responses, has 
important implications for combating many diseases, including AIDS. 
However, the diversity of the immune response, coupled with the 
problems associated with producing human antibodies, has made it 
very difficult to study.
Phage display libraries provide a means of producing a large number 
of antibodies from a single individual, thereby facilitating the 
investigation of a complete immune response. These libraries have 
been utilised to study antibodies specific for the CD4-binding site 
of gp120, and, in conjunction with a binary plasmid system, the 
relative contributions of the heavy and light chains to specificity 
and function of the antibody were demonstrated.
Finally, Fab fragments specific for both metal ions and gp120 were 
produced, in an attempt to catalyse the peptide cleavage of gp120. 
This work has led to an increased understanding of antibody-antigen 
interactions, with specific reference to neutralising the HIV virus, 
and has further investigated the possib ility of constructing 
catalytic metallo-antibodies.
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Fab Fab Fragment of an antibody
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HBV Hepatitis B Virus
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O.D. Optical Density
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PMSF Propylmethylsulphonylflouride
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RU Response units
sCD4 soluble CD4
SDS Sodium dodecyl sulphate
ssDNA single stranded DNA
ssRNA single stranded RNA
TCR T-cell receptor
T -c e l l  T Lymphocyte Cell
TE Tris-EDTA
U Units (enzyme activity)
V1 / V2  Variable loop 1/2 of gp120
V3 Third variable loop of gp120
V region Variable region
VH Heavy Chain Variable region
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v /v  volume per volume
w /v  weight per volume
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INTRODUCTION
1 .0  INTRODUCTION
1 .1 THE IMMUNE SYSTEM.
One of the primary functions of all organisms is the defence of 'the 
se lf from outside invaders. Evolution of the vertebrates over a 
period of millions of years has given rise to a series of protective 
measures known as immunity. This is a complex and elegant 
interaction involving a large number of cellular and molecular 
components, designed to effect the clearance of any foreign 
partic les from the organism's system. This mechanism is 
characterised by the ability to recognise a vast array of foreign 
bodies while maintaining the integrity of the self and also 
memorises any invading body such that it can mount a quick and 
effective response should it meet that invader again in the future. 
These properties are ideal for any potential therapeutic agent that 
could be developed to combat many of the diseases prevalent in 
today's society. As a result, immunity has been the target of much 
research, in an attempt both to understand the mechanisms by which 
this system operates and also to try and harness its activities, in an 
effort to produce analytical, diagnostic and therapeutic agents. The 
experiments presented in this thesis represent one further step in 
the development of this area of research. However, in order to 
understand these studies fully, it is necessary to, first, gain a 
preliminary knowledge of the immune system, particularly as it 
relates to the human situation.
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An invading body generally consists of a large number of molecules 
(antigens) that can be potentially targeted by the host immune 
system and these are dissected to yield an array of smaller 
molecules which can then be presented to the various components of 
the immune system in a way that can be recognised as foreign 
particles. These antigens are recognised by the cellular components 
of the response via cell surface receptors, and these cells produce a 
number of other substances to activate the complete immune 
response. In humans, this response is located in a number of organs: 
the primary organs consist of the bone marrow and the thymus, 
while secondary organs include the spleen, lymph nodes and tonsils. 
The cells of the immune response all originate from a haemopoietic 
stem cell (Roitt, 1985) which then differentiates to yield two major 
cellular classes: the myeloid and the lymphoid systems (Figure 1.1). 
The myeloid cells differentiate further to give monocytes and 
polymorphonuclear monocytes (polymorphs). The monocytes give rise 
to macrophages which are responsible for the endocytosis of 
microorganisms and other foreign bodies. Monocytes can also develop 
to yield antigen-presenting cells (APC) which are involved in the 
presentation of antigen to the other cells of the immune system. The 
polymorphs lead to a number of granulocytic cells all of which 
function in a non-specific way to counteract the affects of invaders 
such as microbes, viral particles and allergens.
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Figure 1.1. Flow diagram showing the differentiation pathways of some
of the cells involved in the immune system. All cells originate from a stem 
cell in bone marrow. From there, they enter the myeloid or lymphoid 
pathways. The cells then differentiate to become one of the many cells 
involved in regulating the immune system and controling infection.
1 .2  T LYMPHOCYTES AND ANTIGEN PRESENTATION.
The lymphoid system consists of two main cellular classes; the B 
cells and T cells. It is the antigen-mediated activation and 
subsequent cooperation between these two cell lines that can 
activate all of the other components of the immune system and clear 
the foreign body from the organism. The specificity displayed by this 
system is characteristic of these two cell types, as is the ability to 
remember antigens. Therefore, these cells are of primary importance
Haemopoietic Stem Cell
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in the overall response. The response begins with the internalisation 
of the foreign antigen by a variety of cells. This can include some of 
the cells described in Figure 1.1, such as macrophages and B cells 
although it is not restricted to cells of the immune response and can 
include any cell that has been invaded by an immunogen such as a
virus. This antigen is then presented to T cells leading to a cascade
of events, resulting in the destruction of the invader.
The T cell response, also known as cell-mediated immunity,
originates in the thymus of humans (Finkel et a!., 1991; Carding et 
a!., 1991). Lymphoblasts (cells that have undergone primary
differentiation from the haemopoietic stem cell) arrive in the
thymus of embryos from the bone marrow or liver. These cells are 
then positively selected for those expressing the correct receptors 
on the surface, followed by negative selection of any cells that
recognise self antigen. This leaves only those cells with the correct 
combination of surface receptors capable of specifically recognising 
foreign antigen and are introduced into circulation to monitor the
presence of immunogenic antigen. All others are destroyed by 
apoptosis and subsequently removed by macrophages (Green et a!.,
1991). The major receptor involved in antigen recognition is the T 
Cell Receptor complex (TCR). This consists of a number of
polypeptide chains coded by an intricate set of genes, thus allowing 
for a high degree of genetic diversity (Rudd, 1990), which translates 
into a large array of diverse TCR receptors such that each T cell 
contains a distinct TCR and so can recognise a different antigen. It 
is, therefore, the TCR that confers specificity on the T cell
response. The process of thymic education and the subsequent
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immune responses are also mediated by a number of substances 
called cytokines which include interleukins, interferons, tumour 
necrosis factor, growth factors and many others. Each cytokine has a 
selective effect on a particular cell type, depending on its stage of 
development and it is through the use of these molecules primarily, 
that the cells of the immune system communicate (Beverley, 1990; 
Noelle et al., 1990; Scott and Kaufmann, 1991). Each cell has a 
distinct receptor on the cell surfaces for cytokines, generally 
classed as 'cluster of differentiation' (CD) antigens. (T cell antigen 
papers, 1989; Knapp et al., 1989; B cell antigens, 1989). Other 
receptors important for T cell antigen recognition include Major 
Histocompatibility Antigens (MHC). These are present on all cells 
capable of communicating with T cells and are classed as MHCI or 
MHCII (Accolla eta!., 1991; Germain, 1991). Both of these are used 
in the presentation of antigen to T cells and it is through these 
receptors that the T cells can distinguish between self and non-self. 
It is the combination of the presented antigen with the correct MHC 
that allows the T cell to determine if this antigen originates from a 
foreign source, and if so, to activate the other components of the 
immune system (Kelly et al., 1991; Rudensky et at., 1991a; Rudensky 
et al., 1991b). Mature T cells can be classified into a number of 
different groupings such as helper cells (Th) and cytotoxic cells (Tc) 
(Darnell et al., 1986). Th cells possess a surface receptor named CD4 
which acts in combination with the TCR to recognise antigens that 
are presented on the surface of other cells in combination with 
MHCII (Rudd, 1990; Scott and Kauffmann, 1991). This leads to the 
production of cytokines by the T cell which can have a number of
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effects, such as the activation of B cells, macrophages, polymorphs 
or a number of other cell types, all of which can bring about the 
destruction of the invader. Th cells can be further classified into
T h1 and Th2 which display different cell surface receptors and have 
slightly different functions (Mosmann et al., 1986; DeKruyff et al., 
1989; Gajewski et al., 1991). Tc cells display CD8 receptors and 
recognise antigen in conjunction with MHCI. This results in the
destruction of the antigen presenting cell, mediated by the T cell,
which would be desirable if the cell was infected by virus, for 
example. Finally, antigen-activated T cells can differentiate to
produce memory cells which are maintained in circulation and can 
mount a quick response against that antigen should it be encountered 
by that individual in the future (Akbar et al., 1991; Beverley, 1990). 
This is the situation when a person is said to be immune to a 
particular disease.
Therefore, the immune response initiates with antigen presentation 
to specific T cells, followed by cytokine-mediated activation of 
other components of the response, finally resulting in the 
destruction of the invader.
1 .3  B LYMPHOCYTES.
The second class of lymphocyte involved in the immune response are 
the B cells which generate what is known as the humoral response. 
This means that these cells, upon activation by antigen, produce 
glycoproteins of the immunoglobulin superfamily, refered to as 
Antibodies which are capable of mediating destruction of an 
immunogen (any substance capable of elictiing an immune response).
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The precise mechanism of B cell activation, leading to antibody 
production, is not fully understood. However, there is evidence which 
supports one particular theory of activation. B cells originate in the 
bone marrow as pre-B cells that express no surface receptor capable 
of binding antigen (Reth eta !.,  1985). These then differentiate to 
form B cell blasts, involving the expression of an antigen-specific 
receptor complex on the cell surface. This consists of a membrane 
bound Immunoglobulin class M molecule (mlgM) coupled with 2 other 
transmembrane molecules that provide signal transduction with 
biochemical cascades within the cell (Reth et a/., 1991; Ales-
Martinez et al., 1991). The complex is similar to the TCR of T cells 
in that it consists of members of the immunoglobulin family and it 
is highly antigen specific, thus conferring specificity on this aspect 
of the immune response also. This ensures that there is a vast array 
of B cells expressing highly diverse antigen-specific receptors 
capable of producing a similar diversity of antibodies.
However, it is necessary to be able to select for those B cells that 
can produce the antibody specific for the foreign antigen at any 
given time (clonal selection), and to be able to induce the 
proliferation of that clone and effect its differentiation to produce 
soluble antibody. A further receptor is then expressed on the B cell 
surface comprising an IgD molecule which is thought to ensure the 
survival of the B cell on activation by antigen. This process of 
activation occurs in the secondary lymph organs such as the lymph 
nodes (Figure 1.2). The B cell blasts are transferred to the cortex of 
the lymph nodes where they are called germinal centre (GC) B cells 
(Dilosa et al., 1991). These GC B cells provide a pool capable of being
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activated by antigen. They enter the lymph nodes by migrating
through the endothelial walls via High Endothelial Venules (HEV) 
using specific receptors on the lymphocyte surface. The antigen is 
carried to the nodes via the lymph system, where it is captured by 
APC, postulated to be Follicular Dendritic Cells (FDC). These cells 
internalise the antigen and present it as Iccosomes-immune complex
coated bodies (Szakal et al., 1988; Kosco et a l,  1988; King and Katz,
1990) in the cortex of the lymph nodes. The B cells are able to bind 
this form of antigen via the mlgM receptor and present it on their 
own surfaces in conjunction with MHCII. This is the initial step in
the antigen-dependent proliferation of B cells.
Figure 1.2 The structure of a lymph node. The follicular dendritic cells (FDC) 
present antigen to the B cells in the cortex and they are then activated by 
T cells in the paracortex. Further differentiation to become memory cells 
occurs in the germinal centers.
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However, binding of the antigen to mlgM is not sufficient to activate 
the cells and this requires contact with Th cells mediated by 
interdigitating cells (Figure 1.3). Antigen binding merely prepares 
the cell for T cell interaction by altering the plasma membrane, 
enhancing antigen processing and upregulating the receptors 
necessary for T cell-mediated proliferation, eg: CD23 (Gordon et al.,
1989).
Figure 1.3 Representation of T cell-dependent B cell activation mediated by 
interdigitating cells. The B cell expresses processed antigen on its 
surface which is recognised by the TCR complex on the T cell. This, in 
turn, secretes IL-4 which upregulates CD23 on the B cell, thereby 
activating it.
The T cell binds the B cell antigen (Ag)-MHCII complex via its own 
TCR-CD4 receptor, and there are probably other interactions
1 0
involved in the paracortex of the lymph node. This induces the 
production of interleukin-4 (IL-4) by the T cell which activates the 
CD23 receptor leading to the antigen specific proliferation of the B 
cell. It is at this stage that somatic mutation is greatest resulting 
in affinity maturation of the antibody (discussed later).
The B cells can then return to the bone marrow, or remain in the 
lymph node. Those that return to the marrow are possibly drawn 
there by lectin binding interactions (Dilosa et a i,  1991; Shieh et al.,
1991). Here they mature to become plasma cells that produce solublè 
antibody which is able to enter circulation. The maturation process 
is enhanced by bone marrow factors that have not yet been fully 
characterised. The B cells that do not leave the lymph nodes are 
called centroblasts. These are rapidly dividing cells lacking the 
mlgM and CD23 receptors and are present in the dark zone of the 
germinal centers in the secondary follicle (Figure 1.4). They then 
move to the light zone, where they become non-dividing B cells 
expressing high affinity mlgM, centrocytes. It is here that they once 
again bind to FDC expressing antigen and are subsequently returned 
to circulation to act as memory cells. Those that do not bind to FDC- 
Ag are destroyed by apoptosis (Liu et at., 1992). Apop tos is , 
otherwise known as programmed cell death, is a distinct form of 
cell death, mediated through specific biochemical pathways and 
characterised by the condensation of chromatin, loss of nuclear 
structure and the formation of plasma membrane blebs (Wyllie et al., 
1980 This ensures a memory of the antibody response as was the 
case with the T cell response.
Figure 1.4 Diagram of the secondary follicle of the lymph node with the light 
and dark zones of the germinal centre indicated. The differentiation of 
activated B cells to memory cells is also shown. B cells enter the dark 
zone where they rapidly divide and lose their surface slg to become 
centroblasts. They then move to the light zone and, once again, express 
slg. The specific, high affinity clones are positively selected via antigen 
on the surface of follicular dendritic cells.
Therefore, in summary, B cells are originally produced in the bone 
marrow, and transported to the secondary lymphoid tissue where 
they undergo T cell-dependent, antigen-mediated clonal selection 
and proliferation. They can then return to the bone marrow where 
they mature to become plasma cells secreting soluble antibody, or
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they can differentiate in the lymph nodes to become memory cells 
for circulation.
Once the antibody has been produced, it can act in a number of ways 
to effect the destruction of the foreign body. Specific binding of the 
antibody to the surface antigen of the invader can induce the 
congregation of macrophages, killer cells or polymorphs that 
phagocytose the unwanted body. Alternatively, antibodies can induce 
the complement function to bring about its destruction. Complement 
is a collection of proteins in the blood that are capable of acting in 
conjunction with antibodies to cause the lysis of invaders such as
microorganisms ( Kinoshita, 1991; Farries and Atkinson, 1991).
The immune system is a highly complicated protective mechanism 
that has evolved over millions of years to become highly effective in 
its operation and there probably exists greater levels of complexity 
that have not yet been established. However, there are instances 
where the system can break down. These include inflammation with 
the overproduction of histamines by basophils, for example, and 
certain autoimmune diseases such as type-1 diabetes, multiple
sclerosis and rheumatism (Cohen and Young, 1991; Todd, 1990).
The remainder of the discussion of the immune system will
concentrate on the antibody molecule, since this is the subject of 
investigation in this thesis.
1 .4  ANTIBODY STRUCTURE.
The antibody molecule consists of two heavy and two light chains, 
50KDa and 25KDa, respectively (Figure 1.5). The heavy chains are 
made up of one variable domain and three constant domains of
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approximately 110 amino acids each with glycosylation of the
second and third of these constant domains. The variable region can
be further subdivided into three Complementarity Determining 
Regions (CDR) separated by four Framework Regions (FR). The first 
and second constant regions are separated by a hinge region which 
allows flexibility of the molecule and contributes to the ability of 
the molecule to bind antigen. The two heavy chains are linked by 
disulphide bonds in the hinge region, the number of bonds depending 
on the class of antibody. There are five classes of heavy chain: 
gamma, delta, epsilon, mu and alpha, resulting in five isotypes of 
antibody: IgG, IgD, IgE, IgM and IgA, respectively. These differ in 
molecular weight, number of units, available antigen binding sites 
and distribution in the blood (Roitt, 1985; O'Kennedy and Roben,
1991). The light chain is divided between a variable region and a 
single constant region. Each light chain is jo ined to its
complementary heavy chain by a disulphide bond in the constant 
regions. There are two classes of light chain: kappa and lambda 
which vary in the diversity of the variable regions, the sequence of 
the constant regions and their distribution in organisms.
The constant domains consist of seven antiparallel B-strands, four 
in one sheet and three in the other, forming a barrel with a
disulphide bond between strands 2 and 6 (Branden and Tooze, 1991). 
The 3-strands are joined by loops. The variable regions include two 
further loops between 3 and 4 named 3a and 3b meaning that there 
are now two sheets of five strands and four strands. The CDR1 
(amino acids 21 to 33), CDR2 (49 to 55) and CDR3 (87 to 96) are 
formed by the loops between strands 2,3; 3a,3b and 6,7 respectively.
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The variable regions associate via their five strand sheets and it is 
the combination of the six CDR regions, three from the heavy and 
three from the light chains, that primarily forms the antigen binding 
site and gives the antibody its specificity, commonly referred to as 
the idiotype of the antibody. It has been estimated that there are as 
many as 108 possible antibody specificities available in humans, 
enough for every known immunogen it may encounter.
FR4(J)
CHc CHc
CH' CH'
Figure 1.5 Antibody structure. There are two heavy and two light chains 
joined by disulphide bonds as indicated. Each chain may be divided into 
variable and constant regions and the variable regions are further subdivided 
into three CDR and four FR regions as shown. Each of the two antigen binding 
sites are made up of a combination of three CDRs from the heavy chain and 
three from the light chain. The abbreviations are: CDR: complementarity
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determining region; FR: framework region; H:hinge; V:variable; CH:constant 
heavy; CL: constant light; Diversity; J:joining region.
1 .5  GENETICS OF ANTIBODY DIVERSITY.
The ability to produce such a diverse array of antibodies must reside 
in a mechanism to produce numerous different structures for the 
CDR regions since these are directly involved in the antigen binding 
site. Yet it would seem impossible to code for all the combinations 
that would be required for such an array. The answer lies in the 
organisation of the genes coding for these molecules.
The kappa light chain locus is arranged into a number of exons. There 
are two or three hundred variable regions (Vk) followed by five 
joining segments (Jk) and a single constant region exon (Gough et a!., 
1979; Watson et at,. 1987; Meindl et a!., 1990; Kabat and Wu, 1991) 
In any given B cell, a recombination event occurs to bring one each of 
the Vk and Jk exons together and it is the random combination of 
these exons that leads to the light chain diversity (Figure 1.6). The 
join between these can also vary depending on the amino acid 
position at the point where the two exons are joined, leading to 
additional diversity. It is also possible to get the insertion of N 
sequences between the two sequences, further increasing the 
diversity (Desiderio et a i,  1984; Decker et al., 1991). This section is 
then transcribed along with the constant region and gene splicing 
occurs to bring the entire locus together which can be then 
translated as the light chain.
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Figure 1.6 Genetic rearrangement of the k light chain locus. The 
recombination event brings the V and J segments together. Splicing brings 
about V-J-C joining and translation of the mRNA gives rise to the complete light 
chain. L represents the leader sequences.
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The lambda gene system is similar but with less potential for 
diversity. There are three constant region exons but each has only 
one associated variable exon.
The heavy chain locus is arranged similarly with variable and joining 
segments (Figure 1.7). However, there is an additional D region 
which, together with the J region codes for the CDR3. This then 
requires 2 recombination events: the first brings the D and J 
segments together and the second adds the selected V region. This is 
the transcribed with the constant region and RNA splicing occurs to 
give the final heavy chain (Yamada et a i,  1991; Givol et a i,  1981; 
Menetski and Gellert, 1990;Alt et a i ,  1992; Alt and Baltimore, 
1982).
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The nature of the D segments is very complex with as many as thirty 
genes thought to exist. There are also many possible mechanisms of 
recombination for these segments, which will be discussed further 
in chapter 4. However, it is sufficient to say that these mechanisms 
may have the potential to generate 1014 different peptides in the 
CDR3 region and are, therefore, a major factor in the diversity of 
antibodies (Sanz, 1991; Matsuoka, 1988; Ichihara et a i, 1988). The 
mechanism of recombination involves two Recombinase Activating 
Genes, RAG-1 and RAG-2 that are known to be essential but not 
sufficient for recombination to occur (Chun et a i,  1991).
Other factors important in this event include enhancer elements 
which are thought to increase the likelihood of recombination 
occurring by causing incidental stand breaks, or by demethylating 
cysteine residues which may allow binding by recombination factors 
(Banerji eta!., 1983; Giles et ai, 1983).
Rearrangements of all these genes occur at the pre-B cell stage in 
the bone marrow. It is thought that heavy chains are arranged before 
the light chains in any one cell (Decker et a!., 1991) and that 
expansion of a clone will only ensue upon productive variable gene 
segment rearrangement and expression of an appropriate heavy 
chain. Perhaps the heavy chain is expressed on the cell surface 
which permits communication with other cells and clonal expansion 
occurs. Furthermore, productive rearrangement of the heavy chain on 
one chromosome prevents the rearrangement of its allele in a 
process known as allelic exclusion. Light chain rearrangement then 
follows and the generation of a complete antibody molecule 
switches off any further rearrangements in the cell (Ritchie et a i,
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1984). The cell then leaves the bone marrow for the secondary 
lymphoid tissues. The process of recombination, therefore is highly 
complex and remains to be completely elucidated (Schroeder et ai, 
1987; Mansikka et a i, 1990).
Another mechanism for the generation of diversity is that of 
somatic affinity maturation. This is a process of hypermutation (as 
many as 10~2 nucleotide substitutions) acting selective ly on 
rearranged immunoglobulin variable region genes. It has been 
suggested that this occurs by a process of error-prone repair of 
nicked DNA or mismatch repair of m isaligned structura l 
intermediates (Malipiero et a i,  1987). It is known to occur in the 
germinal centers subsequent to antigen-mediated activation of the B 
cell and can continue for a number of weeks following immunisation 
suggesting that it is developmentally controlled. The main purpose 
of this phenomenon seems to be to increase the affinity of the 
antibodies to their antigen, although decreases in affinity have also 
been recorded (Griffiths eta!., 1984; Liu et a i,  1989). The degree to 
which this affects other antibody functions has not been examined in 
any great detail. However, it is obviously a major contributory 
factor in the generation of an immune response.
It should now be evident that the generation of an antibody response 
is an extremely complex event involving the interplay of a large 
number of components of the immune system to achieve the most 
efficient and effective means of protecting an organism from attack 
by a foreign immunogen. This has lead to the evolution of an eloquent 
and exquisitely engineered set of antibody molecules that has 
addressed the problems of diversity, specificity, memory and
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flexibility, reflected in the ability to mature the response as the 
antigenic challenge continues. A more complete understanding of the 
mechanisms involved would obviously be beneficial in the design of 
diagnostic or therapeutic agents.
1 .6  ANTIBODY PRODUCTION.
As the potential of antibody molecules became clear, research into 
the in vitro production of antibodies was initiated. The first major 
breakthrough in this area was the development of a system to 
produce monoclonal antibodies through the fusion of B cells from 
immunised mice with immortal cell lines that could be grown in 
flasks (Kohler and Milstein, 1975; Schulmann eta!., 1978). This 
resulted in an antibody-secreting laboratory cell line and it meant 
that for the first time, purified antibodies of defined specificity 
could be produced in relatively large quantities. This approach 
proved extremely useful for the production of many antibodies on a 
commercial level, for diagnostic (Sutherland eta!., 1987), analytical 
(Carlsson et al., 1989) and therapeutic purposes particularly in the 
treatment of tumours (Hale et al., 1988). It has also been suggested 
that they be used as vaccines, through the use of antiidiotypic 
antibodies (Nordling et al., 1991). They also provided vital 
information about antibody structure (Chothia and Lesk, 1987), the 
rearrangement of antibody genes ( Kabat and Wu, 1991) and about 
phenomena such as somatic mutation (Malipiero et al., 1987). 
However, there were a number of drawbacks with this technology 
particularly in the case of human antibodies, including difficulties 
with immunisation, the lack of good human myeloma fusion partners,
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the low secretion rates achieved and the instability of many human 
hybridomas.
A variety of approaches were tested to solve these problems 
including Epstein Barr Virus (EBV) transformation of human B cells 
which met with limited success, although this was improved with 
the use of leucyl-leucine methyl ester (Ohlin et al., 1989). This 
substance was found to significantly increase the proliferative 
capability as well as immunoglobulin production of Epstein Barr 
virus-transformed B cells. The advent of in vitro immunisation 
permitted many more of the problems associated with human 
monoclonal antibody production to be overcome (Borrebaeck et al., 
1986; Carlsson et al., 1989). However, a limited knowledge of the 
extent and functions of cytokines has curtailed the development of 
the technique.
Advances in molecular biology have revolutionised antibody 
production and the study of their structure/function relationships. 
Arguably, the single most important advancement has been the 
development of the Polymerase Chain Reaction (PCR) which permits 
the isolation and cloning of the genes coding for antibodies (Larrick 
et al., 1989; Orlandi et al., 1989; Chaudhary et al., 1990).
This type of technology opened up entirely new areas in terms of the 
manipulations which were now possible with antibody molecules. 
Chimaeric human-mouse antibodies were easily constructed 
(Morrison et al., 1984) and humanisation of antibodies was also 
possible (Queen et al., 1989). This facilitated the use of antibodies 
with mouse spécificités (which could be produced by traditional 
monoclonal techniques) in human systems where the entire mouse
23
antibody would have previously been rejected. The fusion of 
antibodies with unrelated activities such as enzymes or toxins was 
also made easier by DNA techniques (Neuberger et al., 1984; 
Chaudhary et al., 1989). Many different antibody fragments could be 
produced in this way including Fv (Skerra et al., 1991), Fab (Better 
et al., 1988) and even single domains (Ward et al., 1989). These 
recent advances have resulted in associated developments in 
expression systems for antibodies, with a view to increasing protein 
yields, including lymphoid (Watanabe et al., 1986), baculovirus 
(H a s e m a n n  et al., 1990), bacterial (Pluckthun, 1990), Chinese 
hamster ovary (Wood et al., 1990) and plant (Hiatt et al., 1989) 
expression systems.
1 .7  COMBINATORIAL PHAGE-DISPLAY LIBRARIES.
However, many of the above techniques have relied on using mouse 
hybridoma or spleen cells as the starting material and so, have been 
limited to an investigation of the mouse response. Furthermore, none 
of these systems permit the study of an entire immune response, 
either from mice or humans. It could be very important to 
encapsulate the entire human antibody response to an antigen since 
this would provide a pool from which many different antigen- 
specific antibodies could be isolated. It would also facilitate the 
study of the complete response which could yield useful information 
about the immune system. It was for these reasons that the 
combinatorial library, phage-display system of antibody cloning was 
developed ( Devlin et al., 1990; Huse et al., 1990; McCafferty et al., 
1990; Burton, 1991; Burton, 1992). The system used in this thesis
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was that of Huse et al., which will now be examined in more detail. 
It is based on the vector pComb3 (Figure 1.8) which is a phagemid in 
that it codes for the F1 intergenic region of the M13 (fd) phage (Beck 
and Zink, 1981; Watson et al., 1987), while the remainder is based on 
the pBluescript plasmid and contains the ColE1 origin of replication 
(Stratagene; Short et al:, 1988).
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Figure 1.8 Plasmid map of pComb3. The heavy and light chains are inserted 
into the sites Xhol/Spel and Sacl/Xbal, respectively. Both are under the control 
of the LacZ promoter and are preceded by a PelB leader sequence to ensure 
transport to the periplasm. The plasmid also contains the ColE1 origin of 
replication, the M13 fl intergenic region and the bla gene for ampicillin 
resistance.
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The library construction (Figure 1.9) begins with a source tissue, 
usually- from a human subject. This can be blood, bone marrow, 
tonsil, spleen, synovial fluid, etc. The chosen tissue depends on the 
type of antibodies being isolated. For example, antibodies that play a 
role in rheumatism could be isolated from the synovial fluid since 
this is where those cells are likely to have congregated. However, 
the bone marrow is generally a good source of cells when a diversity 
of antibodies is required. The RNA is isolated from the cells and the 
genes coding for antibodies are amplified by PCR using primers as 
discussed in the method. This is then cloned into a vector and 
transformed into bacteria to make the initial library. However, since 
this library could encode for as many as 108 different antibody 
specificities i.e.: the entire human repertoire, a prohibitively large 
number of clones would have to be screened before the desired 
antibody would be found. Therefore, a system of enriching for those 
antibodies before the screening process, had to be devised. The 
problem was to express the Fabs in a form that would make them 
available to antigen binding, while permitting the easy handling of 
extremely large numbers of clones in a way that was compatible 
with the cloning system. The solution was to design a phagemid 
vector based on the M13 phage (Persson et a i,  1991; Zebedee et al.,
1992).
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Figure 1.9 (Seè next page). Flowdiagram of the library construction process. 
The totat cDNA is first isolated from the cells and the antibody-coding genes 
are taken from this using PCR. The heavy chain genes are first cloned into the 
pComb3 vector and amplified in E. coli. The same is then carried out for the 
light chain genes. Following this, the plasmid DNA is isolated from the cells and 
the genelll is removed by restriction. The resulting plasmid can be transformed 
into E. coli once again and soluble Fab can be prepared.
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M13 phage is single stranded DNA (ssDNA) bacteriophage, 6400 base 
pairs in length and codes for 10 gene products involved in the
replication, morphogenesis and capsid structure of the virus. When 
the virus infects the cell, it is converted to a double stranded DNA 
(dsDNA) molecule which is used as a template for replication.
However, it is the ssDNA which buds from the cell and is once again 
encapsulated within the capsid. Gene product II (GPU) is expressed 
upon entry into a cell and this acts on the intergenic region to 
initiate replication. GP V terminates the process. GP VI, GP IX, GP 
VIII and of particular importance, GP III, are all involved in the
capsid structure of the virus. The intergenic region is 508bp in
length with many secondary structures in the ssDNA form. It is this 
region that is responsible for regulation of gene expression and also 
contains the origin of replication. There is also a 'packing origin1 
present which is required for the packaging of the DNA into the 
capsid.
The library system exploits the M13 phage properties through the 
use of a helper phage, VCSM13, and a phagemid, pComb3. The helper 
phage is similar to M13 except that its intergenic region contains
sequences that ensure it is not easily recognised by GPU for
replication, and so will not be replicated or incorporated into the 
new phage capsid. Also, it contains a plasmid origin of replication
which means that when it infects a cell, it will be converted to
dsDNA and will proceed to replicate as a plasmid rather than a 
phage. Furthermore, it contains a gene coding for kanamycin 
resistance and so can be selected for in a bacterial population.
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The phagemid, pComb3, codes for ampicillin resistance. It also 
contains a complete M13 intergenic region which can be recognised 
by phage gene products that will encapsulate a ssDNA form of the 
phagemid DNA into a viral capsid. In addition to this, the heavy chain 
is coded for as a fusion product with the gene III protein under the 
control of the LacZ promoter.
The cells used are Escherichia coli XLIBIue, containing an F' 
episome which codes for tetracycline resistance and also for a 
repressor of the LacZ promoter (which itself is repressed in the 
presence of IPTG). Therefore, if cells containing the phagemid are 
infected with helper phage, the GPU from the phage activates the 
phagemid intergenic region. This facilitates the expression of all the 
phage gene products and so a new viral particle can be constructed. 
However, it is the phagemid ssDNA that is inserted into the particle. 
Furthermore, the heavy chain-GPill fusion product is expressed from 
the phagemid, although poorly, since it is under the control of the 
LacZ promoter, as is the GPIII from the phage is also expressed at 
approximately four times the level of that from the phagemid. Five 
copies of this protein are inserted into the capsid of each phage and 
on average, one of those copies is a fusion product with the heavy 
chain. This is then transported to the cell periplasm (Figure 1.10). 
The light chain is expressed independently and also transported to 
the periplasm where it combines with the heavy chain to give a 
complete Fab bound to the phage surface.
The recombinant phage can be then isolated from the culture 
supernatant and used in the panning procedure, since the Fab protein 
is now available for antigen binding. The panning procedure (see
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methods) ensures that any Fabs specific for the antigen will be 
enriched for over a number of rounds. The monovalent nature of Fab 
expression on the phage surface means that only high affinity Fabs 
will be enriched since there are no avidity effects occurring. A 
similar system using the more prevalent gene VI I I  product is 
influenced by avidity and so can select for low affinity Fabs (Kang et 
al., 1991b; Gram et al., 1992). The enriched population of Fab- 
encoding phage can then be used to reinfect a bacterial culture in the 
absence of helper phage, thus ensuring that they will now be 
transmitted as plasmids. The gene III can then be removed, resulting 
in a library of E. coli. from which soluble Fab fragments can be 
expressed. This library has been enriched and so finding clones 
expressing high affinity, antigen-specific clones should not be too 
difficult. This method of library construction has the potential to 
clone the entire human repertoire of antibodies and select from that, 
antibodies of any specificity we may choose provided that library 
sizes in the order of 108 members can be constructed (Barbas et al.,
1992). It also opens up the possibilities of synthetic antibodies and 
chain shuffling (Kang et al., 1991; Collet et al., 1992; Marks et al.,
1992).
Therefore, there now exists an efficient method of cloning a large 
part of the human repertoire and isolating, from that, antibodies of 
any given specificity. It then had to be decided what specificity was 
required. The chosen antibodies should be relevant to the human 
system and serve some purpose, preferably therapeutic. Antibodies 
capable of neutralising viruses, notably the influenza virus, had 
previously been described.
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Figure 1.10 Scheme of Fab assembly and incorporation into phage. 
The heavy chain-genelll fusion and light chain are expressed separately from 
the phagemid and transported to the periplasm where the heavy chain is 
anchored to the inner membrane via the genelll product. The light and heavy 
chains assemble in the periplasm and are incorporated into the phage via the 
genelll, as the particle buds from the cell.
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Therefore, the AIDS virus, HIV, was identified as the subject of 
these studies as this is a highly prevalent disease for which there 
are no effective therapies at present. An attempt was made to 
isolate antibodies from a library whose source tissue was bone 
marrow from an asymptomatic AIDS patient. However, before this 
could be done, an understanding of the structure and functions of the 
HIV virus was necessary.
1 .8  ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS).
A study isolating and characterising the first Human T cell Leukemia 
Virus (HTLV) was reported in 1980 (Poiesz et a i,  1980). The 
following year, the centers for disease control in America reported 
an unexplained cluster of immunodeficient men in Los Angeles 
(Blattner, 1991). The Human Immunodeficiency Virus (HIV) was 
subsequently discovered in 1983/84 (Barre-Sinousi et a i,  1983; 
Popovic et a i,  1984; Ratner et a i, 1985) and finally, the phenomenon 
of Acquired Immunodeficiency Syndrome (AIDS) was recognised in 
1985 as being a completely new disease. Subsequently two distinct 
types of HIV have been characterised: HIV-1 and HIV-2. HIV-1 is 
thought to be responsible for the majority of AIDS cases worldwide 
while HIV-2 is probably more localised to western Africa and is less 
virulent (Kong et ai, 1988). At present, there are over 10 million 
cases of AIDS worldwide and that figure is increasing all the time 
(Blattner, 1991). The virus is transmitted through behaviour that 
exchanges bodily fluids and the high risk transmission groups have 
been identified as homosexual men, haemophiliacs and intravenous
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drug users who share needles, although the entire population is 
potentially at risk.
The HIV virus acts by depleting the numbers of CD4+ T cells in the 
victim thus causing immunodeficiency (Rosenberg and Fauci, 1991). 
This is particularly detrimental as the CD4+ T cells are instrumental 
in inducing virtually all of the responses of the immune system as 
was discussed earlier in the introduction. It had been argued until 
recently that HIV was not the agent responsible for AIDS since it 
had been proving difficult to find the virus in AIDS patients 
(Culliton, 1992). However, recent reports finding massive infection 
of T lymphocytes and macrophages in the lymph nodes of patients 
would seem to dispel this theory (Embretson et al., 1993; Panaleo et 
al., 1993) along with studies showing the virus exists in a large 
proportion of T cells as integrated DNA (Schnittman et al., 1989). 
When an individual is initially infected with HIV, the virus attacks 
CD4+ T cells, particularly in the peripheral blood, and macrophages 
and monocytes in other tissues. This induces a primary viremia, 
leading to the production of antibodies directed against the virus. 
This generally subsides giving rise to what can sometimes be a long 
latent period, as is the case in asymptomatic patients. As the 
disease progresses, the viral burden in the peripheral blood 
lymphocytes increases dramatically resulting in the depletion of 
these cells and full-blown AIDS, which can often lead to the death of 
the victim. The stimulus that triggers the onset of AIDS is not fully 
understood. However, there are a number of possibilities: a number 
of other viruses such as Cytomegalovirus (CMV), Hepatitis B virus 
(HBV) and herpes simplex virus have been shown to enhance HIV
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replication; certain cytokines including tumour necrosis factor- 
alpha are capable of up-regulating HIV expression; some physical 
stresses such as ultraviolet light and heat have also been implicated 
in the progression of the disease. More studies need to be carried out 
to support these theories.
The mechanism by which the virus kills the T cells also remains 
ambiguous (Rosenberg and Fauci, 1991). There have been a number of 
suggestions as to how this might occur: budding of the virus from 
the cell couid destroy the integrity of the membrane, causing cell 
death. The presence of cytoplasmic viral DNA in the later stages of 
infection could result in the production of viral proteins which 
would interfere with the cellular processes sufficiently to kill the 
cell. An infected cell expresses viral protein on its surface which is 
capable of binding to the CD4 of other cells. This leads to fusion of 
the cells and the formation of syncytia which can often be made up 
of hundreds of cells. In this way, one infected cell can bring about 
the death of many neighbouring uninfected cells. It is also thought 
that viral surface glycoproteins can induce programmed cell death, 
apoptosis, to occur in CD4+ T cells upon binding to the CD4. It may 
also be the case that an infected cell expressing this glycoprotein on 
its surface can induce apoptosis in neighboring T cells, thus killing 
them without necessarily infecting them (Ameisen, 1992).
Finally, the virus is thought to be capable of preventing 
communication between B cells and T cells, as this is achieved via 
CD4 (see earlier in the introduction). This would have the obvious 
effect of impairing the antibody response that may be generated 
against the virus.
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The virus is also capable of altering its coat proteins such that 
antibodies present in the blood stream can no longer recognise it, 
yet the functions of these proteins remain intact. This is known as 
the generation of escape mutants (Nara et a i,  1991). The virus is 
thought to have other detrimental effects on the humoral response 
(Amadori and Chieco-Bianchi, 1990). A continuous viral load and the 
inability to clear it could lead to the uncontrolled expansion of HIV- 
specific B cell clones, leading to B cell lymphoma which appears 
with increased frequency in AIDS patients. Anti-CD4 antibodies 
could be produced through anti-idiotype responses or by targeting to 
CD4 bound-gp120 which would crosslink the CD4 molecules and 
prevent signal transduction in the TCR complex. These cells would no 
longer be able to activate antibody production from B cells.
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Figure 1.11 Structure of the HIV virus, showing the inner core 
containing the RNA and enzymes. This is surrounded by a outer capsid, 
which is, in turn, enclosed by a lipid layer. The surface glycoproteins 
protrude from the outer capsid, through the lipid layer and are critical for 
the initial recognition of CD4 on cell surfaces, gag and env refer to 
structural genes while pol codes for the enzymes needed for viral 
replication and function. LTR signifies the long terminal repeats and all 
other genes code for regulatory proteins (see section 1.9). The diagram 
was adapted from Haseltine, (1991).
38
1 .9 MOLECULAR BIOLOGY OF HIV.
HIV is a retrovirus of the subfamily lentivirus (Haseltine, 1991). 
This implies that it is a diploid ssRNA virus containing two 
identical ssRNA strands bound non-covalently at their 5' ends. There 
is an inner core containing the RNA and a number of enzymes needed 
for replication, including reverse transcriptase, polymerase and 
ribonuclease H. The inner core is surrounded by the capsid proteins 
which is, in turn, surrounded by a lipid membrane. Glycoproteins 
protrude from the capsid through the lipid, to form spikes on the 
viral surface (Figure 1.11). HIV belongs to the class of complex 
retroviruses (as opposed to simple viruses such as avian leukemia 
virus) in that it not only codes for the required structural proteins, 
but it also codes for 6 regulatory proteins, tat, rev, nef, vif, upu and 
vpr, all of which are necessary for the complete replication cycle 
(Figure 1.12). There are two long terminal repeats (LTR). The 5' LTR 
functions to promote viral transcription and the 3' LTR is required 
for efficient polyadenylation of the resultant transcripts. The gag 
gene codes for the capsid proteins, pol codes for the replication 
enzymes present in the inner core and env codes for the surface 
glycoprotein gp160. This is the protein which initially comes in 
contact with the cell and binds the CD4 molecule, thus facilitating 
viral entry.
When the virus enters the cell, a single strand of RNA is converted 
to dsDNA using the reverse transcriptase. This dsDNA then 
integrates into the cell genome to become a provirus, by means of an 
integrase enzyme (Gent et a i,  1991). A minimum basal level of 
transcription is facilitated by cellular transcrition factors, notably
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NF-kB (Cullen, 1991) which gives rise to fully spliced 2kB RNA 
transcripts in the nucleus, coding for tat, rev and net.
Figure 1.12 Representation of the HIV-1 genome. There is a long 
terminal repeat (LTR) at each end. The 3 main structural genes, gag, pol 
and env, are intersrersed with the 6 regulatory genes. The genes coding 
for tat and rev exist as two exons, separated by unrelated sequences. 
The tat response element can be found in the 5' LTR, while the rev 
response element is coded by sequences within the env gene.
The trans-activating element, tat, is responsible for enhancing the 
transcription of viral DNA. It binds to the Tat Response Element 
(TAR) present at the 5' end of all transcripts and is thought to act, 
possibly by stabilising the transcription factors and the RNA 
structure (Feng and Holland, 1988; Subramanian et a!., 1991). 
However, as long as the cell remains resting, only this 2kB
transcript will be present.
On initiation of viral replication, two other types of transcript
appear also: a non-spliced 9kB RNA and a singly spliced 4kB
structure. This single splicing can serve to bring any of the genes
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immediately next to the 5' LTR in order to maximise its translation. 
The only two genes that cannot be spliced in this way are pol which 
is always expressed as a fusion with gag, and upu which is part of a 
bicistronic gene with env.
If the cell becomes activated in some way, the transcription and 
translation factors increase in quantity and this is mirrored by an 
increase in the amounts of rev  protein in the nucleus. When this 
surpasses a threshold level, the 4kB and 9kB transcripts begin to 
appear in the cytoplasm. It is thought that re v  prevents the 
appearance of these transcripts below a certain level, as the cell 
would not have enough manufacturing apparatus to support the high 
levels of protein production required by HIV. However, in activated 
cells, rev permits the transport of the protein-encoding transcripts 
to the cytoplasm, possibly by binding to the splice sites, thus 
preventing the from being spliced to 2kB molecules in the nucleus, 
or by binding to the RNA and mediating its transport through 
vesicles in the nuclear membrane.
The function of net  is not fully understood at this point in time and 
there is still a dispute as to whether this causes an increase or 
decrease in the levels of viral expression.
Translation of the gag-pol transcript ensues to yield a capsid 
polyprotein-replicative enzyme precursor which is transported, with 
the RNA to the cell membrane, where the viral particle is assembled. 
This then buds through the cell membrane. The envelope glycoprotein 
is produced from mRNA,  glycosylated at the rough endoplasmic 
reticulum and passed to the golgi apparatus where it is cleaved to 
its two constituent subunits, gp41 and gp120. These then pass to the
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outer cell surface where they are attached to the outer viral coat 
mediated by the vif protein, probably as it buds through the cell 
membrane. A protein U, coded for by upu, facilitates the transport of 
the virus through the cell membrane and, finally, the vp r  gene 
product helps to gather the enzymes immediately after infection and 
so aids in the production of dsDNA.
1 . 1 0  HIV SURFACE GLYCOPROTEINS.
It was mentioned earlier that the surface glycoprotein, gp160, is 
essential in the initial binding of the viral particle to cells via CD4. 
It has been established that gp160 consists of 2 subunits, gp120 and 
gp41, connected via noncovalent bonds between amino acids in the N 
terminal ends of both molecules (Helseth et at., 1991). The gp41 
consists of an extracellular, a transmembrane and an intracellular 
domains while gp120 is entirely extracellular, and is connected to 
the viral particle via gp41 (Figure 1.13). The gp120 molecule is 
approximately 600 amino acids in length and is highly glycosylated, 
with about 55% carbohydrate and can be divided into regions 
determined by the variability of the amino acids such that there are 
5 variable regions and 5 'constant' regions.
It has been unequivocally established that this is the viral 
component responsible for CD4 binding (Landau et at., 1988; Moore 
and Klasse, 1992). Certain residues have been identified as being 
important in this event and this has lead to the realisation that the 
CD4-binding epitope is highly comformational in nature and involves 
amino acids from many parts of the gp120 molecule, notably 257,
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368, 370 and 457 (Kowalski et a i,  1987; Olshevsky et a i ,  1990; 
Thali et a i,  1992). This was established using antibodies capable of 
blocking the gp120-CD4 binding interaction.
Viral invasion of the cell is a highly complex set of events which is
only initiated by the binding to CD4 (Bentz et a i,  1993). Factors that
may have importance at this stage include the density of CD4 on the
cell surface with increasing density resulting in a parallel increase
In susceptibility. There may also be other cell surface molecules 
involved in the fusion event. This has been supported by the finding 
that CD4 is essential but not sufficient for infection to occur. 
Possible accessory molecules include MHCI and LFA-1. In fact, there 
is evidence to suggest that CD4 is not required (Bedginger et a i,  
1988), or of lesser importance for infection in some cell lines such 
as glial cells or macrophages. Viral entry, in these cases, could be 
antibody-mediated, with viral-bound antibodies being targeted to 
cells containing anti-Fc receptors. The entire complex could then be 
internalised into the cell by endocytosis (Amadori and Chieco- 
Bianchi, 1990).
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GP120
Figure 1.13 Schematic diagram of gp160. It consists of two subunits, 
gp120 and gp41. The subunit, gp41 anchors the molecule to the viral coat. 
gp120 is attached to gp41 by non-covalent interactions not yet defined and 
consists of a series of five variable loops, as indicated by the shaded areas, 
interspersed with more constant regions. The 3-dimensional structure of gp160 
is not known. There are nine characterised disulphide bonds, as indicated by 
the numbers.
The gp120-CD4 binding is not merely a process involving two single 
molecules, but a dimer, or perhaps a tetramer of gp120 molecules 
are required, and that the functional CD4 binding site may
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incorporate regions of a number of gp120 molecules which 
complement each other. The binding to CD4 induces a number of 
conformational changes in the gp120. This binding may begin as a 
low affinity interaction with the changes leading to a higher 
affinity bond being formed at the expense of the gp120-gp41 
interactions. The result is to expose areas usually hidden, such as 
the V3 loop of gp120 and regions of the gp41 molecule. The function 
of the V3 loop at this stage is unclear although it may bind to other 
accessory molecules on the cell surface (Bergeron et a i,  1992).
These reactions finally lead to the shedding of gp120 and although 
the function of this is not fully understood, it may be that it 
facilitates the physical contact between the viral envelope and the 
cell membrane (McKeating et a i,  1990; Moore eta!., 1991). This may 
be followed by insertion of gp41 into the membrane and fusion of the 
virus to the cell. There are many aspects of this response that 
remain to be elucidated, in particular the role of the V3 loop of 
gp120, the structure/function relationship of gp120-gp41 and the 
role of accessory cell surface molecules. It may also be possible 
that some of the replication regulatory genes already mentioned, 
such as vi'f and upu, may be involved in the fusion process. However, 
the critical role that is played by gp120-CD4 binding is well 
established and interference with this step is likely to effect the 
neutralisation of the virus. A possible approach to achieve this can 
be found in the natural humoral immune response mounted against 
the virus in infected patients.
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1.11 NEUTRALISATION OF HIV.
When an individual becomes infected with HIV an antibody response 
is generated against all the various viral protein antigens. Some of 
these antibodies are specific for neutralising epitopes, which 
primarily reside in the envelope glycoproteins, gp41 and gp120 (Ho 
et a i,  1987). There are two major groups of neutralising antibodies 
directed against gp120 (Chamat et at., 1991). The first group are 
specific for the V3 loop (third hypervariable domain) located 
between residues 300 to 328. These antibodies are generally 
produced early in the course of the disease and are present in high 
titres in the serum. They neutralise the virus by interfering with 
some event subsequent to binding of CD4 by gp120. The second set of 
antibodies appear later in the infection and are specific for a 
conformational, discontinuous epitope on gp120. They interfere with 
binding of CD4 to gp120 and are, therefore, specific for the CD4- 
binding site. They are present in lower titres than the other class of 
antibody and so it took longer to isolate and characterise these. The 
two groups of antibody are significantly different in that the V3 
specific group tend only to neutralise a specific viral strain while 
the CD4 binders are capable of neutralising multiple strains which 
may make them more useful for use as therapeutic agents. Many 
antibodies have been generated from both the V3 group (Ho et a i,  
1987; Gorny et a i,  1991) and the CD4 group (Ho et ai, 1991; Kang et 
ai, 1991; McKeating et a i, 1992; Thali et a i, 1991). These have been 
generated in the hope of finding a high efficiency neutralisation 
agent for HIV and also as a tool to investigate the mode of action of 
the virus in more detail. The production of an antibody capable of
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neutralising the virus would obviously be highly desirable. However, 
there are a number of factors to consider before attempting this. 
Firstly, the gp120 interaction has a very high forward rate in the 
order of 1x109M-1s-1 (Nara et a!., 1991; Moore and Klasse, 1992). 
Therefore, any antibody that neutralises by reacting with the CD4 
binding site must have an affinity capable of competing with the 
rapid rate of gp120-CD4 binding. Second, a single antibody is 
unlikely to be effective due to the phenomenon of escape mutants. 
The HIV virus has evolved so as to allow for the selection of viral 
epitopes capable of the conformational flexibility necessary to 
escape from neutralising im m unoglobulin while preserving 
functional integrity for its survival. These mutants are antigenically 
close enough to the parental strain but sufficiently different in the 
presentation of critical epitopes to prevent the neutralisation 
reaction from occurring. Therefore, any therapy must consist of a 
number of antibodies with slightly different specificities to avoid 
this problem. Third, care must be taken to ensure that none of the 
antibodies used carry any negative effects as previously discussed 
(Amadori and Chieco-Bianchi, 1990).
Finally, it must be remembered that the in vitro and in vivo 
situations do not necessarily correlate. Hence, care must be taken 
when interpreting results from in vitro assays such as that 
developed by Nara (Nara and Fischinger, 1988). There have also been 
instances where soluble gp120 and viral gp120 do not yield the same 
results (Ivey-Hoyle et at., 1991; McKeating et a i, 1991; Moore et al.,
1991). This must always be kept in mind.
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1 .1 2 CATALYTIC ANTIBODIES.
Antibodies can be employed for viral neutralisation, as was 
discussed previously, which may become an important mode of 
therapy in a number of diseases of this type. However, recent 
advances in technology permit the manipulation of antibody 
molecules so that they may be adapted for many other applications. 
The immune system is capable of producing a vast repertoire of 
antibodies each with its own specificity and function. It is this very 
diversity and specificity peculiar to antibodies that makes them 
ideal candidates for use in the field of chemistry in that they offer 
the potential of producing highly specific catalysts for a vast array 
of chemical trans fo rm ations , i.e. ca ta ly t ic  an tibod ies . 
Improvements in technology over the last 8 years have made it 
possible to generate antibodies specific for a wide range of 
molecules, including biopolymers, synthetic molecules and drugs. 
Recent advances have also allowed us to engineer antibody 
molecules with a high degree of specificity, thus permitting the 
production of designer proteins. Catalytic antibodies could prove 
invaluable as therapeutic agents, for example, for the break-up of 
blood clots in heart conditions, or vaccines could be designed to 
elicit antibodies capable of the cleavage of viral or cancer cell 
proteins. They might also prove invaluable for use in fine chemical 
production or in the synthesis of pharmaceuticals. These molecules 
could help reduce the cost and increase the safety of a number of 
chemical processes by replacing catalysts which require extreme 
and dangerous conditions to function. A further example of where 
they might be used would be in the synthesis of compounds whose
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stereochemistry is important, such as amino acids, since antibodies 
are known to be highly isomer-specific (Lerner and Tramontano, 
1988).
In order to be catalytic, an antibody must first have the ability to 
bind a component of the reaction it is trying to catalyse and 
secondly, must be able to carry out the conversion of the substrate 
to product.
A number of approaches may be taken in the design of such an 
antibody. An enzyme functions by stabilising the transition state 
thus lowering the energy of the intermediate and allowing the 
overall reaction to proceed. Therefore, if antibodies could be 
designed to bind a transition state, they might function in the same 
way. However, transition states are generally too unstable to exist 
for any period of time and so analogs must be designed which can be 
used to elicit an antibody response. This approach has lead to the 
generation of antibodies that catalyse a number of chemical 
reactions such as ester hydrolysis (Lerner and Tramontano, 1988) 
and amide hydrolysis (Janda et al., 1988).
An alternative approach is to alter, chemically or genetically, the 
antibody in order to introduce an appropriately positioned catalytic 
amino acid side chain, a cofactor, or another catalytic group. This 
has been done to introduce a catalytic imidazole into the active site 
of an antibody so making it hydrolytic (Baldwin and Shultz, 1989). 
Metal ions can be introduced for reactions such as peptide cleavage 
(Iverson et al., 1990; Iverson and Lerner, 1989).
Cleavable affinity labeling groups have also been used for this 
purpose (Pollack et al., 1988; Nakayama and Shultz, 1991). This
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involves coupling an affinity labeling group to an antigen such that 
the antibody binds the antigen, bringing the labeling group close to a 
residue around the active site. The residue and labeling group then 
bind, and the antigen can be cleaved, leaving the labeling group (e.g. 
thiol) which can be used to couple a number of catalytic groups or 
cofactors. A futher approach to this problem was the production of 
phosphorylcholine-specific antibodies by monoclonal technology, 
which were found to catalyse the hydrolysis of choline carbonates 
(Jackson et ai, 1991).
Advances in combinatorial library technology have made it possible 
to screen a far greater number of antibodies, thus increasing the 
chance of obtaining a catalytic molecule. However, this increase in 
the numbers of antibodies can lead to problems in screening for 
those antibodies with the required catalytic activity, as it may be 
difficult to carry out the reaction and detect the products on such a 
large scale. The development of catELISA (Tawfik et ai, 1993) and 
other similar techniques should make it substantially easier to 
achieve the required selection. Finally, there are a number of new 
developments which should help to revolutionise this field further, 
in particular, the ability to solubilise antibody in reverse miscelles 
in order that they may be used in organic solutions (Durfor et a i,
1990).
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1 .1 2  RESEARCH PROPOSALS.
A  n u m b e r  o f  a re a s  w e re  i n v e s t i g a te d  in th e  c o u r s e  o f  t h e  w o r k  
p r e s e n te d  in th is  thes is .  Fi rst ly,  the re  w a s  a s tu d y  o f  the  im m u n e  
s y s te m  a n d  p a r t i c u la r l y  of  the  a n t ib o d y  r e s p o n s e  g e n e r a t e d  w h e n  
c h a l le n g e d  by a spec i f i c  an t igen .  T h e re  is, to  da te ,  ve ry  l i tt le d a ta  on 
the  d iv e rs i t y  o f  a hum ora l  re s p o n s e  f rom  a s ing le  in d iv idua l  in t e rm s  
o f  th e  t y p e s  o f  a n t ib o d y  p ro d u c e d ,  t h e i r  s p e c i f i c i t i e s ,  a f f i n i t i e s  and  
b i o c h e m i c a l  p r o p e r t i e s .  T h i s  l a c k  o f  i n f o r m a t i o n  h a s  p r i m a r i l y  
re s u l t e d  f ro m  the  inab i l i t y  to  c a p tu r e  the  r e s p o n s e  in a w a y  th a t  
m a k e s  it a c c e s s i b l e  to a n a l y s i s .  T h e  f i r s t  a im  o f  t h i s  w o r k ,  
t h e r e fo r e ,  w a s  to  s tu d y  the  f e a s ib i l i t y  o f  u s in g  the  c o m b in a t o r i a l  
l i b ra ry  t e c h n iq u e  as  a m e a n s  o f  a n a l y s i n g  the  c o m p le te  a n t i b o d y  
r e s p o n s e  o f  a H IV  in fe c te d  in d iv i d u a l .  T h e  e x t e n t  to w h i c h  the
a n t i b o d i e s  g e n e r a t e d  f r o m  th i s  a p p r o a c h  r e f l e c t  t h e  in vivo
s i t u a t i o n  w e r e  d e t e r m i n e d  w i t h  a v i e w  to  e s t a b l i s h i n g  th e
a u th e n t i c i t y  o f  th is  a p p ro a c h .  T h e  a n t ib o d ie s  w e re  t h e n  a n a l y s e d ,
b o th  on  a g e n e t i c  a n d  b i o c h e m i c a l  le v e l ,  to a s c e r t a i n  w h a t  
in fo rm a t io n  th is  y ie ld e d  a b o u t  th e  ove ra l l  r e s p o n s e .  T h e  f i n d i n g s  of  
th is  an a ly s i s  w e re  then  re la ted  to the  pa t ie n t ' s  s i tua t ion  in t h e  hope  
of  g a in in g  s o m e  fu r th e r  k n o w le d g e  as  to h o w  his im m u n e  s y s te m  
d e a l s  w i t h  t h e  v i r a l  c h a l l e n g e .  T h e s e  a n t i b o d i e s  w e r e  a l s o  
in v e s t i g a te d  fo r  n eu t ra l i sa t ion  ac t iv i t y  w i th  the  a im  of  f i n d in g  a se t  
o f  a n t ib o d ie s  tha t  m a y  have  po te n t ia l  t h e r a p e u t i c  va lue .  It w a s  a lso  
h o p e d  th a t  t h e s e  a n t ib o d ie s  m a y  be u s e d  to a n a l y s e  f u r t h e r  the  
in te ra c t io n s  oc c u r r ing  be tw e en  g p 1 2 0  and  C D 4  w h ic h  m a y  be  usefu l  
in e lu c id a t in g  the  m e c h a n is m  of v i ra l -ce l l  fus ion .
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A n o th e r  a im  o f  t h i s  w o r k  w a s  to g a m  a b e t t e r  i n s ig h t  in to  the  
s t r u c t u r e / f u n c t i o n  r e l a t i o n s h i p s  in t r ins ic  to t h e  a n t i b o d y  m o le c u le .  
T he  a n t ib o d ie s  i s o la te d  f ro m  the l ibrary w e re  a n a l y s e d  to d e te rm in e  
the  re la t ive  f u n c t io n s  o f  the  heavy  and  l igh t  c h a in s  b o th  in an t igen  
b ind ing  a n d  in v i ra l  neu t ra l i sa t ion .  The c o n t r ib u t io n  t h a t  e a c h  has to 
m a k e  to the  o v e r a l l  s p e c i f i c i t y  of  the a n t ib o d y  a n d  t h e  e f fe c ts  of  
sm a l l  c h a n g e s  in a m i n o  ac id  s e q u e n c e s  w a s  o f  p a r t i c u l a r  in te res t .  
S pec i f ic  e p i to p e  m a p p i n g  expe r im e n ts  a nd  m u t a g e n e s i s  s tu d ie s  w e re  
e m p lo y e d  to e s t a b l i s h  th is  in more  deta i l .  T he  f i n d i n g s  f ro m  th e s e  
e x p e r i m e n t s  w e r e  r e l a t e d  to the  n e u t r a l i s a t i o n  a b i l i t y  o f  th e  
a n t i b o d ie s  in an  e f f o r t  to e s ta b l i s h  a r e l a t i o n s h i p  b e t w e e n  the  
s t r u c t u r a l  f e a t u r e s  o f  t h e  a n t i b o d y  a n d  t h e  f u n c t i o n  o f  t h a t  
motecu le .  It w a s  h o p e d  th a t  these  e x p e r im e n ts  w o u l d  y ie ld  va luab le  
in fo rm a t io n ,  p r e v i o u s l y  u n k n o w n  a b o u t  the e v o l u t i o n  o f  a n t ib o d ie s  
and  the w a y s  in w h i c h  th e y  opera te .  Th is  c ou ld  p r o v e  use fu l  in the  
fu tu re  fo r  d e s ig n in g  a n t ib o d ie s  wi th  d e f in e d  s p e c i f i c i t y  a n d  func t ion  
fo r  use as  a n a ly t i c a l ,  d i a g n o s t i c  or th e ra p e u t i c  a g e n t s .  It m ay  a lso 
g ive  be t te r  in s igh ts  in to  na tu ra l  p roc es s e s  s uch  a s  c lo n a l  se lec t ion  
a nd  s o m a t i c  a f f i n i t y  m a tu ra t io n .
Final ly,  the  in fo rm a t io n  o b ta in e d  from the p re v io u s  s tu d ie s  w a s  used  
in an  a t t e m p t  to c o n s t r u c t  c a ta l y t i c  a n t i b o d i e s  ( N a k a y a m a  a n d  
Schu l tz ,  1991;  L e r n e r  a n d  T ra m o n ta n o ,  1988 ;  S c h u l t z  eta !.,  1990).  
T h e s e  are  a n t ib o d y  m o le c u le s  c a p a b le  of  c h e m ic a l  c o n v e rs io n s ,  an 
ac t iv i ty  not  usua l ly  f o u n d  in nature .  An a t te m p t  w a s  m a d e  to des ign  
a n t ib o d ie s  th a t  w e r e  a b le  to e f fe c t  the p e p t i d e  c l e a v a g e  of  the  
g p 1 2 0  m o lec u le  w i th  th e  aid o f  a meta l  c o fac to r .  T h i s  w a s  don e  in 
t h e  h o p e  of  p r o d u c i n g  an a n t i b o d y  w i th  i m p r o v e d  n e u t r a l i s in g
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ac t iv i t y .  It a ls o  s e rv e d  as a s tu d y  on  the re la t i v e ly  n e w  a r e a  o f  
c a t a l y t i c  a n t i b o d i e s .  F i n a l l y ,  it w a s  u s e f u l  as  a p r a c t i c a l  
d e m o n s t r a t i o n  fo r  an app l ica t ion  o f  the  te c h n o lo g y  be ing  u s e d  in the 
o th e r  s tud ie s .  T h e  abi l i ty  o f  t h e s e  a n t ib o d ie s  to n e u t ra l i s e  th e  v i ru s  
in vitro w a s  a lso  inves t iga ted .
T h e re fo re ,  in conc lus ion ,  it w a s  h o p e d  th a t  t h e s e  s tu d ie s  w o u ld  y ie ld  
s o m e  us e fu l  in fo rm a t io n  a b o u t  the  m o d e  o f  ac t io n  o f  the  a n t ib o d y  
r e s p o n s e  and  h o w  it adap ts  to a n t ig e n ic  c h a l le n g e .  T h e  f u n c t io n s  of  
t h e  a n t i b o d y  m o l e c u l e s  t h e m s e l v e s  w e r e  a l s o  i n v e s t i g a t e d ,  
p a r t i c u l a r l y  in r e la t io n  to  t h e i r  s t ru c tu re ,  b o th  a t  a g e n e t i c  and  
b i o c h e m i c a l  le ve l .  S in c e  al l  t h e  a n t i b o d i e s  to be  s t u d i e d  w e r e  
s p e c i f i c  f o r  th e  H IV  s u r fa c e  g l y c o p r o te in ,  it w a s  h o p e d  t h a t  th is  
w o u ld  g ive  fu r th e r  ins igh ts  into the  m o d e  of  ac t ion  of  th is  v i rus  and  
e s p e c ia l l y  h o w  it in fec ts  CD4+  ce l ls .  F ina l ly ,  th is  t e c h n o l o g y  w a s  
a p p l i e d  to  th e  a r e a  o f  c a t a l y t i c  a n t i b o d ie s ,  bo th  as  a p r a c t i c a l  
a p p l i c a t io n  a nd  in an e f fo r t  to f ind  a th e r a p e u t i c  a g e n t  fo r  th e  A ID S  
v i r u s .
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MATERIALS
2.0 MATERIALS
A l l  c h e m i c a l s ,  a c i d s  o r  s o l v e n t s  u s e d  in t h i s  t h e s i s ,  u n l e s s  
o t h e r w i s e  s ta te d ,  o r ig in a te  f ro m :
Sigma Immunochemicals, St. Louis, Mo 63178, USA.
Al l  e n z y m e s  us e d  in m o le c u la r  b io lo g y  t e c h n iq u e s ,  u n le s s  o th e r w is e  
s ta ted ,  w e re  p u rc h a s e d  f rom:
Boehringer Mannheim, Germany.
Fo l low in g  is a  l ist o f  m a te r ia ls  no t  in c lud ed  in e i th e r  of  the  a b o v e :  
C onsum ab les :
A g a r o s e G ib c o / B R L 5 5 1 0 U A
L o w  M e l t ing  A g a ro s e FMC 5 0 0 8 2
HCI F i s h e r A 1 4 4
C h l o r o f o r m F i s h e r C 2 9 8 - 5 0 0
PEG 8000 F i s h e r B P 2 3 3 - 1
SDS G ib c o / B R L 552 5  UB
R e v e rs e  T r a n s c r i p t a s e G ib c o / B R L 8 0 5 3 5 A
111B g p 120 A m e r i c a n
B i o t e c h n o l o g i e s 012001
111B g p 120 R e p l i g e n 9 2 - 5 7
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Pfu D N A  Po lym era se  
So lub le  C D 4
T 4  D N A  L igase
S t r a t a g e n e
A m e r i c a n
B i o t e c h n o l o g i e s
G ib c o / B R L
A n t ib o d ie s :
H R P - c o n ju g a te d  G o a t  
a n t i - H u m a n  F (a b ')2 
A lk a l i n e  P h o s p h a ta s e  
c o n ju g a te d  G o a t  An t i -  
H u m an  F (ab ')2 
R a b b i t  A n t i - g p 1 2 0
A l k a l i n e  P h o s p h a ta s e -  
c o n ju g a te d  G o a t  An t i -  
R a bb i t  IgG
P i e r c e
P i e r c e
A m e r i c a n
B i o t e c h n o l o g i e s
F i s h e r
K i t s :
S i l v e r  S ta in in g  Ki t  
E C L  W e s te rn  B lo t t ing 
M in i -P ro te a n  II S y s te m  
M in i -T r a n s  B lo t  S y s te m  
P l a s m id - P r e p  Ki t  
S e q u e n c ig  Ki t
P h a r m a c i a l
A m e r s h a m
B io - R a d 1
B io - R a d
Q iagen
U n i te d  S ta te s  
B i o c h e m i c a l s
6 0 0 1 3 5
3 0 0 1
B N P 1 0 2
3 1 4 1 4 X
3 1 3 1 2 X
4 0 2
O B 1 4 2 0 - A L P H
7 - 0 6 1 7 - 0 1  
R PN 2106 
6 1 - 0 9 0 0  
1 7 0 - 3 9 3 0
7 0 7 7 5
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3.1 . GENERAL METHODS
3.1 .1 . PLASMID PREPARATION.
T w o  m a jo r  te c h n iq u e s  w e re  e m p lo y e d  fo r  the p re p a ra t io n  of  p l a s m id
DNA.  T h e  f irst, and  m ore  c o m m o n  t e c h n iq u e  used  w a s  A lka l ine  Ly s is  
( S a m b r o o k  et al., 1987) w h ich  w a s  p e r f o rm e d  using reage n ts  m a d e  in 
the labo ra to ry ,  and also using the Q ia g e n  Mini and Max i  Prep Ki ts.  T h e  
ki ts  w e r e  e s s e n t ia l l y  the  s a m e  as  t h e  lab r e a g e n ts  w i th  th e  o n l y  
d i f f e r e n c e  be ing  th a t  ge l  f i l t ra t ion  c o l u m n s  w e re  s u p p l i e d  w i th  t h e  
k i ts to fu r th e r  pur i f y  the D N A a f te r  ex t ra c t io n .  T he  s e c o n d  t e c h n iq u e  
used  w a s  lysis by  bo i l ing  ( S a m b r o o k  et al., 1987) .  H o w e v e r ,  th is  w a s
o n ly  u s e d  w h e n  the  n u m b e r  o f  s a m p le s  to be p r o c e s s e d  b e c a m e
e x t r e m e l y  la rge ,  s ince  the  bo i l ing  m e th o d  p e rm i ts  the s im u l t a n e o u s  
p r o c e s s i n g  o f  m a n y  m o re  s a m p le s  t h a n  d o e s  t h e  a l k a l i n e  ly s i s  
t e c h n i q u e .
A lka line  Lysis Method of P lasm id Preparation.
B e fo re  c o m m e n c in g ,  the bac te r ia l  c u l tu re  to be used  w a s  s p r e a d  o n  
an a g a r  p la te  and  g ro w n  o v e r n i g h t  a t  37 °C .  S e le c t io n  of  a s in g le  
c o l o n y  f r o m  the  p la te  e n s u re d  a p u re  c u l tu re  and  a h o m o g e n o u s  
p l a s m i d  p r e p a r a t io n .  T h e  c o l o n y  w a s  u s e d  to in o c u la te  a 1 0 m l  
s u p e r b r o t h  ( 1 0g 3 - ( N - m o r p h o l i n o )  p r o p a n e s u l f o n i c  a c i d ;  3 0 g  
t r y p t o n e ;  20g  y e a s t  e x t ra c t ,  p H  7 .0 ,  p e r  l i t re)  c u l tu re .  T h i s  w a s  
g r o w n  o v e r n i g h t  at  37 °C  w h i le  s h a k in g  a t  2 5 0 rp m .  The  ce l ls  w e r e  
t hen  p e l l e t e d  by  c e n t r i f u g a t io n  a t  4 0 0 0 r p m  fo r  15m in .  T h e  p e l l e t  
w a s  r e s u s p e n d e d  in 0 .5m l  bu f fe r  1 ( 5 0 m M  g lu c o s e ;  2 5 m M  T r is -H C I ,  
pH 8 .0 ;  1 0m M  EDTA)  and t rans fe r red  to  a 1 .5ml e p p e n d o r f  tube.  0 .5 m l
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s o lu t i o n  2 ( 0 .2 M  N a O H ;  1 %  (w/v)  S D S )  w a s  th e n  a d d e d  a n d  
im m e d ia te l y  m ix e d  by in v e rs ion .  Th is  w a s  le f t  at  ro o m  t e m p e r a t u r e  
f o r  10 m in  fo l l o w e d  by  th e  a d d i t io n  o f  0 .5 m l  s o lu t i o n  3 ( 6 0 m l  5M  
p o t a s s i u m  a c e ta te ;  1 1 .5 m l  a c e t i c  A c id ;  2 8 . 5 m l  w a t e r ) .  T h i s  w a s  
g e n t l y  s h a k e n  and  left  on ice  fo r  1 0 m in .  T h e  p r e p a r a t i o n  w a s  
c e n t r i f u g e d  a t  1 3 0 0 0 r p m  fo r  3 0 m in  a n d  t h e  s u p e r n a t a n t  w a s  
re m o v e d .  (In the c ase  of  the  Q iage n  kits,  the  s u p e r n a ta n t  w o u ld  be 
p a s s e d  o v e r  the gel  f i l t ra t ion c o lu m n  at  th is  s tage . )  0.8 v o l u m e s  of 
i s o p ro p a n o l  w a s  a d d e d  to th is  and  it w a s  left  to p rec ip i ta te  a t  -20 °C  
fo r  1 hour .  T h e  D N A  w a s  r e c o v e re d  by  c e n t r i f u g a t io n  a t  1 3 0 0 0 r p m  
f o r  3 0 m in  at  4 °C  a nd  i sh ed  on c e  in 7 0 %  e th a n o l .  T h e  p e l l e t  w a s  
r e s u s p e n d e d  in T E  (1 0 m M  T r is -H C I ;  1 0 m M  E D T A ,  pH  8 .0 )  a n d  
e x t r a c t e d  w i th  p h e n o l : c h l o r o f o r m : i s o a m y l a l c o h o l ;  2 5 :2 4 :1  f o l l o w e d  
by  p r e c ip i t a t io n  in e th a n o l .  Th is  D N A  w a s  s u f f i c ie n t l y  p u r e  to be 
used  fo r  c lon ing  or  sequ enc ing .
Lysis by Boiling.
A 10m l cu l tu re  w a s  g ro w n  as  be fo re ,  and  th e  ce l ls  w e re  r e c o v e r e d  
b y  c e n t r i f u g a t i o n  a t  4 0 0 0 r p m  f o r  1 0 m in .  T h e y  w e r e  t h e n  
r e s u s p e n d e d  in 4 m l  S T E T  (0.1 M NaCI ;  1 0m M  Tr is -HC I ,  pH  8 .0 ;  1 mM 
E D T A ;  5 % (v /v )  T r i t o n -X  100) a nd  t ra n s fe r re d  to a 15m l t u b e  w h e re  
50(0.1 R N A s e  (G ibco /B R L ,  1 uni t / | i l )  w a s  a d d e d  pe r  ml of  S T E T  . 200u l  
o f  a 5 0 m g / m l  s o lu t io n  o f  l y s o z y m e  w a s  a l s o  a d d e d  a n d  th is  w a s  
in c u b a te d  at  room  te m p e ra tu r e  fo r  10m in .  T h e  s o lu t i o n s  w e r e  then  
b o i le d  fo r  2min and  c e n t r i f u g e d  at  1 4 0 0 0 r p m  fo r  15m in .  T h e  pe l le t  
w a s  r e m o v e d  w i th  a t o o th p ic k ,  leav ing  the  s u p e rn a ta n t ,  w h ic h  w a s
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e x t r a c te d  w i th  p h e n o l : c h l o r o f o r m : i s o a m y la l c o h o l ;  2 5 :2 4 :1 .  T h i s  w a s  
t hen  p rec ip i ta ted  w i th  2.5 v o lu m e s  of  e thano l  a t  - 2 0 °C  fo r  1 hour.
3 .1 .2  PREPARATION OF SOLUBLE Fab.
E.coli X L IB Iu e ,  t r a n s f o r m e d  w i th  t h e  a p p r o p r i a t e  F a b - e n c o d i n g  
p l a s m id ,  w e r e  u s e d  to i n o c u la te  s u p e r b r o t h  c o n t a i n in g  0 . 5 % ( w / v )  
g l u c o s e ,  10 j- ig/m I t e t r a c y c l i n e  a n d  100 ( i g / m l  c a r b e n i c i l l i n  ( a n d  
30| j .g/ml c h lo ra m p h e n ic o l  in the c ase  o f  the  b in a ry  p la s m id  s y s te m ) .  
T h e s e  c u l tu re s  w e r e  in c u b a te d ,  s h a k in g ,  a t  3 7 ° C  for 8 h o u rs  a f te r  
w h i c h  t im e  1 m M  i s o p r o p y  I 3 - D - t h i o g a l a c t o p y r a n o s i d e  ( I P T G ;  
S t r a ta g e n e  3 0 0 1 2 7 )  w a s  a d d e d  to ea c h  cu l tu re .  T h e s e  w e r e  th e n  
in c u b a te d  fo r  a fu r th e r  12 hou rs  at  2 5 ° C. T h e  ce l ls  w e re  c o l le c te d  
by  c e n t r i f u g a t io n  ( 4 0 0 0  rpm  fo r  10 min a t  4 ° C  ) and  t h e  p e l le ts
r e s u s p e n d e d  in 1 0 m l  10m M  P B S ,  pH  7 .4  c o n t a i n i n g  3 4 ( i g / m l
p h e n y l m e t h y l s u l p h o n y l f l o u r i d e  ( P M S F ;  G i b c o  B R L  5 5 2 1 U B )  a n d  
1 .5 % (w /v )  s t re p to m y c in  s u lp h a te  (S ig m a  S 6 5 0 1 ) .  Th is  w a s  s u b je c te d  
to t h re e  f r e e z e - t h a w  cy c le s  f o l l o w e d  by c e n t r i f u g a t io n  ( 1 7 0 0 0  rpm 
fo r  30  min at  4 ° C  ). T h e  s u p e rn a ta n ts  w e re  c o l le c te d  and  c le a re d  by  
f i l t r a t io n  t h ro u g h  0 .2 [ im  f i l te rs  and  w e re  u s e d  d i re c t l y  fo r  a n a ly s i s ,
o r  a l te rna t i ve ly ,  pu r i f ied  f u r th e r  on an a f f in i t y  c o lu m n  as d e s c r i b e d
in the  nex t  sec t ion .
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3 .1 .3  PURIFICATION OF Fab.
So lub le  Fab w a s  pu r i f ied  by a s ingle  pass o f  the s u p e rn a ta n ts  o v e r  an 
a f f in i t y  c o lu m n  as fo l low s .  T he  co lum n  c o n s i s te d  o f  g o a t  a n t i - h u m a n  
F ( a b ')2 a n t ib o d y  (P ie rc e )  l inked  to G a m m a  B in d  G  s e p h a r o s e ™  
( P h a r m a c ia ) .  It w a s  e q u i l i b r a t e d  in 3 c o l u m n  v o l u m e s  o f  8 7 . 2 %  
p h o s p h a t e  b u f fe r  ( 0.1 M s o d iu m  p h o s p h a te ,  d i b a s i c ;  0 .5M  s o d iu m  
ch lo r ide ) ,  1 2 .8 % (w /v )  c i t ra te  bu f fe r  ( 0 .05M  c i t r ic  a c id ;  0 .5M  s o d iu m  
ch lo r ide  ) and  the  s u p e rn a ta n ts  w e re  loaded  o n to  th e  c o lu m n  in the 
s a m e  buf fer.  The  c o lu m n  w a s  w a shed  unti l  the  O .D . ( 2 8 0 n m )  (O p t ica l  
Dens i ty  a t  2 8 0 n m )  o f  the pass - th ro ugh  re tu rned  to a base l ine  leve l .  
The  Fab w a s  then  e lu te d  in 10 .8%  p h o s p h a te  bu f fe r ,  8 9 .2 %  c i t ra te  
b u f fe r  a n d  the  c o l l e c t e d  f r a c t io n s  w e re  n e u t r a l i s e d  w i th  1M  tr is -  
HCI,  pH 9 .0  and c o n c e n t ra te d  to a f inal v o lu m e  o f  a p p ro x im a te ly  1ml.
3 .1 .4  A N A L Y S IS  OF PURIFIED Fab BY SD S-G EL 
ELECTROPHORESIS.
S D S -ge l  e le c t r o p h o re s is  w a s  used  to d e te rm in e  the  pu r i t y  of  th e  Fab 
a f t e r  p u r i f i c a t i o n  b y  a f f i n i t y  c h r o m a t o g r a p h y .  T h e  P h a s t ™  gel  
e l e c t r o p h o r e s i s  s y s t e m  ( P h a r m a c ia )  w a s  u s e d  in al l  c a s e s ,  in 
co n ju n c t io n  w i th  s i l v e r  s ta in ing  of  the gel .
Running the gel:
2 j l l I  of Fab s a m p le  w a s  m ixed  with 2j i l  s a m p le  b u f fe r  and  b o i le d  for
i
30 s ec on ds .  A  1 0 - 1 5 % ( w /v )  S D S  g rad ien t  ge l  w a s  re m o v e d  f r o m  its 
pa c k a g e  a nd  p la c e d  on  the ge l  bed. Im p re s s io n s  o f  the w e l l s  to be 
used  w e re  p r e s s e d  o n to  p a ra f i lm  using the  t e m p la t e  p r o v id e d  and  
2¡i\ of  e a c h  bo i led  s a m p le  w a s  p laced  In ea c h  w e l l ,  w i th  R a in b o w ™  
m arke rs  ( A m e rs h a m )  in one  wel l .  These s a m p le s  w e re  p ic k e d  up in
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the  a p p ro p r ia te  com b,  wh ich  w a s  then  pos i t ione d  a b o v e  the gel  u s in g  
the  s lo t s  p ro v id e d .  The  ge l  w a s  run  f o r  2 0 m in  a t  5 8 V  a n d  t h e n  
r e m o v e d  fo r  s ta in ing .
S ta in in g  :
S i l v e r  s t a in in g  w a s  used  in the  d e t e c t io n  o f  F a b  p r o te in  a s  t h i s  
t e c h n i q u e s  m o r e  s e n s i t i v e  t h a n  C o o m a s s i e  b l u e ,  a n d  t h e  
c o n c e n t r a t i o n  o f  o u r  Fabs  w a s  g e n e r a l l y  qu i te  low  (in the  o r d e r  o f  
0 . 0 5 m g /m l ) .  The  fo l low ing  s o lu t io n s  w e r e  m a d e  up and  a t ta t c h e d  to  
the  e l e c t r o p h o r e s is  m ach in e  by  p la c in g  a s e le c t io n  of  t u b e s  m a r k e d  
by  n u m b e r s  into the so lu t ions  as  in d ic a te d  fo l lo w in g :
L ine  3: 10%  (v /v )E thano l ;  5 % (v /v )  A c e t i c  Ac id  3 0 0 m l
L ine  4:  5% (v /v )  G l u t a r a l d e h y d e  1 0 0 m l
L ine  5: W a t e r  5 0 0 m l
L ine  6 : 0 . 4 5 % ( w /v )  S i l v e r  N i t r a te  1 0 0 m l
L ine  7: 2 %(v /v )  F o r m a ld e h y d e  in
2 .5% (w /v )  S o d iu m  C a rb o n a te  
L ine  8 : 5g S o d iu m  T h io s u lp h a te
+ 3.7g Tr is -HCI  in W a te r  
L ine  9: 1% (v /v )  G ly c e r o l 5 0 0 m l
1 0 0 m l
1 0 0 m l
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T he  m a n u f a c t u r e r ' s  r e c o m m e n d e d  p ro g ra m  fo r  s i l v e r  s t a in in g  w a s  
then app l ied  a n d  th e  gel  w a s  rem o ved  fo r  e x a m in a t i o n .  T h e  ge l  w a s  
then dr ied  fo r  s to ra g e .
3 .1 .5  ENZYME-LINKED IMMUNOABSORBENT ASSAY, ELISA.
A n u m b e r  of  E L I S A s  w e re  c a r r ie d  ou t  for  the  a n a l y s i s  o f  th e  Fab  
f rag m en ts .  T he  in i t ia l  one  w a s  a s im p le  spo t  E L I S A  to d e t e r m in e  if 
the  Fab b e in g  s t u d ie d  b o u n d  g p 1 2 0 .  C o m p e t i t i i v e  E L IS A s  w e re  
p e r f o rm e d  to d e t e r m i n e  the re la t ive  a f f in i t y  o f  t h e  F a b s  to g p 1 2 0  
and to d e t e r m in e  if the  in te rac t io n  w a s  c o m p e t i t i v e l y  in h ib i t e d  by 
soluble CD4.
Spot ELISAs on gp120.
The we l l s  of  a C o s ta r  E . I .A . /R . I .A .  p late w e re  c o a t e d  w i th  0.1 p.g of 
IIIB g p 1 2 0  ( A m e r i c a n  B io te c h n o lo g ie s )  at  4 °C  o v e r n i g h t .  T h e  p la te  
was  w a s h e d  10 t im e s  wi th  PBS conta in ing  0 .0 5 %  T w e e n - 2 0 ,  and  then 
co a te d  w i th  3% ( w / V )  Bov ine  S e ru m  A lb u m in  ( B S A )  in 10m M  PBS,  
pH 7 .4  at  3 7 ° C  fo r  1 hour.  The  B S A  w a s  d i s c a r d e d  a nd  50( i l  o f  Fab 
sa m p le  w a s  a d d e d  to each  wel l  fo r  2 hours  a t  3 7 ° C  A f te r  w a s h in g  
aga in ,  50 [ i l  of  a 1 /5 0 0  d i lu t ion  o f  an a lka l ine  p h o s p h a t a s e - l a b e l e d  
g o a t  a n t i - h u m a n  F ( a b ')2 a n t ib o d y  (P ie rce 3 1 3 1 2X )  w a s  in c u b a te d  in 
each  wel l  fo r  3 0 m in .  T he  plate w a s  ¡shed once m o r e  and  25u l  o f  an 
a lka l ine  p h o s p h a t a s e  s u b s t ra te  (Pha rm ac ia )  w a s  a d d e d  to e a c h  wel l  
a t  r o o m  t e m p e r a t u r e .  T h e  O .D .  a t  4 0 5 n m  w a s  r e a d  a f t e r  
a p p ro x im a te ly  2 0 m in .  For  each  ant igen ,  a n e g a t i v e  c on t ro l  e x t ra c t  of  
XLI B lue  t r a n s f o r m e d  wi th  e m p ty  p la s m id  w a s  u s e d  to d e t e r m in e  
w h e th e r  o th e r  c o m p o n e n t s  in E.coli had an a f f in i t y  for  the a n t ig ens
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in t h e  a s s a y .  Each  e x t ra c t  w a s  a s s a y e d  fo r  b in d in g  a c t i v i t y  w i th  
BS A ,  and  a lbum in -b ind ing  c lo n e s  w e re  c o n s id e re d  to be neg a t i ve .  Any  
c lo ne  s h o w in g  a s igna l  o f  3 t im es  the neg a t i ve  con t ro l  o r  h ig h e r  w a s  
c o n s id e r e d  pos i t i ve .  The  t i t re o f  any  pos i t i ve  c lo n e  w a s  a s s a y e d  by 
m a k in g  a ser ia l  d i lu t ion  o f  t h a t  Fab  and  tes t ing  e a c h  d i lu t io n  on the  
E L IS A  as  d e s c r ib e d .  T he  t i t re  w a s  taken  as th a t  d i lu t io n  w h ic h  ga v e  
a s igna l  equa l  to ha l f  the s igna l  g e n e ra te d  by  the  u nd i lu te d  Fab, and  
th is  w a s  the  d i lu t ion  used in all s u b s e q u e n t  a s s a y s .
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gp120 C om petit ion  ELISAs.
T h e s e  a s s a y s  w e re  used  to d e te rm in e  the re la t ive  a f f in i t y  o f  an Fab 
fo r  gp120 .  The  plate w a s  coa ted  w i th  gp1 20  and  b lo c k e d  with  B S A  as 
be fo re .  T he  Fab w a s  d i lu ted  in 1% (w /v )  B S A - 1 0 m M  PBS,  p H 7 .4  to a 
d i l u t i o n  c o r r e s p o n d in g  to tw ic e  i t 's t i t re  a n d  25 ( i l  o f  t h i s  w e re  
a d d e d  to each  of  7 we l l s .  111B g p 1 2 0  w a s  se r ia l ly  d i lu ted  f ro m  2x10-  
6 M to  2 x 1 0 ’ 12 M a n d  25(_il o f  t h e s e  d i l u t i o n s  w e r e  a d d e d  
c o n s e c u t i v e l y  to each  of  the  7 we l l s  and  m ix e d  w i th  the  Fab .  The  
E L IS A  w a s  then  p e r f o rm e d  as  d e s c r ib e d  fo r  the  s p o t  E L IS A s .  The  
resu l ts  fo r  each  Fab  were  p lo t ted as %  m a x im u m  O.D .  ( M a x im u m  O.D. 
be ing  the  s igna l  w h e n  on ly  Fab w a s  ad d e d  to the  we l l  a t  a d i lu t ion  
c o r r e s p o n d in g  to i t 's t i t re )  v e r s u s  I o g ( g p 1 2 0  c o n c e n t r a t i o n ) .  T h e  
re la t i v e  a f f in i t y  w a s  d e t e r m i n e d  to be t h a t  c o n c e n t r a t i o n  o f  f ree  
g p 1 2 0  resu l t ing in 5 0 %  of m a x im u m  O.D.
CD4 Inh ib it ion  ELISA.
T h e s e  a s s a y s  w e re  c a r r ie d  o u t  in a s im i l a r  w a y  to  t h e  g p 1 2 0  
c o m p e t i t i o n  E L IS A s  e x c e p t  the  f ree  an t ig en  c o m p e t in g  w i th  the  Fab 
in th is  c ase  w a s  so lub le  C D 4  (sCD4) .  S e r ia l  d i lu t io n s  of  s C D 4  are 
m a d e  in the  range  2 x 1 0 '7 M to 2 x 1 0 '1 2 M and  th e s e  d i lu t io ns  are  c o ­
in c u b a te d  w i th  the Fab  as be fo re .  The  %  m a x im u m  O.D .  w a s  p lo t ted  
a g a in s t  the log [sC D4 ]  and the conce n t ra t io n  of  s C D 4  resu l t ing  in 5 0 %  
in h ib i t ion  of  b ind ing  w a s  d e te r m in e d  as the  inh ib i t ion  c o n s ta n t .
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3 .1 .6  SEQUENCING OF CONSTRUCTS.
It w a s  c r u c ia l  to d e te rm ine  the s e q u e n c e  o f  ea c h  Fab  c o n s t r u c t  in 
o rd e r  to b e  ab le  to in te rpre t  any  resu l ts  o b ta in e d  f rom  a s s a y in g  t h e  
s o lu b le  F a b  f r a g m e n ts .  C o n s t r u c t s  w e r e  e i t h e r  s e q u e n c e d  f r o m  
s ing le  s t r a n d e d  DNA,  or d i rec t ly  f rom  th e  d o u b le - s t r a n d e d  p la s m id s .  
Bo th  t e c h n i q u e s  w e re  fo u n d  to be  e q u a l l y  s u c c e s s f u l  a n d  a re  
d e s c r ib e d  b e low .
Prepara tion of Single-Stranded DNA (ssDNA).
Th is  m e t h o d  w a s  used wi th  c o n s t ru c ts  in the  p h a g e m id  p C o m b 3  as  
the re  w a s  a s ta g e  in the life cyc le  o f  th e  M 13  p h a g e  (upon  w h ic h  
p C o m b 3  w a s  b a s e d )  wh e re  i ts D N A  w a s  s in g le  s t ra n d e d .  A  5 m l  
cu l tu re  o f  E.coli  con ta in ing  the c o n s t r u c t  w a s  g row n  in s u p e r b r o t h  
s u p p l e m e n t e d  w i th  100 | i g /m l  c a r b e n  ici  11 i n , 10 | i g /m l  t e t r a c y c l i n e  
and  20m M  M g C l2 a t  37°C  ove rn igh t .  100(il o f  th is  cu l tu re  w a s  th e n  
used to i n o c u la te  13ml of  f resh m e d iu m  a n d  th is w a s  g row n  fo r  1.5  
hours  at  3 7 °C .  50[ i l  of  V C S M 1 3  he lpe r  p h a g e  at  1012p fu /m l  ( p la q u e  
f o rm in g  u n i t s )  w a s  a d d e d  a nd  i n c u b a t e d  fo r  a f u r t h e r  2 h o u rs ,  
f o l l o w e d  b y  the  add i t ion  of  k a n a m y c in  to  a f ina l  c o n c e n t r a t i o n  o f  
70 ( ig /m l .  T h e  cu l tu re  was  then g ro w n  fo r  a m in im u m  of 18 h o u rs  at  
37°C .  T h e  ce l ls  w e re  re m o v e d  by  c e n t r i f u g a t io n  and  3 .7 m l  o f  2 0 %  
p o l y e t h y le n e  g lyco l  (PEG) 800 0 ;  1 .8m l  5M  NaCI  are a d d e d  to th e  
s u p e r n a t a n t ,  w h i c h  w a s  c h i l l e d  on  ic e  f o r  3 0 m in .  T h i s  w a s  
c e n t r i f u g e d  at  11000  for 15min  a nd  the  s u p e rn a ta n t  w a s  d i s c a rd e d .  
T h e  p e l l e t  w a s  re s u s p e n d e d  in 6 0 0 | i l  T E  a nd  e x t ra c te d  tw ic e  w i th  
e q u a l  v o l u m e s  of  p h e n o l :T E ,  f o l l o w e d  b y  a s in g le  c h l o r o f o r m
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e x t r a c t i o n .  T h e  s s D N A  w a s  t h e n  be r e c o v e r e d  b y  e t h a n o l  
p r e c i p i t a t i o n .
S equenc ing  Protocol.
W h e n  d o u b le - s t r a n d e d  D N A  ( d s D N A )  w a s  be ing  used ,  it w a s  f i r s t  
d e n a t u r e d  b e fo re  a n n ea l ing  to t h e  p r im e r .  H o w e v e r ,  th is  w a s  n o t  
n e c e s s a r y  in the case  of ssDNA.
D N A  D éna tu ra t ion :
4 | i g  o f  d s D N A  in 8 | i l  was  added  to 4 j i l  o f  2M N a O H  and  left  a t  r o o m  
t e m p e r a t u r e  fo r  10m in .  The f o l l o w in g  r e a g e n ts  w e re  th e n  a d d e d  to 
th e  reac t ion :  4.5(j.l of  2M a m m o n iu m  ace ta te  pH 4.5,  5.5} i l  w a t e r  a n d  
60( i l  e t h a n o l .  T h e  m ix tu re  w a s  t h e n  in c u b a te d  a t  -7 0 °C  fo r  1 h o u r  
a f t e r  w h i c h  t im e ,  the  D N A  w a s  r e c o v e r e d  by  c e n t r i f u g a t i o n  a t  
1 4 0 0 0 r p m  fo r  3 0 m in .  T he  pe l le t  w a s  w a s h e d  in 7 0 %  e t h a n o l  a n d  
d r ie d  u n d e r  v a c u u m .  Th is  DN A w a s  then  ready  fo r  a n n e a l in g  to  t h e  
s e q u e n c in g  p r im er .
P r im e r  A n n e a l in g .
A l l  r e a g e n ts  us e d  for the fo l low ing  p r o c e s s e s  w e re  d e r iv e d  f r o m  t h e  
U n i te d  S ta tes  B iochem ica l  S e q u e n a s e  Ve rs ion  2.0 D N A  s e q u e n c in g  Ki t  
( 7 0 7 7 0 ) .  1(j.l p r im e r  (a t  0 . 1 ( ig / j i l )  a n d  2( i l  r e a c t io n  b u f f e r  w e r e  
a d d e d  to the d r ie d  DNA,  and  m a d e  up to 10(i l  w i th  wa te r .  T h is  w a s  
h e a te d  a t  6 5 ° C  fo r  2m in  and  s u b s e q u e n t l y  let coo l  to 3 5 ° C  o v e r  a 
p e r io d  o f  30m in .
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S e q u e n c in g  R e ac t ion
T h e  fo l l o w in g  c oc k ta i l  w a s  m a d e  w h i le  the  a n n e a l in g  r e a c t io n s  are  
c o o l i n g :
1: 2: 0.5 0.1 M DTT:  1/6 d i lut ion of  labe l ing  mix: 35S A T P
A 1/16 d i lu t ion  of  the s e q u e n a s e  e n z y m e  w a s  m ade ,  in the  e n z y m e  
buf fer,  and  a 1/16 d i lu t ion of  p y ro p h o s p h a ta s e  w a s  m ade  in the  s a m e  
s o l u t i o n .  T h e  p y r o p h o s p h a t a s e  p e r m i t s  l o n g e r  i n c u b a t i o n s  a nd  
p reven ts  s h a d o w  ban d s  appear ing .
4|_il cock ta i l  and  2 (j.l e n z y m e  d i lu t ion  w e re  a d d e d  to e a c h  a n n e a l in g  
reac t ion .  Th is  w a s  in c uba ted  fo r  3m in  at  ro o m  te m p e ra tu re .  
T e r m i n a t i o n :
2.5( i l  of  each  of  the d id e o x y n e u c le o t id e s  (ddN T P )  w e re  a d d e d  to each  
of  4 we l ls  in a 96  we l l  p late fo r  each  c lone  to be s e q u e n c e d .  3 .5 | i l  of  
the s e q u e n c in g  reac t ion  w a s  then a d d e d  to each  of  the 4  w e l l s  and  
th is  w a s  in c u b a te d  a t  37 °C  for 5m in .  S to p  s o lu t ion  m ay  be a d d e d  at  
t h i s  s t a g e .  H o w e v e r ,  if t h e r e  a re  p r o b l e m s  w i th  s e c o n d a r y
s t ruc tu res ,  a n u m b e r  of  add i t iona l  s teps  are  adv isab le :
I n c u b a t e  th e  p la te  a t  5 5 ° C  fo r  1 0 m in .  A d d  "{¡il o f  T e r m i n a l  
D e o x y n e u c le o t i d e  T ra n s fe r a s e  (T D T )  m ix  (1 m M  d N T P s  in 1X T D T
b u f fe r  w i th  0 .5) i l  T D T  fo r  eve ry  4 we l ls )  to ea c h  we l l  and  in c uba te
f o r  a f u r t h e r  3 0 m in  a t  3 7 ° C .  T h i s  p e r m i t t e d  th e  a d d i t i o n  o f
n u c le o t id e s  to th e  e n d s  of  all s t ra n d s  not  t e rm in a te d  c o r re c t l y .  T h e y  
then  e x te n d e d  s uch  tha t  they  cou ld  not  e n te r  the s e q u e n c in g  ge l  and  
so w o u ld  not  a p p e a r  as u n w a n te d  ar t i facts .
A d d  s top  so lu t ion  a nd  s tore  the p la te  at  - 2 0 °C  unt i l  ready  to run the 
ge l .
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Se q u e n c in g  Gel
A  6 % ( W / V )  p o l y a c r y l a m i d e  ge l  w a s  p o u r e d  a c c o r d i n g  to  
m a n u fa c tu re r ' s  (P h a ra m c ia )  r e c o m m e n d a t io n s .  2 .5 j i l  o f  e a c h  re a c t io n  
w a s  loaded  in each  we l l  in a p rede f ined  order .  T h e  ge l  w a s  th e n  run 
a t  50°C  for va ry ing  a m o u n ts  of  t ime dep end ing  on the d e s i r e d  a re a  of  
s e q u e n c e .  On c o m p le t io n  o f  the run, the gel  w a s  r e m o v e d  a n d  d r ied  
on to  a p iece of  f i l ter  p a p e r  in a gel  d ry e r  at  8 0 ° C  fo r  1 hou r .  It w a s  
t hen  e x p o s e d  und e r  X - ray  f i lm  (Am ersham )  fo r  at  leas t  24  hou rs .  The  
se q u e n c e  cou ld  then be read  from the au to rad iog raph .
3 .1 .7  NEUTRALISATION ASSAYS.
It w a s  n o t  p o s s i b l e  to c o n d u c t  n e u t r a l i s a t i o n  a s s a y s  in th e  
l a b o ra to ry ,  s in ce  the  fac i I I i t ies  to ha n d le  l i ve  H IV  v i r u s  w e r e  no t  
a v a i la b le  to us.  T h e r e f o r e ,  two  ex is t ing  a s s a y s  w e r e  u s e d  fo r  th is  
p u rpo s e .  The f i rs t  w a s  ca r r ied  out  by Dr. Ew a  B jör l ing  a n d  Dr. Er l ing  
N o r r b y  a t  th e  K a r o l i n s k a  Ins t i tue ,  S w e d e n ,  a n d  m e a s u r e d  th e  
p ro d u c t i o n  of  v i ra l  p r o te in  p 24  in the  s u p e r n a t a n t  ( B a r b a s  et al., 
1992) .  T he  secon d  w a s  p e r fo rm e d  by Dr. N a nc y  D u n lo p  a n d  Dr. Pe te r  
N a ra  a t  the N a t iona l  C a n c e r  Inst i tu te,  M a ry la n d  a nd  w a s  b a s e d  on 
s y n c y t iu m  fo rm a t ion  (N a ra  and  F ish inger ,  1988) .
p24 N eutra lisa tion  Assay.
D i lu te d  t i s s u e  c u l t u r e  s u p e r n a t a n t s  of  H I V -1 I I IB o r  M N - i n f e c t e d  
p e r ip h e ra l  b lood  m o n o n u c le a r  ce l ls  (P B M C s )  w e re  i n c u b a t e d  fo r  2
: I
hous  at  37°C  wi th  ser ia l ly  d i lu ted  Fab sam p le s .  105 P B M C s  w e re  then 
a d d e d  to the v i r u s / a n t i b o d y  m ix tu re s  and  i n c u b a t e d  f o r  1 h o u r  at
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37°C .  T h e  ce l ls  w e r e  then w a s h e d  and  i n c u b a t e d  w i th  RP M I  164 0  
s u p p l e m e n t e d  w i t h  10% (v /v )  foe ta l  c a l f  s e r u m ,  1 .5 m M  g lu ta m in e ,  
a n t ib io t ic s  a n d  in te r le uk in  2. T he se  w e re  then  in c u b a te d  fo r  7 d a y s  
w i th  m e d iu m  c h a n g e s  a t  d a y s  1 a n d  4.  A f t e r  i n c u b a t i o n ,  th e  
s u p e r n a t a n t s  w e r e  a n a l y s e d  by H IV -1  p 2 4  c a p t u r e  E L I S A  as  
d e s c r i b e d  p r e v i o u s l y .  ( S u n d q v i s t  et al., 19 8 9 ) .  A re s u l t  w a s  
d e t e r m in e d  p o s i t i v e  if an 8 0 %  reduc t io n  in o p t i c a l  d e n s i t y  o c c u r r e d  
as c o m p a r e d  w i th  a negat ive  hum an s e rum .  T h e  pos i t ive  con t ro l  used  
w a s  a k n o w r r  m o u s e  neutra l is ing an t ibody  and  its Fab f ra g m e n t  (2F5) .
S y n c it iu m -F o rm in g  N e u tra l isa t ion  Assay .
T h is  a s s a y  u s e d  a L e u -3 a  pos i t i ve  C E M  c e l l  l ine ( C E M - S S )  th a t  
e x p re s s e s  C D 4  on its cel l su r face  and  fo rm  s y n c i t ia  on in fec t ion  by 
H IV -1 .  W e l l s  o f  a  f la t  b o t t o m e d  96 w e l l  p l a te  (C os ta r )  w e re  f i r s t  
co a te d  w i th  5 0 f i l  o f  a 50 f ig /m l  so lu t ion  o f  p o ly -L - l y s in e  and  a l l o w e d  
to s tand  a t  r o o m  te m p e ra tu re  fo r  1 hour .  T h e  P L L  w a s  re m o v e d  and  
th e  w e l l s  w e r e  c o a te d  w i th  50 | i l  o f  1 . 0 x 1 0 6 c e l l s / m l  C E M - S S  
s u s p e n s io n .  T h e  ce l ls  had been  in a l o g a r i t h m ic a l l y  g row ing  in RP M I  
1 6 4 0 ,  1 0 %  s e r u m , 1%  a n t ib io t i c s ,  i m m e d i a t e l y  p r io r  to t h is ,  to 
e n s u re  s t a n d a r d i s a t i o n  o f  the  as s a y .  T h e  c e l l s  w e re  a l l o w e d  to
i
a t ta tch  to the  p la te  at  37 °C  fo r  30 m in u te s  a n d  the s u p e rn a ta n t  w a s  
th e n  d i s c a r d e d .  5 0 j i l  of  100 s ync i t ia l  f o r m in g  un i ts  o f  a p re t i t r e di
v i ra l  s t o c k  w e r e  m ix e d  w i th  5 0 | i l  o f  s e r i a l l y  d i l u t e d  a n t i b o d yl
s a m p le s .  50p.l o f  e a c h  v i r u s - a n t i b o d y  m i x t u r e  w a s  d i v i d e d  in to  
d u p l i c a te  w e l l s  c o n ta in in g  the  C E M - S S  c e l ls  a n d  in c u b a te d  fo r  60  
m inu tes .  T h e  m e d iu m  w a s  rep la ced  w i th  200 (il of  c o m p le te  m e d iu m  
and  the  p la te  w a s  in cuba ted  at  37°C fo r  5 d a y s ,  w i th the add i t ion  of
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a f u r t h e r  2 0 0 j i l  o f  m e d iu m  on d a y  3 .  T h e  w e l l s  c o u ld  t h e n  be  
e x a m in e d  u n d e r  an  inverted m ic ro s c o p e  fo r  s y n c i t i u m  fo rm a t io n .  T h e  
n e g a t i v e  c o n t r o l  us e d  invo lved  the a d d i t io n  o f  P B S  in th e  p l a c e  o f  
v i ru s .  T h e  p o s i t i v e  con t ro l  e x c lu d e d  t h e  n e u t r a l i s i n g  a n t i b o d y  a n d  
the  n u m b e r  o f  s y n c i t i a  fo rm ed  in th is  w e l l  w a s  d e s ig n a te d  V 0 , w h i l e  
the  n u m b e r  p r e s e n t  in the a n t ib o d y  w e l l s  w e r e  d e s ig n a te d  V n . T h e  
ra t io  V n/ V 0 w a s  c a lc u la te d ,  and  an a n t i b o d y  w a s  d e t e r m i n e d  to  
n e u t ra l i s e  a t  t h a t  d i lu t ion  if the  ra t io w a s  0.1 o r  lo w e r  ( i .e . :  9 0 %  
n e u t r a l i s a t i o n ) .
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3 .2  LIBRARY CONSTRUCTION
3.2 .1  RNA ISOLATION.
R N A  w a s  p r e p a r e d  f r o m  b o n e  m a r r o w  c e l l s  t a k e n  f r o m  an  
a s y m p t o m a t i c  A ID S  pat ient .  These  cel ls h a d  bee n  rende red  safe upon  
i s o la t io n  b y  in a c t i v a t io n  of  a n y  v i r u s  p a r t i c l e s  p re s e n t .  10 ml of  
g u a n id iu m  i s o th io c y a n a te  w e re  then  a d d e d  to 108 cel ls  and  th e s e  
w e r e  h o m o g e n i s e d  f o r  1 m i n u t e  in a t h i c k - w a l l e d  5 0 m l  
p o l y p r o p y le n e  tube .  1ml of  2M s o d iu m  a c e t a t e  w a s  a d d e d  to th is  
s o lu t io n ,  f o l l o w e d  by  c e n t r i f u g a t io n  a t  1000 rpm  fo r  20min at  4°C.  
T h e  s u p e r n a t a n t  w a s  r e m o v e d  and  a d d e d  to an equa l  v o lu m e  of  
i s o p ro p a n o l .  T h is  w a s  a l low ed  to p rec ip i ta te  fo r  1 hour  at  -20°C,  and  
th e n  c e n t r i f u g e d  as  abo v e .  The  p e l l e t  w a s  r e s u s p e n d e d  in 3m l  
g u a n id i u m  i s o t h i o c y a n a t e  a n d  the  i s o p r o p a n o l  p r e c ip i t a t i o n  w a s  
repea ted .  T h e  f ina l  pel le t  w a s  r e s u s p e n d e d  in 3m l  7 0%  e thano l  and  
c e n t r i f u g e d  fo r  10 min.  Th is  w a s  d r ie d  u n d e r  v a c u u m  a n d  f ina l ly  
r e s u s p e n d e d  in 1ml die thy l  p y ro c a rb o n a te  ( D E P C )  t rea ted  wa te r .  The  
quan t i ty  o f  R N A  was  de te rm ined  by read ing  the  O .D . (260n m ) .  An O.D. 
of  1.0 w a s  e q u iv a le n t  to 40} ig /m l RNA.
3 .2 .2  cDNA PRODUCTION.
The  p r im e r  used  in c D N A  p roduc t ion  w a s  a 24  base  pai r  (bp) ol igo dT
p r im er ,  as  th is  s e e m e d  to g ive be t te r  re s u l t s  than  a spec i f i c  p r im e r
(da ta  no t  s h o w n ) .  0 .5 | ig  R N A  in 8 | i l  w e r e  a d d e d  to 2\i\ p r im e r  at  
0.1) j .g/ml.  2u l  R N A s in  w e re  a d d e d  to t h is  and  it w a s  in c u b a te d  at  
70 °C  fo r  10min.  Th is  was  c oo led  on ice a n d  the fo l low ing  add i t ion s
71
w e re  m ade :  5 j i l  1 0 X  re v e r s e  t ransc r ip t ion  b u f fe r  (G ib c o  B R L ) ;  3f i l  
d N T P  mix (50) iM  e a c h  o f  d A T P ,  dG TP ,  d C T P  and  d T T P ) ;  5) i l  0.1 M 
D i t h io t r e i t o l  ( D T T ) ;  2 j i l  B R L  S u p e r s c r i p t  R e v e r s e  T r a n s c r i p t a s e  
(200U/JJ.I). T h is  w a s  in c u b a t e d  at  ro o m  t e m p e r a t u r e  fo r  1 0 m in ,
f o l l o w e d  by 4 2 ° C  f o r  5 0 m in .  The  reac t ion  w a s  t e rm in a te d  a t  90 °C  
fo r  5m in  and  th e n  c o o le d  on ice fo r  10min.  F ina l ly ,  the re a c t io n  
m ix tu re  w a s  in c u b a t e d  w i th  1(il R N A se  H at  3 7 ° C  fo r  3 0 m in .  T h e  
c D N A  was  s to red  a t  -20°C .
3 .2 .3  PCR AM PLIFICATION OF GAMMA AND KAPPA
CHAINS.
T h e  D N A encod ing  the  g a m m a  and kappa  ch a in s  o f  the a n t ib ody  we re  
th e n  iso la ted  f rom  the  c D N A  using the P o ly m e r a s e  C ha in  R e a c t io n  
(P C R ) .  In o rde r  to a c h ie v e  this,  a se t  o f  p r im e rs  w e re  d e s ig n e d  by 
B u r to n  et  al. ( 1 9 9 1 )  to s p e c i f i c a l l y  a m p l i f y  d i f f e r e n t  s u b c la s s e s  of  
g a m m a  and k appa  cha ins .  The  5' pr im ers  w e re  d e s ig n e d  to be spec i f ic  
fo r  the N ' - te rm in u s  o f  the  va r iab le  reg ions ,  and  the  3' p r im e rs  w e re  
d e s ig n e d  to be c o m p le m e n t a r y  to the C ' - t e r m in a l  e nd  of  the  C H i  
reg ion  in the case  o f  g a m m a  chains,  or  the C ' - te rm ina l  end o f  the Ck
reg ion  in the case  o f  k a p p a  cha ins .  The  p r im e rs  w e re  also d e s ig n e d
to  i n c o r p o r a t e  r e s t r i c t i o n  s i t e s  s u i t a b l e  f o r  c l o n in g  t h e  P C R  
f r a g m e n t s  f o r  l i b r a r y  c o n s t r u c t i o n .  T h e  f o l l o w i n g  is a l i s t  of  
p r im e r s  used ,  w i th  th e  res t r ic t ion  s i tes  in d ic a te d  in i ta l ics:
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Human kappa 3' primer. CK1z:
Xba 1
5 ' -G C G  C C G  T C T  A G A  A C T  AA C A C T  C T C  C C C  T G T  T G A  A G C  T C T  TTG  
T G A  C G G  G CG  ATC T C A G-3'
Human kappa variable chain 5' prim ers:
Sac I
5 '-G AC ATC G A G  C TC A C C  CAG T C T  CCA-3 '  V K 1 a
5 ' -G A A  A T T  G AG  CTC AC G  CA G  T C T  CCA-3 '  V K 3 a
5'-G A T  A T T  G A G  C T C  A C T  CAG T C T  C C A -3 ’ V K 2 a
Human gamma chain 3' primer:
Spe 1
5 ' -G C A  T G T  A C T  A G T  TTT  G TC A C A  A G A  T T T  G G G -3 '  CG1 z
Human gamma variable chain 5' prim ers:
Xhol
5'-CAG GTG CAG CTC GAG CAG TC T  GGG-3 '  V H 1 a
5 '-GAG GTG CAG CTC GAG GAG TC T GGG-3 '  V H 3 a
5'-CAG G TG  CAG CTG CTC G AG  T C T  GGG-3 '  V H 1 f
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5' -GAG GTG CAG CTG CTC G AG  TC T GGG-3 ' V H 3 f
5 '-CAG G TG  CAG C TA  CTC G AG  TCG  GG-3'  V H 2 f
5 '-CAG G TG  CAG CTG  CTC GAG TCG GG-3'  V H 4 f
5 '-CAG G TA  CAG CTC G AG  CAG T C A G G - 3 '  VH6a
Each P C R  reac t ion  con ta ined  the 3' g a m m a  or  k a p p a  p r im e r  p lus  one 
a p p ro p r i a te  5' p r im er .  It w a s  on ly  a f te r  the  c o m p le t i o n  of  P C R  tha t  
the  v a r io u s  s u b c la s s e s  w e re  m ixed  fo r  l ib ra ry  c o n s t ru c t io n .
PCR Reaction.
In i t ia l ly ,  a m a s te r  P C R  mix w a s  m a d e  w h ic h  w a s  then  be s to re d  at  
-2 0 °C .  Th is  c o m p r is e d :
792 ( i l  s te r i le  w a te r .
8 (il d N T P  mix (50 | iM  each  nuc leo t ide ) .
100(0.1 10X  T aq  reac t ion  bu f fe r  (P ro m e g a ) .
Each  reac t ion  tube  w a s  then a s s e m b le d  as  fo l low s :
90| i l  P C R  mix.
3| i l  3'  p r im e r  
3|ol 5' p r im e r  
3|ol D N A  ( a p p ro x im a te ly  1( ig)
[^x\ T a q  p o l y m e r a s e  ( 2 .5 u n i t s /m l )
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T h e  PC R cond i t ions  w e re  var ied  d e p e n d in g  on the D N A  and  p r im e r  
be ing  used .  H o w e v e r ,  t yp ica l  c o n d i t io n s  fo r  l i b ra ry  c o n s t r u c t i o n  
w e r e :
T e m p  T i m e
9 5 ° C  1 m in
5 2 ° C  3 0 s e c
7 2 ° C  1 m in
Fo l low ed  by: 72 °C  5 m in .
P urif ica tion  of PCR Products.
T h e  P C R  re a c t io n s  w e re  d i re c t l y  run on a 1 .5 %  lo w  m e l t in g  p o in t  
a g a ro s e  gel  fo r  1 hour,  a t  80vo l t s .  T h e  b a n d  c o r re s p o n d in g  to  7 0 0 b p  
in s ize  w a s  cu t  f rom  the gel  and  th is w a s  m e l ted  a t  65 °C  fo r  10min .  
T h i s  w a s  th e n  c o o le d  to 4 2 ° C  a nd  in c u b a t e d  w i th  1jol B -a g a ra s e  
(1uni t / |o l )  ( N e w  E n g la n d  B io la bs )  o v e r n ig h t .  A  1 /10  v o l u m e  of  3M 
s o d i u m  a c e ta te ,  p H 5 .3  w a s  a d d e d  a n d  th is  w a s  c e n t r i f u g e d  at  
1 3 0 0 0 r p m  fo r  2 0 m in  to r e m o v e  a n y  r e m a in i n g  c a r b o h y d r a t e .  2.5  
v o l u m e s  of  e th a n o l  w a s  a d d e d  to the  s u p e r n a ta n t  a nd  in c u b a te d  at  
- 2 0 ° C  fo r  1 hour ,  f o l l o w e d  by  c e n t r i f u g a t io n  as  b e fo re .  T h e  p e l le t  
w a s  w a s h e d  in 7 0 %  ethano l  and re s u s p e n d e d  in 20| i l  TE. T h e  D N A  was  
qu a n t i f i e d  by  O .D .  a t  2 6 0 n m .  An  O .D . ( 2 6 0 n m )  o f  1.0 c o r r e s p o n d s  to 
50| j .g/ml DNA.
3 .2 .4  RESTRICTION OF PCR FRAGMENTS.
T h e  fo l l o w in g  w a s  a t yp ica l  r e a c t io n  m ix tu re  fo r  the  re s t r i c t io n  of  
g a m m a  cha in  P C R  f ragm en ts :
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1j ig D N A  in 1j i l  
2(i l Xho  I (B o e h r in g e r  M a n n h e im ,  50U / j i l )
2\x\ Spe  I (B o e h r in g e r  M a n n h e im ,  50U/( i l )
5 f i l  10 Bu f fe r  H 
4 0 | i l  s te r i le  w a te r .
Incubate  at  37 °C  fo r  2 hours .
A  s im i l a r  r e a c t io n  w a s  c a r r i e d  ou t  fo r  k a p p a  c h a i n s  u s in g  the  
e n z y m e s  S a c  I and Xba I in Bu f fe r  A.
A l l  r e s t r i c t i o n  w e r e  i n a c t i v a t e d  by  h e a t i n g  to  6 5 ° C  f o r  5 m in  
f o l l o w e d  b y  a s i n g l e  e x t r a c t i o n  w i t h  
P h e n o l : C h lo r o f o r m : l s o a m y la l c o h o l ;  2 5 :2 4 :1 .
3 .2 .5  PREPARATION OF THE VECTOR.
T h e  4 0 0 0 b p  v e c t o r  u s e d  in t h e  c o n s t r u c t i o n  o f  c o m b i n a t o r i a l  
l i b ra r ie s  w a s  k n o w n  as p C o m b 3 .  T h is  v e c t o r  w a s  c o n s t r u c t e d  oy 
C a r lo s  F. B a rba s  III, and p repa red  by him in the  fo l low ing  w a y :
E. coli X L I B I u e  w e re  t r a n s fo r m e d  w i th  the  pCormb3 p h a g e m id  a nd  
g r o w n  o v e r n ig h t  in s u p e rb ro th  m e d iu m  s u p p le m e n t e d  w i th  100( ig /m l  
C a r b e n i c i l l i n .  A p l a s m id  p r e p a r a t i o n  w a s  th e n  p e r f o r m e d ,  by  the  
a l k a l i n e  lysis m e th o d ,  on the  c u l tu re  to g ive  t y p ic a l  p l a s m id  y ie ld s  
o f  1mg.  50 | ig  of  p lasm id  w e re  d iges ted  with 150 un i ts  each  o f  X h o  I 
a n d  S p e  I res t r ic t io n  e n z y m e s  in a 300jj.I re a c t io n  a t  3 7 ° C  f o r  2 
h o u r s .  T h i s  w a s  t h e n  e x t r a c t e d  o n c e  w i t h  
p h e n o l : c h l o r o f o r m : i s o a m y la l c o h o l  25 :24 :1  a n d  e th a n o l  p r e c ip i t a t e d .  
T he  D N A  w a s  then  t rea ted  fo r  1 hou r  a t  3 7 °C  wi th  100 un i ts  o f  Ca l f  
I n t e s t i n a l  P h o s p h a t a s e  ( B o e h r i n g e r  M a n n h e i m )  f o l l o w e d  by  ge l
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p u r i f i ca t ion .  T he  v e c to r  w a s  t h e n  ready  fo r  in s e r t io n  o f  t h e  g a m m a  
c h a in  inse r ts .
3 .2 .6  LIGATION OF THE PLASMID AND INSERT.
It w a s  a t  th is  s ta g e  tha t  the d i f fe re n t  g a m m a  c ha in  s u b c la s s  inse r ts  
o b t a i n e d  f r o m  the  P C R  r e a c t io n s  w e re  m ix e d  w i th  t h e  r e s t r i c te d  
v e c t o r  DN A.  T h e s e  w e re  then  l iga ted  to th e  p r e p a r e d  v e c t o r  in the  
m o la r  ra t io  o f  2:1,  in se r t :vec to r .  T h e  reac t ion  m ix  u s e d  w a s :
2 | ig  V e c to r  D N A  
0 .4 j i g  Inser t  D N A  
3 |J  L igase  (G ibco  BRL,  1 unit/(jJ)
30  |ol 5 X  buf fe r  
2\i\ d A T P ( 1 0 0 m M )
112 .6 (j.l w a t e r  
Incuba te  a t  16°C  ove rn igh t .
3 .2 .7  TRANSFORMATION OF LIGATIONS.
T h e  l iga ted  D N A  w a s  t ra n s fo r m e d  in E.coli XL IB iue ,  w h ich  c o u ld  be 
s e le c te d ,  as  it c o d e d  fo r  t e t r a c y c l in e  r e s is ta n c e  on an F' e p i s o m e .  
H o w e v e r ,  i t  w a s  n e c e s s a r y  to m a k e  c o m p e t e n t  c e l l s  b e f o r e  
t r a n s f o r m a t i o n .
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P repara t ion  of E lec trocom peten t Cells.
A  1 0 m l  c u l tu re  o f  E.coli X L IB Iu e  w a s  s u p p le m e n t e d  w i th  10 j i g / m l  
t e t r a c y c l i n e  a n d  g ro w n  o v e rn ig h t  a t  37 °C .  5 ml o f  each  c u l tu re  w a s  
t h e n  u s e d  to i n n o c u la te  5 0 0 m l  o f  s u p e rb ro th ,  a n d  th is  w a s  g r o w n  
unt i l  an  O .D . ( 5 5 0 n m )  of  0.8 w a s  re a c h e d .  A t  th is s tage ,  the  c u l t u r e s  
w e r e  c h i l l e d  on ice fo r  15m in  and  th e n  c e n t r i f u g e d  a t  4 0 0 0 r p m  fo r  
1 5 m i n  a t  4 ° C .  T h e  c e l l s  w e r e  r e s u s p e n d e d  in 1 l i t re  10% ( v / v )  
g l y c e ro l  a n d  recen t r i fuged .  Th is  w a s  fo l l o w e d  by a w a s h  w i th  5 0 0 m l  
1 0 % ( v / v )  g l y c e ro l  and  f in a l l y  a 2 0 m l  w a s h .  T h e  p e l le t  w a s  t h e n  
r e s u s p e n d e d  in its ow n  v o lu m e  by  s t i r r ing  w i th  a p ipe t te ,  d i s p e n s e d  
in to  250|ol  a l iquo ts  and  im m e d ia te ly  f rozen  in an e thano l  bath  c o o le d  
w i th  d r y  ice. T he  cel ls w e re  then  s to re d  at  -80°C.
T rans fo rm a tion  of the heavy chain library.
2 } ig  o f  l i g a t e d  D N A  in w a t e r  w a s  m i x e d  w i t h  3 0 0 j_i I 
e l e c t r o c o m p e t e n t  ce l ls  in a 0 .2 c m  e le c t ro p o ra t io n  cuv e t te .  T h is  w a s  
t h e n  p u ls e d  at  a res is tance  of  200m n  and  a vo l tag e  o f  2 .5 K v .  Th is  
w a s  w a s h e d  im m e d ia te ly  w i th  1m l  S O C  m e d iu m  (20g  t r y p t o n e ;  5g 
y e a s t  e x t ra c t ;  0 .5g  NaCI ;  2 .5 m M  KCI;  1 0 m M  M g C l2; 2 0 m M  g l u c o s e ,  
p H 7 . 0  p e r  l i t re)  ( S a m b r o o k  et a i,  1989 )  fo l l o w e d  by  a f u r t h e r  2 ml 
w a s h ,  a nd  the ce l ls  w e re  g ro w n  a t  3 7 °C  fo r  1 hour .  A t  th is  s t a g e  
10m l o f  s u p e r b r o t h  c o n t a i n in g  10 j i g / m l  t e t r a c y c l i n e  a n d  20 j i g / m l  
c a rb e n ic i l l i n  w a s  a d d e d  and  the c u l tu re  w a s  g rown  fo r  an a d d i t i o n a l  
h o u r  a t  37 °C .  This w a s  then a d d e d  to 100ml supe rb ro th  s u p p le m e n t e d  
w i th  5 0 ( ig /m l  ca rben ic i l l in  a nd  g r o w n  ove rn igh t .  P h a g e m id  D N A  w a s  
p r e p a r e d  f ro m  this  cu l tu re .
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Insertion of the Kappa L igh t Chains.
10( ig  of  D N A  from the a b o v e  p repa ra t ion  w a s  cut wi th S a c  I a n d  Xba I 
r es t r ic t io n  e n z y m e s ,  as  d e s c r i b e d  p rev io us ly ,  and  the  k a p p a  inser ts  
w e r e  l i ga ted .  The vec to r ,  n o w  c o n ta in e d  both  hea vy  a n d  l igh t  cha in  
D N A ,  w a s  t ran s fo rm ed  as b e fo r e  and  sca led -  up to the 1 0 0 m l  cu l tu re  
s ta g e .  It w a s  at  th is p o in t  t h a t  the p an n in g  p ro c e d u re  to  s e le c t  fo r  
g p 120- s p e c i f i c  a n t ib o d ie s  w a s  p e r fo rm e d .
3 .2 .8  PURIFICATION OF PHAGE PARTICLES.
T h e  t r a n s fo rm e d  cu l tu re  w a s  g ro w n  in 100m l  s u p e r b r o t h  c o n ta in in g  
5 0 ( ig /m l  ca rben ic i l l i n  and  10 (j.g/ml t e t r a c y c l in e  fo r  1 h o u r  a t  37 °C .  
0 .5 m l  o f  V C S  M 13  h e lp e r  p h a g e  (S t ra ta g e n e )  a t  1012 p fu /m l  w e re  
a d d e d  and  g rown  for a f u r t h e r  1 hou r  a t  37°C .  K a n a m y c in  w a s  then 
a d d e d  to a f inal  c o n c e n t r a t i o n  of  70p.g/ml in o rd e r  to s e l e c t  fo r  the 
p h a g e .  Th is  cu l tu re  w a s  t h e n  g ro w n  ove rn igh t .  T h e  c e l l s  w e re  then 
s e p a ra te d  f rom  the s u p e r n a ta n t  by  cen t r i fuga t ion ,  and  p h a g e m id  D N A  
w a s  p r e p a r e d  f ro m  th e  c e l l s  fo r  s to ra g e .  P h a g e  p a r t i c l e s  w e re  
pu r i f ie d  f rom  the s u p e r n a ta n t  us ing  the fo l low ing  t e c h n iq u e :
4g o f  po lye thy lene  glycol  (P E G )  8000 and 2g NaCI w e re  a d d e d  to each 
1 0 0 m l  o f  s u p e rn a ta n t  a n d  c h i l l e d  on ice for  1 hour.  T h i s  w a s  then 
c e n t r i f u g e d  a t  9 0 0 0 r p m  f o r  20  min.  T h e  s u p e rn a ta n t  w a s  d i s c a rd e d  
a n d  the  pe l le t  w a s  r e s u s p e n d e d  in 2 ml PBS.  Th is  w a s  c le a re d  by 
c e n t r i f u g a t i o n  a t  3 5 0 0 r p m  f o r  15 m in  f o l l o w e d  by  1 4 0 0 0 r p m  fo r  
5m in .  The  phage  were  t h e n  t i t red  to d e te rm ine  the in i t ia l  quan t i ty .
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Phage T itres.
T h e  p h a g e  o b ta in e d  f rom  the a b o v e  p ro c e d u re  w e re  s e r ia l l y  d i lu ted  
to 1 C H 2 . E ach  d i lu t io n  f rom  10 ' 6 a n d  lo w e r  w e re  m ix e d  w i th  50| i l  
E.coli  cu l tu re  a t  37 °C  fo r  10 min.  25 j i l  of  these  w e re  p la te d  ou t  on 
a g a r  p la te s  s u p p le m e n t e d  w i th  100 | i g /m l  c a rb e n ic i l l i n  fo r  c o u n t i n g  
the  nex t  day.  The  resu l t  cou ld  then be e x p re s s e d  as  n u m b e r  o f  phage  
pe r  ml.  It w a s  pos s ib le  to t i t re the  p h a g e  in th is  w ay ,  s in ce ,  in the  
a b s e n c e  of  he lpe r  pha ge  they  p ropa ga ted  as a p lasmid .
3 .2 .9  PANNING.
T h e  we l l s  o f  C o s ta r  E . I .A . /R . I .A .  p la tes  w e re  c o a te d  w i th  0 .8 j i g /w e l l  
111B g p 1 2 0  ( A m e r i c a n  B i o t e c h n o l o g i e s )  in 1 0 m M  P B S ,  p H 7 .4 ,  
o v e rn ig h t  at  4°C .  The  we l ls  w e re  w a s h e d  w i th  w a te r  and  c o a t e d  with 
3% ( w /v )  B S A - P B S  fo r  1 h o u r  a t  37 °C .  A f t e r  w a s h in g  o n c e  w i th  
1 % ( w /v )  B S A - P B S ,  25 | i l  o f  p h a g e  w e re  a d d e d  to e a c h  w e l l  and  
in c u b a te d  a t  3 7 ° C  fo r  1 hou r .  T h e  n o n -s p e c i f i c  p h a g e  w e r e  then  
r e m o v e d  a n d  the  w e l l s  w e re  w a s h e d  w i th  6 X 1 0 m in  w a s h e s  in 
1% (w /v )  B S A - T B S  T w een ,  f o l l o w e d  by a fu r th e r  w a s h  in w a te r .  The 
spec i f i c  p h a g e  w e re  then e lu ted  in 50jj,I of  e lu t ion  b u f fe r  (1 .6 m l  12N 
HCI in 150 m l  w a te r  w a s  a d jus ted  to pH to 2.2 w i th  so l id  g l y c in e ;  a 
f u r t h e r  200 ml w a t e r  w a s  t h e n  a d d e d  a n d  t h e  s o l u t i o n  w a s  
a u to c la v e d )  fo r  10 min at  room  te m p e ra tu r e .  If a n u m b e r  o f  we l l s  
w e re  used , they  w e re  c o m b in e d  at  th is s tage  and  3|ol 2M Tr is,  pH 8.0, 
w a s  a d d e d  pe r  50)j.l e lua te  to neu t ra l ise  the pH. Th is  w a s  a d d e d  to 
2ml of  f re s h ly  g ro w n  E.coli X L IB Iu e  cu l tu re  and  i n c u b a te d  a t  37°C  
fo r  1 5 m in .  1 0 m l  s u p e r b r o t h  c o n t a i n in g  20 ,ug/m l c a r b e n i c i l l i n  a nd  
10(j.g/ml te t ra c y c l in e  w e re  then  add ed .  20 , 1.0 and  0.1 ul v o l u m e s  are
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r e m o v e d  a t  t h is  s t a g e  a n d  p la te d  o u t  on  c a r b e n i c i l l i n  p la te s  to 
m e a s u r e  the  in p u t  t i t re  o f  p ha ge .  T h e  1 0 m l  c u l tu re  w a s  g r o w n  fo r  
a n o t h e r  ho u r  f o l l o w e d  by the  ad d i t io n  o f  1 0 0 m l  o f  b ro th .  T h i s  w a s  
c u l tu re d  fo r  1 hour,  and ,  if a fu r the r  round  of  p a n n in g  w a s  requ i red ,  
he lp e r  pha ge  w e re  add ed  and the pann ing  p ro c e s s  repea ted .  W h e n  the 
f in a l  r o u n d  w a s  r e a c h e d ,  the  c e l ls  a re  g r o w n  o v e r n i g h t  in th e  
a b s e n c e  of  h e lp e r  p h a g e  a nd  p la s m id  p r e p a ra t io n s  w e re  c a r r ie d  ou t  
to re t r ie ve  the D N A  c od ing  fo r  the a n t ig e n - s p e c i f i c  a n t ib o d y  l ib rary .
3 .2 .1 0  REMOVAL OF THE GENEIII FROM THE LIBRARY.
T h e  p l a s m id  D N A  p r e p a r e d  a f te r  p a n n in g  w a s  d i g e s t e d  w i th  the 
e n z y m e s  N h e  I a n d  S p e  I as  d e s c r i b e d  f o r  v e c t o r  p r e p a r a t i o n  
p re v io u s ly .  T h e  resu l t in g  4 .7 K b  f r a g m e n t  p r o d u c e d  w a s  p u r i f i e d  by 
ge l  e l e c t r o p h o r e s i s  a n d  c o u ld  be s e l f - l i g a t e d  in th e  p r e s e n c e  of  
l igase ,  d ue  to the  c o m p a t ib le  ends  tha t  w e re  p r o d u c e d  by  res t r ic t ing  
w i th  t h e s e  tw o  e n z y m e s .  T h is  p la s m id  D N A  w a s  t r a n s f o r m e d  i r t o  
E.coli and  p la ted  ou t  on ca rben ic i l l i n  p la tes.  C o lo n ie s  w e re  re m o v e d  
f ro m  th e s e  p la tes  to p ro d u c e  so lub le  Fab  f r a g m e n ts  to be te s te d  for 
gp 1 2 0  b ind ing  on EL ISA.
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3 .3  BIOCHEMICAL ANALYSIS OF Fab FRAGMENTS
3.3 .1  Fab INHIBITION ELISAs.
M ic r o t i t r e  w e l l s  w e r e  c o a t e d  w i th  0.1 | ig NIB g p 1 2 0  ( A m e r i c a n  
B io t e c h n o lo g ie s ,  C o lu m b ia  M D  ) C o m p e t i t i v e  E L IS A s  b e t w e e n  the  
pan e l  o f  F (ab )s  used  in the b ioc hem ic a l  a n a ly s i s  and  w h o le  a n t ib o d y  
13 w e re  p e r f o rm e d  us ing  a s im i la r  m e th o d o lo g y  to th a t  u s e d  fo r  the 
g p 1 2 0  c o m p e t i t i v e  E L IS A s  as d es c r ib ed  in m e th o d s  sec t ion  3 .1 .5 .  T h e  
f o l l o w i n g  a n t i b o d y  d i l u t i o n s  w e r e  u s e d :  W h o l e  a n t i b o d y  13 w a s  
o b ta in e d  by  fus ing  the Fab wi th  an Fc por t ion  o f  IgG,  and  e x p re s s in g  
th e  p r o d u c t  in C h in e s e  H a m s t e r  O v a ry  ce l ls  to y ie ld  a w h o le  IgG 
m o le c u le .  Th is  w a s  then  used  at  a c o n s t a n t  d i lu t io n  o f  1 :1 0 0 0 0  in 
th e  E L IS A  as th is  w a s  f o u n d  to be the  t i t re fo r  th is  a n t ib o d y .  T he  
p u r i f i e d  F ab  f r a g m e n t s  ( in i t ia l l y  a t  10 0 ( ig /m l )  w e r e  s e r ia l l y  d i l u t e d  
f ro m  1 :100 to 1 :3200 0  and  incuba ted  w i th  the IgG in the E L IS A  p la te  
fo r  2 hou rs .  A f te r  w a s h in g ,  the  a m o u n t  of  w h o le  a n t ib o d y  re m a in in g  
b o u n d  to the  p la te  w a s  d e te c te d  us ing  a p e r o x i d a s e - l a b e l e d  g o a t  
a n t i - h u m a n  a n t ib o d y  (P ie rce  3 1 3 1 2 X )  s p e c i f i c  fo r  the  Fc po r t ion  of  
IgG.
3 .3 .2  DETERMINATION OF RELATIVE AFFINITIES USING 
BIACORE™.
T h e  p r o c e s s  o p t im is e d  fo r  use  w i th  the  F ab  f r a g m e n ts  in v o lv e d  a 
n u m b e r  of  s teps.  T w o  sepa ra te  channe ls  on a b io s e n s o r  ch ip  had  to be 
c o a t e d  w i th  I IIB g p 1 2 0  ( R e p l ig e n ,  C a m b r i d g e  M A)  s u c h  t h a t  one
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c h a n n e l  cou ld  be used  fo r  the d e te rm in a t io n  o f  a s s o c ia t io n  c o n s ta n t s  
( k 0n) and  the  o th e r  fo r  the  d e te r m in a t io n  o f  d i s s o c ia t i o n  c o n s t a n t s
( k o f f ) .
Im m ob iliza tion  of Antigen on the Sensor Surfaces.
A  f lo w ra te  o f  5 ( i l /m in  of  1 0 m M  PBS,  pH 7 .4 ,  o v e r  the  b io s e n s o r  ch ip  
w a s  f i r s t  e s ta b l i s h e d .  The  ch ip  w a s  a c t i v a te d  by  in jec t in g  3 0 | i l  o f  
a c t i v a t io n  s o lu t i o n  ( P h a r m a c ia  B io s e n s o r ,  5 0 % ( v /v )  0 .2 M  /V -e th y l - /V  
' - ( 3 - d i e t h y l a m i n o p r o p y l ) - c a r b o d i i m i d e ,  5 0 % ( w / v )  N - 
h y d r o x y s u c c in i m i d e ) .  T h e  f l o w r a t e  w a s  th e n  a d ju s t e d  to 10fo l /m in  
a n d  the  an t igen  w a s  in jec ted  in 1 0m M  s o d iu m  ac e ta te  bu f fe r  pH  4 5. 
A  25(0.1 s a m p le  o f  g p 1 2 0 ,  (10 | ig /m l ) ,  w a s  in je c te d  w h e n  a s s o c ia t i o n  
c o n s ta n t s  w e re  to be d e te r m in e d  ( resu l t ing  in a f inal  leve l  o f  4 0 0 0  
R e s p o n s e  U n i t s  (R U ) ) .  H o w e v e r ,  20|ol o f  g p 1 2 0  at  2 |og /m l w a s  
in je c te d  f o r  the  d e te r m in a t io n  o f  d i s s o c ia t i o n  c o n s t a n t s  ( g i v in g  a 
f in a l  le ve l  o f  8 0 0 R U ) .  In bo th  c a s e s ,  a f l o w r a t e  o f  5^1 /m in  w a s  
r e e s t a b l i s h e d  f o l l o w i n g  t h e  g p 120 i n j e c t i o n  a n d  t h e  c h i p  w a s  
b l o c k e d  f r o m  a n y  f u r t h e r  im m o b i l i s a t i o n  by  in je c t in g  30|ol o f  1M 
e th a n o la m in e ,  pH 8 .5  (P h a rm a c ia  B iosenso r ) .
Determ ination of Assoc ia tion  Constants  (kon)- 
A s e r i e s  o f  d i l u t i o n s  w e r e  m a d e  f o r  e a c h  F a b  to  g i v e  f in a l  
c o n c e n t r a t i o n s  in the  range  of  1 -20 | ig /m l .  30j_il o f  each  d i lu t io n  w a s  
i n je c te d ,  in t u rn ,  o v e r  th e  im m o b i l i z e d  a n t i g e n  a t  a f l o w r a t e  o f  
5(ol /min.  T h e  c h a n g e  in r e s p o n s e  pe r  un i t  t im e  (dR /d t )  w a s  p lo t te d  
a g a in s t  t im e (t) fo r  each  c o n c e n t ra t io n .  T he  s lo p e s  o f  e a c h  of  these  
g r a p h s  w e re  then  p lo t ted  a g a in s t  t h e i r  c o r r e s p o n d in g  c o n c e n t r a t i o n s  
to g ive  a f ina l  g raph  f rom  w h ich  the  a s s o c ia t io n  c o n s ta n t  w a s  read.
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Dete rm ina tion  of D issoc ia t ion  C onstan ts  (ko ff) .
3 0 jj.I o f  e a c h  F a b  s o l u t i o n  a t  150 j j . l /ml  w a s  i n j e c t e d  o v e r  the  
im m o b i l i z e d  a n t ig e n  a t  a f low ra te  o f  5 ( i l /m in .  O n c e  the  re a c t io n  had 
re a c h e d  e q u i l i b r i u m ,  the Fab w a s  r e m o v e d  f r o m  the  a n t ig e n  a t  a 
c o n s t a n t  f lo w ra te  o f  5 0 j i l /m in .  A  p lo t  w a s  then  m a d e  of  l n (R i /R o )  
a g a i n s t  t i - to  fo r  the  d i s s o c ia t i o n  p h a s e  (Ri w a s  the  r e s p o n s e  at  
t im e  ti; Ro w a s  the init ial r e s p o n s e  at  t im e  to )  and  the  s lope  o f  th is 
g ra p h  w a s  taken  to be the  d i s s o c ia t i o n  c o n s ta n t .  R e la t i v e  a f f in i t ie s  
w e re  then  c a lc u la te d  as  k o n / k o f f -
3 .2 .3  EPITOPE MAPPING USING BIACORE.
A f lo w ra te  o f  5 ( i l /m in  1 0 m M  PB S ,  p H 7 .4  w a s  e s t a b l i s h e d  a n d  the  
b i o s e n s o r  c h ip  w a s  a c t i v a te d  as  a b o v e .  4 0 | i l  o f  g o a t  a n t i - h u m a n  
F ( a b ')2 (P ie rce )  a t  4 0 ( ig /m l  w a s  in jec ted  in 1 0 m M  s o d iu m  a c e ta te  
bu f fe r ,  p H 4 .5  to g iv e  a f ina l  leve l  o f  im m o b i l i z a t i o n  o f  1 0 0 0 0 R U .  
T h e  c h ip  w a s  then  b lo c k e d  as d e s c r ib e d  a b o v e .  T h e  f l o w ra te  w a s  
a d j u s t e d  to 1( i l /m in  a n d  4(j,l o f  the  f i r s t  F a b  a t  100p .g /m l w a s  
i n je c te d ,  im m e d i a t e l y  f o l l o w e d  by  4( i l  of  an  a n t i - c y t o m e g a l o v i r u s  
Fab  ( 1 5 0 | i g /m l )  to b lo c k  a n y  re m a in in g  s i tes  on the  s u r fa c e .  4|j.l of  
111B g p 1 2 0  (10 ( ig /m l )  w a s  in jec ted  ov e r  th is,  f o l l o w e d  by 4( i l  o f  the 
s e c o n d  Fab  a lso  a t  a c o n c e n t ra t io n  of  100( j.g/ml.  T h e  en t i re  s u r fa c e  
w a s  r e g e n e ra te d  w i th  25| i l  o f  6 0 m M  HCI so th a t  the  nex t  cy c le  cou ld  
be run. Each  Fab w a s  run a g a in s t  all the o th e r  Fabs  to g ive a m o s a ic  
of  b ind ing  pa t te rns  and  so es tab l ish  an ep i tope  map.
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3 .3 .4  KNOCKOUT ASSAYS WITH HxB2 gp120 MUTANTS.
H IV -1  e n v e l o p e  g l y c o p r o t e i n s  w e r e  o b t a i n e d  by  u s i n g  c u l t u r e  
s u p e r n a t a n t s  f r o m  C O S -1 c e l l s  t r a n s f e c t e d  w i t h  p l a s m i d s  
e x p r e s s in g  e i th e r  w i ld - t ype  or  m u ta n t  g p 1 2 0 .  T h e s e  m o le c u le s  w e re  
th e n  c a p t u r e d  o n to  the s u r fa c e  o f  an  E L IS A  p la te  us ing  a n t i b o d y
D 7 3 2 4  ( A a l to  B i o r e a g e n t s ;  D u b l in ,  I r e l a n d )  w h i c h  b i n d s  to  th e
co n s e rv e d  15 am ino -a c id  pep t ide  a t  the  C O O H  te rm in u s  of  g p 1 2 0 .  The
b ind ing  o f  a r e fe re n c e  HIV-1 po s i t i v e  h u m a n  s e ru m  to e a c h  m u ta n t  
w a s  a s s a y e d  by  incuba t ing  the  s e ru m  w i th  the  im m o b i l i s e d  g p 120 in 
t h e  p r e s e n c e  o f  0 . 5 % ( v / v )  T w e e n - 2 0 ,  a n d  b o u n d  a n t i b o d y  w a s
d e te c te d  by  m e a n s  of  a s e c o n d ,  e n z y m e - c o n j u g a t e d  a n t ib o d y .  Th is  
resu l t  w a s  t a k e n  as the  re fe re n c e  v a lu e  fo r  each  m u ta n t .  T h e  Fabs  
w e re  then  a s s e s s e d  for b ind ing  to the  m u ta n t  pane l  in the  s a m e  w a y  
a n d  the  b in d in g  ra t io  of  the  te s t  a n t ib o d y  to re fe re n c e  s e r u m  w a s  
d e t e r m in e d  fo r  each  g p 1 2 0  m u ta n t .  T he  a v e ra g e  rat io fo r  the  en t i re  
p a n e l  w a s  c a l c u la te d  and  a n y  in d iv i d u a l  ra t io  d e v i a t i n g  f r o m  the  
m e a n  by  less  than  0 .5  t im e s  w a s  c o n s id e r e d  to be an in h ib i t o ry  
m u ta t ion ,  wh i le  those  d e v ia t in g  by  m o re  than  1.5 t im e s  in d ic a te d  an 
e n h a n c in g  m u ta t io n .  In th is  w a y ,  a m a p  of  m u ta t i o n s  a f fe c t i n g  the 
b ind ing  of  the Fab to gp120  w a s  ob ta ined  fo r  each  c lone.
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3 .4  BINARY PLASMID SYSTEM
3.4 .1  PREPARATION OF EXPRESSION PLASMIDS.
T h e  b in a r y  p la s m id  s y s te m  c o n s i s t s  o f  tw o  p l a s m i d s  d e s i g n e d  to 
fa c i l i t a te  s e p a ra te  c lo n in g  of  the  h e a v y  a n d  l igh t  c h a in s .  T h e  l igh t  
c h a in s  a re  c lo n e d  into p la s m id  p T C 0 1 ,  w h i le  the  h e a v y  c h a in s  are  
in s e r ted  into p T A C O IH .  The  c o n s t ru c t i o n  o f  t h e s e  tw o  p l a s m id s  has  
bee n  d e s c r ib e d  p re v io u s ly  by  C o l le t  et  a l . ( 1 992 ) .  C lo n in g  w i th  t h e s e  
tw o  p l a s m id s  is v e r y  s im i l a r  to th e  l i b ra ry  c o n s t r u c t i o n  d e s c r i b e d  
e a r l i e r .
C ons truc t io n  of L ight C ha in -con ta in ing  P lasm ids
V e c to r  w a s  p re p a re d  by d ig e s t in g  pTC 01  w i th  S a c l  a n d  X b a l  a nd  
t re a t i n g  it w i th  5 un i ts  o f  c a l f  i n te s t in a l  p h o s p h a t a s e  ( B o e h r i n g e r  
M a n n h e im )  f o r  1 h o u r  a t  3 7 ° C ,  f o l l o w e d  b y  10m in  a t  6 5 ° C  to 
inac t i va te  th e  e n z y m e .  L igh t  cha in  in se r t  w a s  o b ta in e d  by  d ig e s t in g  
th e  p C o m b 3 - b a s e d  p a r e n t  p l a s m id  w i th  t h e  s a m e  c o m b in a t i o n  of  
e n z y m e s  a n d  iso la t ing  the  0 .7  kb f r a g m e n t  us ing  low m e l t in g  po in t  
a g a r o s e  g e l  e l e c t r o p h o r e s i s  f o l l o w e d  b y  B - a g a r a s e  d i g e s t i o n .  
L iga t ion  w a s  a t  16° C ov e rn ig h t  u n d e r  s tan d a rd  c ond i t ion s  u s ing  a 5:1 
i n s e r t - t o - v e c t o r  r a t i o .  B e f o r e  t r a n s f o r m a t i o n ,  b a c k g r o u n d  w a s  
re d u c e d  by d iges t ing  the l iga t ion m ix  w i th  X ho l .  G lu c o s e  w a s  u s e d  at  
a c o n c e n t r a t i o n  o f  1 %  (w /v )  in al l  l i q u id  c u l t u r e s  to s u p p r e s s  
e x p re s s io n  o f  the  c lo ned  inserts .
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C o ns truc t ion  of Heavy C ha in -con ta in ing  P lasm ids
V e c to r  w a s  p re p a re d  by d iges t ing  p T A C O IH  w i th  X h o l  a n d  S p e l  and  
t r e a t i n g  it w i t h  c a l f  i n t e s t i n a l  p h o s p h a t a s e  a c c o r d i n g  to  th e  
p ro to c o l  a b o v e .  H e a v y  cha in  in s e r t  w a s  o b ta in e d  by  P C R  f r o m  the 
p C o m b 3 - b a s e d  pa re n t  p lasm id :  the  fo l lo w in g  m ix tu re  w a s  s u b je c te d
to 30 cyc le s  of  amp l i f i ca t ion  (1 min a t  94° C, 0 .5  min at  52° C, and  2 
min at  72° C) fo l low ed  by ex tens ion  a t  72° C fo r  10 min:  50  m M  KCI, 
10 mM  T r is -HC I  (pH 8.8 at  25° C),  1.5 mM MgCI, ,  0 .1 % (v /v )  T r i ton  X- 
100, 200  | iM  of  each  dN TP ,  1.25 un i ts of  T aq  P o ly m e ra s e  (P ro m e g a ) ,  
3 ng of  p lasm id  ta rge t  D N A  and  a p p ro x im a te ly  600  nM of ea c h  pr imer :  
V H 1 a  fo r  the fo rw a rd  d i rec t ion  a nd  C H 1 z  for the rev e rs e  (s u p p l ie d  by 
A m e r i c a n  S y n th e s is ) .  P C R - p r o d u c t  o f  the  c o r re c t  s ize  (0 .7  kb)  w a s  
s e p a r a te d  by  low  m e l t ing  p o in t  ge l  e l e c t r o p h o r e s i s ,  i s o la t e d  us ing  
g l a s s m i l k ,  a nd  d i g e s te d  w i th  X h o l  a n d  S p e l .  T h e  d i g e s t e d  P C R -  
p r o d u c t  w a s  pu r i f ie d  as b e fo re  and  l iga ted  to the  p r e p a r e d  h e a v y  
c h a in  v e c t o r  us ing  a 1:2 v e c t o r - t o - in s e r t  ra t io .  G lu c o s e  ( 1%  (w/v) )  
w a s  used  at  in all l iqu id  c u l t u r e s  to s u p p r e s s  e x p r e s s i o n  o f  the 
c lo n e d  inse r ts .
3 .4 .2  CO-TRANSFORMATION OF THE BINARY PLASMIDS.
D u e  to th e  v e r y  la rge  n u m b e r  o f  t r a n s f o r m a t i o n s  r e q u i r e d  to 
c o m p le te  th is  e x p e r im e n t ,  it w a s  d e c id e d  no t  to use e l e c t r o p o ra t i o n  
in th is  c a s e  as th is  w o u ld  be  too  t im e  c o n s u m i n g  a n d  w o u ld  be 
p r o h ib i t i v e l y  e x p e n s iv e .  In s te a d ,  the  t e c h n iq u e  o f  c a l c i u m  c h lo r i d e  
t r a n s fo r m a t i o n  w a s  c h o s e n .  C a lc iu m  c h lo r id e -  c o m p e t e n t  c e l ls  w e re  
p re p a re d  fo r  th is  t e c h n iq u e .
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Calcium Ch loride Competent Cells.
A 10ml.  cu l tu re  of  E.coli X L IB Iue  w a s  g ro w n  o v e r n ig h t  in s u p e rb ro th  
c o n ta in in g  10 jxg/ml te t ra c y c l in e .  Th is  w a s  then  us e d  to i n o c u la te  a 
1 l i tre c u l tu re  (wi th  no an t ib io t ic )  w h ic h  w a s  g ro w n  at  3 7 ° C  unt i l  an 
0 , D . ( 5 5 0 n m )  of  0.8 w a s  reached .  A t  th is  po in t ,  the  ce l ls  w e re  ch i l led  
on ice fo r  1 5 m in  a n d  r e m o v e d  f ro m  c u l t u r e  by  c e n t r i f u g a t i o n  a t  
4 0 0 0 r p m  fo r  10m in .  The  ce l ls  w e re  r e s u s p e n d e d  in 1 l i t re o f  bu f fe r  
( 0 1 . M C a C l2; 2 0 m M  Tr is -HCI,  pH 8.0) a nd  re c e n t r i f u g e d .  T w o  fu r th e r  
w a s h e s  w i th  5 0 0 m l  and  2 5 m l  o f  b u f fe r  w e r e  c a r r i e d  ou t ,  a n d  the  
f inal  cel l  pe l le t  w a s  r e s u s p e n d e d  in i t 's ow n  v o lu m e  by s t i r r ing  w i th  
a p ipe t te .  T h is  w a s  f rozen  to - 8 0 °C  im m e d ia te l y  in a d ry  ice ba th ,  
unti l  r eady  fo r  use.
T ra n s fo rm a t io n  P ro toco l-
50 (iI C a C I 2- c o m p e t e n t  X H B I u e  ce l ls  w e r e  i n c u b a t e d  w i th  0 .5  j ig  
pur i f ied  D N A  of each  p lasm id  fo r  30  m in  on ice,  h e a t - s h o c k e d  for 1 
min at  42° C, and  incuba ted  for 2 min on ice. 0.3 ml S O C  ( S a m b r o o k  et 
al., 1989)  w a s  a d d e d  and  the  c u l t u r e s  w e re  g r o w n  w i th  m o d e r a t e  
s h a k in g  at  37° C fo r  1 hour.  T h e  p re s e n c e  of  bo th  p la s m id s  and  the  
e p i s o m e  w a s  s e le c te d  fo r  by  p la t in g  0.1 ml of  t h e s e  c u l t u r e s  on 
t r i p l e - a n t i b i o t i c  a g a r  p l a te s  ( 1 0 0  ( ig /m l  c a r b e n i c i l l i n ;  30  | i g /m l  
c h l o r a m p h e n i c o l ;  10 ( ig /m l t e t r a c y c l i n e ;  32  g/l LB a g a r )  a t  37° C 
o v e r n i g h t .  T h e  e x p r e s s i o n  o f  F a b  f r a g m e n t  in al l  D N A  c lo n in g  
e x p e r im e n ts  w a s  s u p p re s s e d  by add ing  1%  (w/v) g lu c o s e  to all m e d ia  
and p la tes.
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3 .4 .3  PREPARATION OF RECOMBINANT Fab FRAGMENT
B a c t e r i a l  c u l t u r e s  fo r  d e t e r m i n a t i o n  o f  a n t i g e n - b i n d i n g  a c t i v i t y  
w e re  g r o w n  in 96  w e l l - t i s s u e  c u l tu re  p l a te s  ( C o s ta r  35 9 6 ) .  2 5 0  j i l  
S u p e r b r o t h  c o n t a i n in g  30 jog/ml c h l o r a m p h e n i c o l ,  1 0 0  ( ig /m l  
c a r b e n i c i l l i n ,  a n d  1% ( w /v )  g l u c o s e  w e r e  a d d e d  p e r  w e l l  a n d  
i n o c u l a t e d  w i t h  a s in g le  d o u b l e - t r a n s f o r m a n t  u s in g  a s t e r i l e  
t o o th p ic k .  P l a te s  w e re  in c u b a te d  w i th  m o d e r a t e  s h a k in g  (200  rpm) 
on a h o r iz o n ta l  s h a k e r  for  7-9  hours  a t  37° C, unt i l  the O .D . ( 5 5 0 n m )  
w a s  a p p r o x im a t e l y  1-1.5.  T he  ce l ls  w e r e  c o l l e c te d  by c e n t r i f u g a t io n  
of  the m ic ro t i t r e  p la te  (1 ,500g fo r  30 m in  a t  4° C), the  s u p e r n a ta n t s  
w e re  d i s c a r d e d ,  a n d  the ce l ls  w e re  r e s u s p e n d e d  in f re s h  m e d ia  
c o n t a i n i n g  1 m M  i s o p r o p y l - b - D - t h i o g a l a c t o - p y r a n o s i d e ,  b u t  no 
g lucose .  I n c u b a t io n  was  c o n t in u e d  at  r o o m  t e m p e ra tu r e  o v e r n i g h t  to 
in d u c e  e x p r e s s i o n  o f  Fab f ra g m e n t .  C e l l s  w e re  then  h a r v e s t e d  by 
c e n t r i f u g a t io n  as  be fo re ,  r e s u s p e n d e d  in P B S  c o n ta in in g  34  f ig /m l  
p h e n y lm e t h y l s u l f o n y l  f lu o r id e  a nd  1 .5 %  (w /v )  s t r e p t o m y c in  s u l fa te ,  
a nd  lysed  by  3 f r e e z e - t h a w  cyc les  b e t w e e n  -80° C and  37° C. The  
c ru d e  e x t r a c t s  w e re  pa r t ia l ly  c le a re d  b y  c e n t r i f u g a t i o n  ( 1 ,5 0 0 g  fo r  
45 min a t  4° C) be fo re  a n a ly s i s  by  a n t i g e n - b i n d in g  E L IS A .  T h e s e  
f ra g m e n ts  w e r e  then  used in EL IS A  a n a ly s i s  as d e s c r ib e d  in sec t ion
3 .1 .5  o f  the  m e th ods .
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3 .4 .4  Fermentation Methods.
T h e  fo l l o w in g  is t h e  m in im u m  m ed ium  d e s ig n e d  f o r  m a x im a l  E. coli 
g ro w th  and  Fab  e x p re s s io n :
C o m p o n e n t  Q u a n t i t y ( g / i )  C o n c e n t r a t i o n ( m M )
Na2H P 0 4 20.1 7  5
KH2PO4 2 .4 5  1 8
N a s C i t r a t e  1.21 4.1
(NH4)2S 0 4 3 .3  5  0
NaCI 6 8
N H 4CI 2 .6 7  5 0
C i t ra te  or
G lu c o s e
C a s e in ( D i f c o )
T h i a m i n e ( 5 0 m g / m l )  
f ron  C i t r a t e ( 3 0 m g / m l )  
T race  E le m e n ts  
N a M o04
C a C I2(1 M)
M g S 0 4(1M)
10 g / I  1%
2 0 g/1 2%
1 2 g / 1 1.2%
1 m I / I  
1 ml / l  
1 m I /1 
1 m l / l
0 . 5  m I/ 1 0 .5
2 0  m I / I  2 0
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101 o f  w a te r  w e re  a d d e d  to  the f e rm e n te r  v e s s e l  c o n ta in in g  all the 
s a l ts  l is ted a b o v e  and  t h e y  w e re  s te r i l i sed  in situ a c c o r d i n g  to the 
f e r m e n t e r  s p e c i f i c a t i o n s .  A l l  o t h e r  m e d i u m  c o m p o n e n t s  w e r e  
s te r i l i s e d  by  a u to c la v in g  s e p e ra te l y .  T h e y  w e re  th e n  a d d e d  upo n  
c o m p l e t i o n  o f  th e  f e r m e n t e r  s t e r i l i s a t i o n  p r o g r a m .  T h e  v e s s e l  
c o n te n t s  w e re  b ro u g h t  to  a  t e m p e ra tu r e  o f  3 7 ° C  a n d  a p H  of  7.0 
(N aO H  and K H 2P O 4  w ere  used  for pH control ) .  T h e  ox y g e n  m e te r  w a s  
th e n  c a l ib ra ted  and  the o x y g e n  leve l  w a s  a d ju s te d  to the  m a x im u m  
level ,  a t  an in le t  p re s s u re  o f  a p p ro x im a te ly  1.5 Bar.  0.5I  o f  cu l tu re  
had  been g row n  up ove rn igh t ,  and th is  w a s  then a d d e d  to th e  vesse l  
w h i c h  w a s  t h e n  s t i r r e d  w i th  an  a g i t a t o r  s p e e d  o f  1000 rpm .  
A n t ib io t i c s  w e re  a d d e d  a l o n g  w i th  the  c u l tu re  a t  the  f o l l o w in g  f ina l  
c o n c e n t r a t i o n s :  C h l o r a m p h e n i c a l ,  3 0 j i g /m l ;  C a r b e n  ici 11 i n , 1 0 0 | i g / m l  
a n d  T e t ra c y c l i n e ,  5 j ig /m l .  T h e  c u l tu re  w a s  a l l o w e d  to g r o w  u n d e r  
the  abo v e  c o n d i t io n s  o v e r n ig h t  us ing P o ly p ro p y le n e  g lyco l  2 0 0 0  (PPG  
I n d u s t r i e s )  as  a n t i f o a m .  G lu c o s e  w a s  a d d e d  to th e  c u l t u r e  at  
in te rv a ls  unt i l  the  op t ica l  d e n s i t y  had  r e a c h e d  a v a lu e  o f  a t  leas t  
60 .0 ,  a t  w h ic h  p o in t  no f u r t h e r  g lu c o s e  w a s  a d d e d  and  t h e  le ve ls  
w e re  m o n i to re d  unt i l  t h e y  re a c h e d  0 .2 %  o r  lower .  T h e  t e m p e r a tu r e  
w a s  th e n  a d j u s t e d  to 3 0 ° C  a n d  IP T G  w a s  a d d e d  to  a f in a l  
c o n c e n t ra t io n  o f  1m M . T h is  w a s  c u l tu red  fo r  a fu r th e r  6 h o u rs  and  
then  ha rves ted .
F iltra t io n  and C oncen tra tion .
Both  o f  th e s e  ta s k s  c o u ld  be a c h ie v e d  us ing  the  P e l l i con  f i l t ra t ion  
s y s t e m  ( M i l l i p o re ) .  A 0 .2 ( iM  f i l te r  w a s  u s e d  fo r  f i l t r a t i o n  a n d  a 
10 0 0 0 M W  c u t  o f f  f i l te r  w a s  used  fo r  c o n c e n t r a t i o n ,  t h u s  re ta in in g
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the Fab (M w  is 500 00 ) .  The  un i t  w a s  a s s e m b le d  and  run a t  an  in le t  
p res s u re  o f  12 P.S.I.  and  an ou t le t  p ressu re  o f  a p p ro x im a te ly  3 P.S.I .  
T h e  o u t le t  p re s s u re  w a s  c o n to l le d  us ing  the  in le t  p r e s s u r e  a n d  the 
f l o w r a t e  o f  t h e  r e t e n í a t e  f r a c t i o n .  T h e  h i g h e r  t h e  r e t e n í a t e  
f l o w ra te ,  i h e  lo w e r  íhe  o u i l e f  p r e s s u r e .  D u r i n g  c o n c e n t r a t i o n ,  the  
re te n ía te  w a s  c h a n n e le d  b a c k  into the in le t  s a m p le  and  the p ro c e s s  
w a s  p e r f o r m e d  c o n i i n u o u s l y  un i i l  i h e  in le i  s a m p le  r e d u c e d  i o  Ihe  
re qu i re d  v o lu m e .  T h e  s u p e r n a ia n i  f rom  a 121 f e r m e n ie r  run c o u ld  be 
re d u c e d  io a v o lu m e  of  5 0 0 m l  in a p p r o x im a ie l y  3 hou rs .  A f t e r  the  
c o m p le t io n  o f  a run, the  s y s te m  w a s  w a s h e d  in w a te r  and  s to re d  in 
0 .0 5 %  s od ium  azide.
3 .4 .5  METAL AFFINITY CHROMATOGRAPHY
C h e la t in g  S e p h a r o s e  Fas t  F lo w  ( P h a rm a c ia )  w a s  lo a d e d  w i th  Z n C l2 
a c c o r d i n g  to m a n a f a c t u r e r s  i n s t r u c t i o n s .  T h e  a n t i b o d y  c o u l d  be  
b o u n d  to the resin  by  e i the r  s t i r r ing  the  a n t ib o d y  and  res in  o v e r n ig h t  
a t  4 ° C  or  by  p o u r i n g  the  c o lu m n  f i r s t  a n d  lo a d in g  th e  a n t i b o d y  
s a m p le  o v e r  the  c o lu m n  a n u m b e r  o f  t im e s  to e n s u r e  t h a t  the  
m a x im u m  a m o u n t  o f  sam p le  had bound .  The  tw o  bu f fe rs  used  to e lu te  
the  a n t ib o d y  w e re  as fo l lows :
B u f fe r  A: 5 0 m M  S o d iu m  P h ospha te
1M S o d iu m  Ch lo r ide  
pH 7.0
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B u f fe r  B: 5 0 m M  S o d iu m  P h ospha te
1M S o d iu m  Ch lo r ide  
1 0 0 m M  H is t i d in e  
0 .5M  Im idazo le  
p H  6.0
T h e  c o lu m n  w a s  run in a g ra d ie n t  o f  0 -1 0 0 %  bu f fe r  B o v e r  a p e r io d  of  
6 h o u rs  a t  a f lo w ra te  of  8 m l/m in .  5 0 m l  f ra c t io n s  w e r e  c o l l e c t e d  and  
e a c h  o f  t h e s e  w e re  a s s a y e d  fo r  Fab c o n te n t  by  d i re c t  E L IS A .  T h e  
c o lu m n  w a s  w a s h e d  af te r  each  run in 5 0 m M  s o d iu m  p h o s p h a te ;  5 0 m M  
E D T A .  A n y  f r a c t i o n s  c o n t a i n in g  F a b  a c t i v i t y  w e r e  p o o le d  a n d  a 
s a m p l e  w a s  a s s a y e d  f o r  p u r i t y  b y  S D S - p o l y a c r y l a m i d e  ge l  
e l e c t r o p h o r e s i s .
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3 .6  METAL METHODS
3 .6 .1  INTRODUCTION.
T h e  f i n a l  a r e a  s t u d ie d  in t h i s  t h e s i s  w a s  t h a t  o f  c a t a l y t i c
a n t i b o d i e s .  T h e  t y p e  o f  c a t a l y s i s  i n v e s t i g a t e d  w a s  t h e  m e t a l -
m e d ia t e d  c le av age  of  a p e p t id e  bon d .  Th is  re q u i re d  th a t  a m e ta l -  
b in d in g  si te be eng ine e re d  into the  a n t ib ody .  It a lso  n e c e s s i t a te d  the  
d e v e l o p m e n t  of  a n u m b e r  of  a s s a y s  to f a c i l i t a te  m e a s u r e m e n t  of  
m e ta l - b in d in g  by the a n t ib o d y  a n d  to m e a s u r e  the  e f fec ts  t h a t  th is  
w a s  hav ing  on the Fab func t ion .  Th is  sec t ion  d e s c r ib e s  the m e t h o d s  
d e s ig n e d  to rea l ise  those  ob jec t ives .
3 .6 .2  CONSTRUCTION OF FAB FRAGMENTS.
T h e  h e a v y  cha ins  used in the c o n s t ru c t io n  o f  t h e s e  f r a g m e n ts  w e r e
c h o s e n  fo r  the i r  ab i l i ty  to b ind g p 120 , w h i le  the  l igh t  c h a in s  w e r e
s e le c te d  base d  on the ir  ab i l i ty  to b ind  m e ta l  ions.  T h e s e  w e r e  then  
t r a n s f o r m e d  and e x p r e s s e d  in E. coii to y ie ld  so lub le  p r o te in ,  as  
d e s c r i b e d  be low.
L igh t chains.
T h e  l i g h t  c h a in s  u s e d ,  in t h e s e  e x p e r i m e n t s  w e re  f l u o r e s c e i n -  
s p e c i f i c  m o u s e  l igh t  c h a in s  s p e c i f i c a l l y  m u t a t e d  to i n c o r p o r a t e  
h i s t i d i n e  r e s id u e s ,  t h u s  a l l o w in g  t h e m  to  b i n d  m e t a l s .  T h r e e  
d i f f e r e n t  m u ta n ts  w e re  p ro d u c e d  as d e s c r ib e d  p re v io u s ly  ( S a s t r y  et 
al., 1989) .  The  f i rst ,  e n t i t le d  LC Q ,  w a s  a l t e r e d  with the  f o l l o w i n g  
m u ta t io n s :  39 R/H, 41 Y/L,  94  S /H  and  96 S/H.  R e s idu es  39 a n d  41 
e x i s t  in the C D R 1 w h i le  94 a n d  96 c o n s t i t u t e  par t  of  the  C D R 3 .
9 4
T h e r e f o r e ,  the  m e t a l - b i n d i n g  s i te  c r e a t e d  by  t h e s e  m u t a t i o n s  
r e s id e s  in the inne r  reg io n  o f  the  a n t ig e n - b in d in g  p o c k e t  ( B r a n d e n  
a n d  T oo ze ,  1991). The  s e c o n d  m u ta n t  LCC w a s  c o n s t ru c te d  w i th  the 
f o l l o w in g  a l te ra t ions :  54 Y/H ,  5 5  K/H and  57  N/H.  A l l  of  t h e  a b o v e  
m u t a t i o n s  are in the  C D R 2  r e g io n  and  so, th is  m e t a l - b in d in g  s i te  
w i l l  r es ide  near  the  o u te r  r im o f  the a n t ig e n -b in d in g  poc k e t .  A  th i rd  
m u t a n t ,  L C Q C ,  w a s  c o n s t r u c t e d  w i th  al l  s e v e n  o f  t h e  a b o v e  
m u t a t i o n s .
E a c h  o f  the  3 c h a in s  w e r e  th e n  a d d i t i o n a l l y  a l t e r e d  in o r d e r  to 
fa c i l i t a te  c o m b in a t io n  o f  t h e s e  m o u s e  l ight  c h a in s  w i th  h u m a n  h e a v y  
c h a in s .  It w a s  d e e m e d  n e c e s s a r y  to s w a p  the  m o u s e  l i g h t  c h a in  
c o n s t a n t  reg ions  fo r  a h u m a n  c o n s ta n t  reg ion  f rom  one  of  t h e  m o s t  
p r o m is c u o u s  l ight cha ins ,  b22.  Th is  w a s  ach ie v e d  by  ove r lap  P C R  in a 
s i m i l a r  w a y  to the  m u t a g e n e s i s  p r o t o c o l  d e s c r i b e d  p r e v i o u s l y  
(F ig u re  3.1).  A m p l i f i c a t io n  o f  t h e  c o n s ta n t  h u m a n  reg ion  in v o l v e d  a 
3 ’ r e v e rs e  pr imer ,  C k 1z, as  d e s c r i b e d  p re v io u s ly ,  and  a 5 '  f o rw a r d  
p r im er ,  C o nK a p .  Th is  p r im e r  c o d e d  fo r  4 res idues  a t  the  5' e n d  o f  the 
c o n s t a n t  reg ion and  5 r e s id u e s  a t  the  3' end  o f  the  v a r ia b le  reg ion  
¡ m e d ia t e l y  u p s t re a m  f r o m  th e  c o n s t a n t  re g io n .  T h e s e  5 r e s i d u e s  
w e re  in c luded  because  they  a re  c o m m o n  to both  the hu m a n  a n d  m o u s e  
s e q u e n c e s  and, due  to an e r ro r  in the m o u s e  l ight  cha in  c o n s t ru c t io n ,  
t h e y  w e r e  m iss in g  f ro m  th is  c h a in .  T h e re fo r e ,  i n c lu s io n  o f  t h e s e  
a m in o  a c id s  in th is  p r im e r  p r o v id e d  an o v e r la p  f o r  th e  P C R  and  
p e r m i t t e d  the i r  r e in s e r t io n  in to  th e  l igh t  cha in .  A m p l i f i c a t i o n  o f  the  
m o u s e  var iab le  reg ion used the  5' fo rw ard  pr imer ,  AK1 (G C C  G A G  C T C  
G T T  A T G  A C T  C A G  A C A  C C A ) ,  and  the  3' reverse  p r im er  V a rC o n .  Th is  
r e v e r s e  p r im e r  c o d e d  fo r  5 r e s id u e s  at  the  3' e n d  o f  t h e  v a r ia b le
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reg ion  and  the  5 m iss ing  res idues,  thus  o v e r la p p in g  w i th  the pr imer ,  
C o nKap .  The  s e q u e n c e s  of both  ove r lap  p r im e rs  are  as fo l lows:
ConKap: 5 '  ctg gag ate aaa cga act  gtg get  gca  3'.
L E l  K R  T V A  A 
Var iab le(over lap)  | C o n s ta n t
V a rC o n :  5 '  ag t  teg ttt ga t  ctc cag ccg ttt gg t  gee tee ace 3'
Over lap | Var iab le
T h e  ov e r la p  P C R  w a s  c a r r ied  ou t  as  d e s c r ib e d  p re v io u s ly  and  the 
resu l t ing  f r a g m e n ts  we re  pur i f ied  and  c lo ned  as  d i s c u s s e d  be low.  
Heavy Chains.
T h e s e  w e re  o b ta in e d  f rom  a l ib rary  c o n s t r u c te d  by  B a rb a s  et al., 
(1991 ) .  T he  m a te r ia l  to c o n s t r u c t  th is l i b ra ry  had  bee n  taken  from 
an  a s y m p t o m a t i c  A ID S  p a t ie n t  and ,  t h e r e fo r e ,  c o n t a i n e d  a h igh 
p r o p o r t i o n  o f  a n t i b o d i e s  s p e c i f i c  f o r  g p 1 2 0 .  T h e  l i b r a r y  w a s  
o b ta in e d  at  the s ta g e  wh e re  on ly  the heavy  c h a in s  had  been  c loned 
into the v e c to r  p C o m b 3 ,  and so w a s  devo id  of  all l igh t  cha ins .
C ons truc t ion  of Expression L ibraries.
T h re e  d is t in c t  l ib ra r ies  w e re  p ro d u c e d  by s e p a ra te l y  c lon ing  each  of 
the  th ree  m u ta n t  l igh t  cha ins  into the h e a v y  cha in  l ib rary  as  fo l lows. 
T h e  l ight  cha in  in se r ts  w e re  p re p a re d  by d ig e s t io n  w i th  the en z y m e s  
S a c l  and  X b a l  (B o e h r in g e r  M a n n h e im )  wi th s u b s e q u e n t  pur i f ica t ion of 
th e  0 .7  k i l o b a s e  f r a g m e n t  on a low  m e l t i n g - p o in t  a g a r o s e  gel , 
f o l l o w e d  by B -a g a ra s e  d ig e s t io n  (N e w  E n g la n d  B io la bs ) .  T he  heavy
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chain library in pComb3 was digested with the same combination of 
enzymes, and was ligated to the insert at 16°C overnight with an 
insert:vector molar ratio of 5:1. The three libraries were subjected 
to 4 rounds of panning as described previously (methods section 
3.2.9). A separate panning was carried out for each library, plus one 
panning was performed using an equal mixture of all three libraries.
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3 .6 .3  SCREENING OF LIBRARIES FOR gp120-BINDING 
CLONES.
A to ta l  o f  1000  c o l o n ie s  w e r e  s c r e e n e d  f r o m  the  3 l i b ra r ie s .  
C u l t u re s  w e re  g rown  in 9 6 - w e l l  t i s s u e  c u l tu re  p la te s  ( C o s ta r  359 6 )  
a nd  so lub le  Fab was  e x p r e s s e d  as d e s c r ib e d  by  C o l le t  e t  al. (1992)  
T h e  p re s e n c e  of  g p 1 2 0 -s p e c i f i c  a n t ib o d ie s  w a s  d e te r m in e d  by  EL ISA,  
in w e l l s  c o a te d  w i th  0.1 u g  11 IB g p 1 2 0  ( A m e r i c a n  B i o t e c n o l o g i e s  
01 2 0 0 1 ) .  S u p e r n a ta n t  f r o m  E. coli t r a n s fo r m e d  wi th  e m p t y  p la s m id  
w a s  u s e d  as  a n e g a t i v e  c o n t r o l ,  w h i l e  an E. coli s u p e r n a t a n t  
c o n t a i n in g  a k n o w n  g p 120 - b in d in g  a n t ib o d y  w a s  e m p lo y e d  as a 
p o s i t i v e  c o n t ro l .  A c lo n e  w a s  d e t e r m i n e d  to be p o s i t i v e  if the  
O .D . ( 5 5 0 n m )  g e n e ra te d  w a s  a t  le a s t  3 t im es  th a t  of  the  n e g a t i v e  
c o n t r o l .
3 .6 .4  ZINC-BINDING ASSAYS.
T w o  m e th o d s  for d e te rm in in g  if the Fabs  bound  Z inc  w e re  used .  The  
f i r s t  m e t h o d ,  i n i t i a l l y  d e v e l o p e d  b y  J o h n a t o n  R o s e n b l u m  
(u n p u b l i s h e d  data) ,  in v o lv e d  an E L IS A  te c h n iq u e .  It w a s  c r i t ica l  tha t  
u l t r a p u r e  ( i o n - e x c h a n g e d  a n d  d i s t i l l e d )  w a te r  w a s  u s e d  fo r  all
d i l u t i o n s  in th is ,  and  a n y  o t h e r  m e ta l - b in d in g  E L IS A  a s s a y s ,  as 
c o n ta m in a t i n g  meta l  ions  w o u l d  y ie ld  in a c c u ra te  resu l t s .  T h e  w e l l s  
o f  a m id a t e d  p la tes  ( C o s t a r  2 0 3 8 8 )  w e re  c o a te d  w i th  5 0 f i l  o f  a 
1 m g /m l  so lu t ion  of  a l i n k e r  m o le c u le  B S 3 (P ie rce  215 7 9 )  a t  4 ° C  for 
4  hours .  Th is  so lu t ion  w a s  t h e n  d i s c a rd e d  and  50 ul o f  a 1 0 m g /m l  
s o lu t ion  of  che la t ing  a g e n t ,  im in o d ia c e t i c  ac id  (S igm a) ,  w a s  a d d e d  
to each  we l l  at  4 ° C  o v e r n i g h t  f o l l o w e d  by  a n u m b e r  o f  w a s h e s  in
0.1 M E D T A  and w a te r .50.uI of  a 1m M  Z inc  solut ion w a s  then  added  for
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1 hour  at  3 7 ° C .  0.1 M EDTA in 1% (w/v)  B S A - P B S  was  added  in the case 
o f  al l n e g a t i v e  co n t ro ls .  T h e  p la te s  w e r e  w a s h e d  10 t im e s  w i th  
0 . 0 5 %  (v/v)  T w e e n - P B S .  10Oul of 3 % ( w / v )  B S A - P B S  w a s  p lac ed  in 
e a c h  w e l l  f o r  1h o u r  a t  3 7 ° C  to  b l o c k  a n y  n o n - s p e c i f i c  s i tes .  
S o lu t io n s  o f  the Fabs,  d i lu ted  in 1% (w /v )  B S A - P B S ,  w e re  then  added  
for  2 hou rs  a t  3 7 ° C .  1% (w /v )  B S A - P B S  w a s  u s e d  as a b a c k g ro u n d  
con t ro l .  T h e  Fab  w a s  de tec ted  us ing an a l k a l i n e  p h o s p h a ta s e - la b e le d  
g o a t  a n t i - h u m a n  F ( a b ')2 a n t ib ody  (P ie rce  3 1 3 1 2 X ) .
Zinc W estern Blots.
T h e  s e c o n d  m e th o d  used to d e te c t  z in c - b i n d i n g  by the Fabs  was  a 
w e s te rn  b lo t t ing  techn ique .  5 | ig of pu r i f ied  F a b  w e re  run on an SDS-  
ge l  (B io -R a d  mini  Pro tean  II s y s tem  1 6 5 - 2 9 4 0 )  and  b lo t ted  on P V D F  
m e m b r a n e  ( B io -R a d  170 -3946) .  The  b lo t  w a s  w a s h e d  fo r  1 hou r  in 
m e ta l - b in d in g  bu f fe r  (100mM  Tr is -HCI ,  pH  6 .8 ; 5 0 m M  NaCI)  a t  room 
t e m p e r a t u r e .  10p.l Z n 6S (A m e rs h a m )  w e re  d i l u t e d  to 5m l  in Blot to ( 
0 .1 6 M  NaCI ;  1 0 m M  Sod iu m  P h os pha te  pH  7 .2 ;  0 .01% (v /v )  th im eroso l ;  
5% (w /v )  n o n - fa t  d ry  milk) and  used to p r o b e  the  blot  for  1.5 hours  at 
r o o m  t e m p e r a t u r e .  Th re e  w a s h e s  fo r  10 m in u t e s  each  w e re  then  
ca r r ied  ou t  on  the  blot  and it was  e x p o s e d  to X - ray  f i lm (A m ersh am )  
fo r  2 d a y s  a t  - 7 0 ° C  in the p re s e n c e  o f  an  a m p l i f y in g  s c reen .  The  
n e g a t i v e  c o n t r o l s  used  .were  o th e r  g p 1 2 0  b in d in g  F ab  f r a g m e n ts  
p r o d u c e d  f r o m  c o m b i n a t o r i a l  l i b r a r i e s  in E. coli th a t  d id  not 
in c o rp o r a te  a m e ta l - b in d in g  site.
Com petition ELISA using gp120 and Z inc.
W e l ls  o f  an  E . I .A . /R . I .A .  96 wel l  E L IS A  p l a te  (Cos ta r )  w e re  coa ted  
w i th  0.1 fj.g 11 I B g p l  20, as d e s c r ib e d  p r e v io u s l y .  Fab  and  c o m p e t in g
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z in c  w e re  then  a d d e d  to a s e r ie s  o f  we l l s ,  as  d e s c r i b e d  f o r  o th e r  
c o m p e t i t i o n  ELISAs,  and in c u b a te d  at  37°C  fo r  2 hours .  T h e  F a b  was
a d d e d  to al l we l ls  at  a c o n s t a n t  d i lu t ion  c o r r e s p o n d in g  to i t ’s t i t re,
w h i le  the z inc  was  added  in a se r ies  of  d i lu t ions  rang ing  f r o m  0.1 mM 
to  10mM. The  we l ls  w e re  w a s h e d  and  the Fab  w a s  d e t e c t e d  us ing  a 
g o a t  a n t i - h u m a n  F ( a b ')2 a n t i b o d y  as  be fo re .  T w o  n e g a t i v e  c o n t ro ls  
w e re  used  in th is EL ISA:  t h e  f i r s t  w a s  the b u f fe r  used  to  d i lu te  the 
a n t i b o d ie s  and  the s e c o n d  w a s  a se t  o f  a n t i b o d ie s  d e s i g n e d  to 
i n c o rp o r a te  a h is t id ine  ta i l  o f  5 h is t id ine  r e s id u e s  at  t h e  c a r b o x y l  
e n d  of  t h e i r  heavy  cha ins .  T h e s e  a n t ib o d ie s  w e re  d e s i g n e d  to b ind 
m e ta l ,  bu t  w o u ld  not  be c o m p e t e d  by the  g p 120 , as  t h e i r  m e ta l  
b ind ing  and  g p 120 b inding s i tes  are  a t  opp os i te  e nd s  of  the  m o lecu le .
B ifunc t iona l ELISA assay.
Th is  EL IS A  was  des igned  to d e te c t  b ind ing  of  the  Fab  to b o th  gp1 20  
a n d  z in c  a t  the s a m e  t im e .  A m id a t e d  p la te s  (C o s ta r )  o r  C o v a l i n k  
p la te s  (Nunc )  we re  c oa ted ,  v ia  a l i nke r  a nd  c h e la to r ,  w i th  z inc ,  as 
d e s c r ib e d  above .  The p la te s  w e r e  then  b lo c k e d  w i th  3 % ( w / v )  B S A -  
P B S  and  incuba ted  with F ab  a t  a d i lu t ion  c o r re s p o n d in g  to  i t 's t i t re,
fo r  1 h o u r  at  37°C .  The  p la te s  w e re  then  in c u b a te d  w i th  gp120 at  a
c o n c e n t r a t i o n  of  2 j i g / m l ' f o r  1 hou r .  A ra b b i t  a n t i - g p 1 2 0  a n t i b o d y  
(A m e r i c a n  B io te c h n o lo g ie s  0 0 0 4 0 2 )  w a s  t h e n  a d d e d  a t  a 1 :1 0 0 0  
d i l u t i o n  fo r  a f u r t h e r  1 h o u r .  T h is  w a s  t h e n  d e t e c t e d  w i th  a 
h o r s e r a d i s h  p e r o x i d a s e - c o n j u g a t e d  g o a t  a n t i - r a b b i t  a n t i b o d y  
(S ig m a ) .  The  an t ib od y  d i lu t io n  bu f fe r  and  a n t ib o d ie s  d e s i g n e d  on ly  
to  b ind g p 120 and not meta l ,  w e re  used  as nega t ive  con t ro ls .
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3 .6 .5  PEPTIDE CLEAVAGE ASSAY.
0.5jog o f  pu r i f ie d  Fab  and  0 .2 j i g  g p 1 2 0  w e r e  a d d e d  t o g e t h e r ,  bo th  
w i th  and  w i th o u t  th e  p re s e n c e  of  1m M  Z n C I 2. Th is  w a s  in c u b a te d  at  
3 7 ° C  o v e r n ig h t  and  then  run on an S D S -g e l  a nd  b lo t ted  o n to  P V D F  
m e m b r a n e  as  b e fo re .  T he  m e m b r a n e  w a s  b l o c k e d  in B lo t to  f o r  2 
h o u rs  a t  ro o m  te m p e ra tu r e  a nd  then  w a s h e d  fo r  0 .5  h o u rs  in 0 .1 %  
(v/v)  T w e e n  T B S  wi th  2 c h a n g e s  o f  buf fer .  It w a s  then  p r o b e d  w i th  a 
1 : 1 0 0 0  d i l u t i o n  o f  r a b b i t  anti-111B g p 1 2 0  a n t i b o d y  ( A m e r i c a n  
B i o t e c n o l o g i e s  0 0 0 4 0 2 )  a t  4 ° C  o v e r n i g h t .  A f t e r  w a s h i n g ,  a 
h o r s e r a d i s h  p e r o x i d a s e - l a b e l e d  g o a t  a n t i - r a b b i t  a n t i b o d y  ( S ig m a )  
w a s  a d d e d  fo r  1 h o u r  at  3 7 ° C .  F ina l ly ,  6 ml o f  a c h e m i l u m i n e s c e n t  
s u b s t ra te  ( A m e r s h a m  E C L  ki t R P N  210 6 )  w a s  a d d e d  fo r  1 m in .  T he  
b lo t  w a s  then  im m e d ia te ly  e x p o s e d  to X -R a y  f i lm  for 10 s e c o n d s  and  
d e v e lo p e d .
CHAPTER 4
4.1 INTRODUCTION.
4 .1 .1  OVERVIEW.
A n im a ls  re s p o n d  to an t igen ic  c h a l le n g e  by g e n e ra t in g  a d i v e r s e  a r ray  
o f  a n t ib o d ie s  ( M a y e r  et al., 1987 ) .  T h e  c h a r a c t e r i s a t i o n  o f  s u c h  a 
r e s p o n s e  w o u ld  h a v e  im p o r ta n t  im p l i c a t io n s  fo r  u n d e r s t a n d in g  the  
in te rp la y  b e t w e e n  in fec t io us  a g e n ts  and  a n t ib o d ie s ,  w h i c h ,  in turn ,  
c o u ld  lead  to th e  p ro d u c t io n  o f  r e a g e n ts  o f  p o te n t ia l  t h e r a p e u t i c  
v a lu e .  T h is  is p a r t i c u la r ly  r e le v a n t  w i th  the  f in d in g  t h a t  a n t i b o d y  is 
c a p a b l e  o f  p r o v i d i n g  p r o t e c t i o n  a g a i n s t  v i r a l  c h a l l e n g e  in 
c h im p a n z e e s  ( B e rm a n  et al., 1991).
A s  w a s  d i s c u s s e d  in sect ion 1.10, h u m a n s  w i l l  r e s p o n d  to  c h a l le n g e  
by  the  H IV  v i rus  by  p rodu c ing  a n t ib o d ie s  d i re c te d  a g a in s t  tw o  m a jo r  
v i ra l  su r face  an t igens ,  gp120  and  gp41 (Kang  et al., 1992 ;  C h a m a t  et 
al., 1992 ) .  M o s t  o f  the  n e u t ra l i s in g  ac t i v i t y  is a s s o c ia t e d  w i th  the  
th i rd  h y p e rv a r ia b le  d o m a in  (V3) o f  g p 1 2 0  (F reed  et al., 1991 )  and  the 
c o n f o r m a t i o n a l l y  sens i t i ve ,  d i s c o n t in u o u s  C D 4  b in d in g  s i te  o f  g p 1 2 0  
(Ho et al., 1991) .  An t ibod ies  to th is  s i te a p p e a r  la te r  in the  c o u rs e  of  
H IV  in fec t ion  a nd  are  c apa b le  o f  neu t ra l i s in g  m u l t ip le  s t ra in s  of  the  
v i rus .  H o w e v e r ,  th is  fo rm  of n e u t ra l i s a t io n  is on ly  o b s e r v e d  a t  low  
d i l u t i o n s  in th e  p a t ie n t ' s  s e r u m ,  s u g g e s t i n g  t h a t  th e  t i t re  a n d /o r  
a f f in i t y  o f  the  a n t ib o d ie s  is low  ( Ho et al., 1 9 8 7 ) .  R e c e n t l y ,  t h e  
im p o r ta n c e  of  a n t ib o d ie s  to the  V 2 loop in the  n e u t ra l i s in g  re s p o n s e  
has  a lso been  repor ted .
T h e  c o m p l i c a t e d  a n d  d i v e r s e  n a tu r e  o f  th e  h u m o r a l  r e s p o n s e  
g e n e r a te d  a g a in s t  HIV,  in c o n ju n c t io n  w i th  the low t i t res ,  h a s  m a d e
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it ve ry  d i f f i c u l t  to s tudy  th is  r e s p o n s e  a t  a m o le c u la r  leve l .  It is 
a lso wel l  k n o w n  tha t  the v i rus  can u n d e r g o  m u ta t io n s  wh ich  re n d e r  a 
p r e v io u s ly  n e u t ra l i s in g  a n t ib o d y  r e s p o n s e  in e f f e c t i v e  ( G o u d s m i t  et  
al., 1991;  N a r a  et al., 1991) ,  w h ich  f u r t h e r  c o m p l i c a t e s  an  a n a ly s i s  
of  th is t y p e .  H o w e v e r ,  it is pa r t icu la r ly  im p o r t a n t  in the c a s e  o f  HIV 
to u n d e r s t a n d  the  in te rac t ions  b e tw e e n  t h e  v i r u s  and  th e  im m u n e  
response ,  in o rde r  to be able to d e v e lo p  a  th e ra p e u t i c  reagent.
4 .1 .2  COMBINATORIAL LIBRARIES.
A s  w a s  d i s c u s s e d  ear l ier ,  an t ib ody  p r o d u c t i o n  a t  p re s e n t  is m a in ly  
in the  r e a l m  of  an im a l  im m u n is a t i o n  a n d  h y b r i d o m a  t e c h n o l o g y .  
H o w e v e r ,  b o th  o f  the se  t e c h n iq u e s  a re  t e d i o u s  and  in e f f i c ie n t  and  
the p r o d u c t i o n  o f  hum an  an t ib o a ie s  is v e r y  d i f f i c u l t  in b o th  c a s e s  
(Roben a n d  O 'Kennedy ,  1991).
It w a s  b e c a u s e  of  these  l im i ta t i o n s  t h a t  w e  c h o s e  to u s e  the  
t e c h n iq u e  o f  c o m b in a t o r i a l  p h a g e - d i s p l a y  l i b r a r ie s  to p r o d u c e  a 
pane l  of  F a b  f ra g m e n ts  spec i f i c  fo r  H IV  s u r fa c e  g ly c o p ro te in  (H use  
et al., 1 9 8 9 ;  M c C a f fe r t y  et al., 1 9 9 0 ) .  T h i s  p r o v id e s  a m e a n s  of  
p ro d u c in g  a  la rge n u m b e r  of  d ive rse  a n t i b o d ie s ,  spec i f i c  f o r  a g iven  
a n t ig e n .  H ig h  a f f i n i t y  a n t ib o d ie s  w e r e  s e l e c t e d  f ro m  t h e  l i b ra ry  
us ing  a p r o c e d u r e  k n o w n  as p a n n in g  ( B a r b a s  et al., 199 1 ) .  B o ne  
m a r row  w a s  ch o s e n  as the source  o f  a n t i b o d y  R N A  for the l ib rary  as  
th is  has b e e n  s h o w n  to be a m a jo r  r e p o s i t o r y  fo r  d i f f e r e n t ia t e d  B 
ce l ls  t h a t  s p o n t a n e o u s l y  p ro d u c e  a n t i b o d y  to m a in ta in  c i r c u la t i n g  
an t ibody  t i t r e s  ( Lum et al., 1990) .  The  R N A  leve ls  in these  cel ls  has  
bee n  s h o w n  to be e le v a te d  up to 1 0 0 0 - f o l d  o v e r  res t ing  B ce l ls  
( S c h i e b l e r  et al., 1978) .  A c o m b i n a t o r i a l  l i b ra ry  w a s  p r o d u c e d ,
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a c c o r d i n g  to  th e  m e th o d s  p r e v io u s ly  d e s c r i b e d  ( m e t h o d s  s e c t io n  
3.2),  us ing  the  b o n e  m arrow  of an a s y m p t o m a t i c  A ID S  pa t ie n t  a n d  a 
pane l  o f  t h i r t y  s ix  Fab f rag m en ts  s p e c i f i c  f o r  111 B g p 1 20, 111 B g p  160, 
S F 2 g p 1 20  a n d  a V3  loop pept ide  J S I S I G P G R A F Y T G Z - C - N H 2 had been 
p ro d u c e d  ( B a rb a s  et al 1993).  The la rge  d i v e r s i t y  o f  Fabs  p r o d u c e d  
f rom th is  o n e  ind iv idua l  p rov ided  and  id e a l  o p p o r tu n i t y  fo r  s tu d y in g  
the h u m o r a l  r e s p o n s e  of  tha t  ind iv idua l  w h e n  c h a l le n g e d  w i th  HIV-1 .
4 .1 .3  GENETIC ANALYSIS.
T h e  i n i t i a l  a n a l y s i s  i n v o lv e d  s e q u e n c i n g  th e  f r a g m e n t s  a n d  a 
m o le c u la r  p ro f i l e  w a s  then car r ied  o u t  o n  al l  the s e q u e n c e s .  Th is  
led to t h e  a r r a n g m e n t  of  all the F a b s  a c c o r d i n g  to h e a v y  cha in  
s equ ence .  T h e  com b ina t ion  of V, D and  J g e n e s  used in each  f ra g m e n t  
w a s  e s t a b l i s h e d  a nd  from this, a n u m b e r  o f  o b s e rv a t io n s  as  to the 
c lona l  o r ig in  o f  th e s e  f ragm en ts  cou ld  be  d ra w n .  A c o m p a r is o n  w a s  
m a d e  b e t w e e n  the  d ive rs i ty  of  h e a v y  a n d  l i g h t  c h a in s  a n d  the  
p r e d o m in a n c e  of  cer ta in  heavy- l igh t  c ha in  c o m b in a t io n s ,  le ad ing  to a 
n u m b e r  of  c o n c lu s io n s  abou t  the in vivo d is t r ibu t ion  of  these  cha ins  
and  the  re la t i v e  con t r ibu t ion  of  each to a n t ig e n  spec i f i c i t y .
4 .1 .4  BIOCHEMICAL ANALYSIS.
T h e  s e c o n d  h a l f  of  th is  s t u d y  i n v o l v e d  t h e  s e l e c t i o n  o f  a 
r e p r e s e n t a t i v e  c ro s s  sec t ion  of  the F a b s  th a t  had p re v io u s ly  been  
a n a ly s e d  a t  a m o le c u la r  level and  t h e  f u r t h e r  c h a r a c te r i s a t io n  of  
t h e s e  a t  a b i o c h e m ic a l  level .  It w a s  c o n s i d e r e d  i m p o r t a n t  to 
es tab l ish  w h e t h e r  the d ivers i ty  of  a n t i b o d ie s  seen  at  a g e n e t i c  level  
w a s  r e f l e c te d  in the  b iochem ica l  p r o p e r t i e s  of  these  m o le c u le s  Th is
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c o u ld  y ie ld  im p o r t a n t  i n fo r m a t i o n  a b o u t  h o w  th e  im m u n e  s y s t e m  
d e a ls  w i th  p h e n o m e n a  such  as  the a r ray  of  e p i to p e s  be ing  p r e s e n te d  
on the  vi ra l  su r face ,  v i ra l  es c a p e  m u ta n ts  and  a n t ig e n  s h e d d in g .  
I n i t i a l l y  th e  e p i t o p e  s p e c i f i c i t y  o f  t h e  F a b s  w a s  e x a m i n e d  by 
c o m p e t i t i v e  E L IS A s  w i th  so lub le  C D 4  an t ig e n  (sC D 4 ) .  T h e i r  a f f in i t ie s  
w e re  a lso  e s ta b l i s h e d  by  m e a n s  o f  inh ib i t ion  E L IS A s .  Bo th  o f  th e s e  
tw o  te c h n iq u e s  ind ica ted  th a t  the se le c te d  F a b s  w e re  v e ry  s im i la r  in 
t e r m s  o f  t h e i r  a f f i n i t y  a n d  s p e c i f i c i t y ,  if no t  id e n t i c a l .  H o w e v e r ,  
n e i t h e r  m e th o d  w a s  t h o u g h t  to be s e n s i t i v e  e n o u g h  to  d e t e c t  a n y  
s u b t l e  d i f f e r e n c e s  in e p i t o p e  s p e c i f i c i t y  w h i c h  m a y  be im p o r t a n t .  
T h e r e f o r e ,  a m e t h o d o l o g y  to  m e a s u r e  t h e  a f f i n i t i e s  o f  t h e s e  
f r a g m e n t s  u s i n g  R e a l - T i m e  B i o s p e c i f i c  I n t e r a c t i o n  A n a l y s i s  
( B I A c o r e ™ )  w a s  d e v e lo p e d  ( K a r ls s o n  et a i ,  1991 ;  V a n C o t t  et al., 
1992) .  Th is  s y s te m  also p ro v id e d  the  m e a n s  to m e a s u r e  the  e p i to p e  
spec i f i c i t y  o f  the Fabs  in g re a te r  de ta i l  than  w i th  the  E L IS A ,  a n d  an 
e p i t o p e  m a p p in g  t e c h n iq u e  w a s  d e v e lo p e d  to  a c h ie v e  th is .  S m a l l  
d i f f e r e n c e s  in s p e c i f i c i t y  t h e n  b e c a m e  a p p a r e n t  b e t w e e n  the  
f r a g m e n t s  s h o w in g  th e y  w e r e  n o t  id e n t i c a l  b i o c h e m ic a l l y .  F ina l l y ,  
th is  w a s  c o n f i rm e d  by  Dr. Jo h n  M oo re  (Aaron  D ia m o n d  A ID S  C en te r ,  
N e w  Y o rk ) ,  us ing  a pan e l  o f  g p 1 2 0  m u ta n ts  in a k n o c k o u t  a s s a y  
s y s te m .  T h is  s y s t e m  is c a p a b le  o f  d e f in in g  a r e a s  or  r e s id u e s  on 
g p 1 2 0  tha t  d i rec t ly  a f fec t  the b ind ing  by the Fab , and so he lp  de f in e  
the  e p i to p e  r e q u i re d  by  the  a n t ib o d y .  U s ing  th is  t e c h n iq u e ,  it w a s  
p o s s i b l e  to s h o w  s ig n i f i c a n t  d i f f e r e n c e s  in e p i t o p e  s p e c i f i c i t y  fo r  
the  Fabs  stud ied.
4 .2  RESULTS
4.2 .1  PANNING OF THE LIBRARY.
T h e  l ibrary was  s u b je c te d  to four  rounds  o f  p a n n in g  a g a in s t  the four 
a n t i g e n s  ( I I IB g p l  20,  S F 2 g p 1 2 0 ,  111 B g p 1 60  a n d  V3 lo op  p e p t id e )  
w h i c h  p r o d u c e d  an a m p l i f i c a t i o n  o f  100  to 1 0 0 0 - fo l d .  E. coli 
X L I B I u e  w e re  then  t ra n s fe c te d  with the p h a g e  a nd  the  g e n e l l l  was
r e m o v e d  f rom  the  r e s u l t i n g  p la s m id  to y ie ld  a l i b ra ry  c a p a b le  of
sec re t ing  so lub le  Fab. F o r ty  co lon ies  w e re  g r o w n  f rom  e a c h  an t igen  
l ib rary  and the s u p e r n a ta n t s  were  sc re e n e d  in E L IS A  a s s a y s  aga ins t  
the  an t igen  used  in p a n n in g .  C lones  y ie ld ing  a pos i t i ve  res u l t  w e re  
then  taken  for f u r th e r  a n a ly s i s .  The  c lo n e s  w e re  a s s i g n e d  n a m e s  
acco rd ing  to the an t igen  a g a in s t  wh ich  they  had  been p a n n e d .  Those  
p a n n e d  a g a in s t  111Bgp 120 w e re  ca l led  bn ,  w h e r e  n is th e  c lo ne  
n u m b e r  (e.g . :  b 1, b2,  e t c . . ) ,  111 Bg p 160 c l o n e s  w e re  c a l l e d  Bn,
S F 2 g p 1 2 0  were sn and V 3  loop c lones were  pn. I I I B g p l 20 w a s  used in
all s ubs e quen t  assays .
4 .2 .2  RELATIVE AFFINITIES.
T h e  re la t ive  a f f in i t y  of  e a c h  c lone  w a s  d e t e r m in e d  by c o m p e t i t i v e  
EL ISA.  N ine teen  Fabs  w e r e  der ived f rom p a n n in g  w i th  I I I B g p l 20 and 
e igh t  f rom pann ing  with S F 2 g p 1 2 0 .  These  w e re  all assaye d  by  EL ISA 
a nd  all gave  s im i la r  a f f i n i t y  c o n s ta n ts  in the  range  1 x 107 to 1x 10s 
M ' 1. S ix teen  c lo n e s  w e re  the p rodu c t  of p a n n in g  with I I I B g p l 60, but 
on ly  six of  these w e re  a l s o  reac t ive to I I I B g p l 20.  The  o the r  ten only 
r e a c te d  v e ry  w e a k l y  w i t h  I I I B g p l 60  a n d  c o u ld  no t  be  a s s a y e d
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fu r the r .  It is p o s s ib le  tha t  th e s e  F ab s  w e r e  d i re c te d  a g a in s t  gp4 1 .  
T h e  a f f i n i t i e s  of  t h o s e  th a t  c r o s s - r e a c t e d  w i th  111Bgp120 s h o w e d  
s im i la r  a p p a r e n t  a f f in i t ie s  to the  111 B g p 12 0 - s p e c i f i c  Fabs. F ou r  Fabs  
w e re  d e r i v e d  f rom pann ing  a ga ins t  V 3  lo o p  pep t ide ,  bu t  on ly  two  o f  
t h e s e  s h o w e d  reac t iv i ty  to g p 1 2 0  (SF2)  w i th  a f f in i t ie s  va lu e s  o f  1 0 8 
M ‘ 1 . A l l  r e la t i v e  a f f i n i t y  v a l u e s  a re  g i v e n  in T a b le  4 .1 .  T h e  
c o m p e t i t i v e  E L IS As  for the S F 2 g p 1 2 0  c lo n e s  are  g iven in F igure  4.1.
log( gp120 m o la r ity )
Figure 4.1: Specif ici ty of ant igen bind ing shown by compet i t ive
ELISA. The Y-axis expresses the O .D .405 as a percentage of the value 
obtained when PBS was used in the place of  compet ing gp120, so giving 
the maximum value. The relative affinity (Ka) for each clone is determined 
to be the molar i ty of compet ing gp120  resul t ing in 50% inhibit ion of 
ant ibody- immobi l ised gp120 binding. Al l values are given in Table 4.1.
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Those Fabs, derived from panning with IIIBgp120 and IIIB gp l60, 
were tested for reactivity against SF2gp120, and all were found to 
react. Therefore, all Fabs, with the exception of those derived from 
panning with V3 loop peptide, reacted with gp120 of either IIIB or 
SF2 strains.
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Panning Antigen Clone Name Ka*108 (M*1) Kj(CD4)*108M-1
g p 1 20 IIIB b 1 5.0 6.0
b 2 7.0 0 .5
b 1 4 5.0 1.0
b 2 4 2.0 5 . 0
g p 1 6 0  IIIB B 2 3 .0 0 .5
B 3 0 0 .4 4 .0
g p 1 2 0  IIIB b 3 3 .0 6.0
b 5 4 .0 5 .0
g p 1 6 0  IIIB B 2 0 0.8 0 . 4
g p 120 SF2 s 2 11.0 0.1
s 3 3 .0 5 . 0
s 5 7 .0 0.2
s 7 11.0 0 . 5
g p 1 20 IIIB b 4 3.0 5 .0
b 7 3 .0 9 .0
b 1 2 7.0 0 . 5
b 21 0.8 0 .9
gp 1 20 IIIB b 6 5.0 0 .4
b 20 6.0 0.1
g p 120 SF2 s 6 7.0 0.8
g p 1 20 IIIB b 8 5.0 2.0
D 1 3 4 .0 5 .0
b 1 8 5.0 0 .5
b 22 3 .0 1.0
b 2 7 5 .0 0 .9
g p 1 60 IIIB B 8 4 .0 0 .3
B 2 6 0.8 0.8
B 3 5 4 .0 0.1
g p 1 20 SF2 s 4 4 .0 0.1
g p 1 20 IIIB b 11 4.0 4 . 0
b 2 9 2.0 0 .3
g p 120 SF2 s 8 11.0 0.1
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4.2.3 CD4 INHIBITION ELISAs.
The Fabs were screened for CD4 inhibition of their binding to 
111 Bgp 120 and all, with the exception of the V3 loop binders, showed 
sensitivity to CD4 inhibition (Table 4.1). The inhibition constants 
were in the range 1X107 to 1X109 M -1 and were generally greater 
than the corresponding affinity constants. The CD4 inhibition curves 
for the SF2gp120 clones are given in Figure 4.2.
log (CD4 molarity)
S2
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s6
-------1— s7
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Figure 4.2: Graph showing specificity of SF2 gp120 Fabs for the
CD4-binding site of gp120, by competition ELISA with soluble CD4. The 
Kj values for these and all the other Fabs are given in table4.1 .Loop 2 is 
a Fab Specific for the V3 loop peptide and was included as a negative 
control in this experiment, since it should not be inhibited by sCD4.
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4.2.4 SEQUENCE ANALYSIS.
Thirty three heavy chain variable regions (VH) and corresponding 
light chain variable regions (VL) were sequenced and are given in 
Figures 4.3 and 4.4, respectively. It was immediately obvious that 
the heavy chains could be separated into eight groups on the basis of 
close relationships in their sequences, as is shown in Fig. 4.3. The 
light chains were organised into the same groups as defined by their 
corresponding heavy chain. The predominant sequence for each of the 
groups is given in full, while the sequences of the remaining 
members of the group are given as a series of dots to indicate 
similarity to the predominant sequence. Only those residues that 
differ are shown. It is interesting to note that the members of a 
particular group have not necessarily been panned with the same 
antigen. This demonstrates that it is possible to use a number of 
slightly different antigens to isolates Fabs with similar primary 
sequences.
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Figure 4.3: Amino acid sequences of the variable heavy (VH) regionsof the Fabs binding to gp120. The
predominant sequence in each group is given in full. Simialrities to this in the other sequences are 
indicated by a dot, while differences are given.
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Figure 4.4: Amino acid sequences of the variable light regions of the gp120 binders. These are arranged
into groups according to their corresponding heavy chains in fig.4.3.
4.2.5 Heavy Chains.
The first observation to make is that the similarity of sequence 
within a particular group is subject to variation. The group headed 
by clone b8 exhibits a very high degree of sequence-similarity 
between its members, with an average discrepancy between 
sequences of only 1.1. This figure is comparable to the typical rate 
of error for PCR using Taq polymerase (Saiki et a!.., 1985; Tindall e t
a!.., 1988), and so these chains may originally have been all be
identical, while any differences may simply be an artifact arising 
from the PCR. It is also interesting to note that there is only 1 
difference in the CDR3 region implying that the same V-D-J
combination is used in a.\ cases.
The b3 group display a greater diversity than the b8 group, having an 
average discrepancy of 3.3. This would suggest that these are all 
somatic variants of one particular sequence.
The b1 group show a different pattern. Clones b1 and b14 are very 
similar to one another, as are clones b2 and B2. However, these two 
pairs differ from one another by twenty three amino acids. The 
remaining two members of the group are quite dissimilar from each 
other and from the two pairs b1/b14 and b2/B2. However, all the 
members of this group are very similar in their CDR3 sequences, 
suggesting that they use the same D-J segments. This may be 
explained either by extensive somatic mutation, cross-over events 
between different germline genes and the same D-J region, or a 
convergent type of evolution in an effort to conserve that particular 
D-J region.
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A further analysis of the germline genes shows that the homology 
between these genes and the Genbank database of VH is less than 
90%, which would suggest that these are completely new germlines, 
or that extensive somatic mutation has occurred. The exception to 
this is the b8 group which shows 93% homology with germline 2P1 
(Schroeder et al., 1987).
All the members of a particular group use the same JH minigene 
(Figure 4.5b). However, the overall usage of these genes is unusual in 
that 4 groups use JH6, 3 use JH3 and 1 use JH4. JH6 is usually used 
to a lesser extent than the other 2. (Yamada et al., 1991; Sanz, 1991)
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Jk i:  t g g  acg t t c  ggc caa ggg acc aag g t g  gaa a te  aaa c g t .
W T F G G G T K V E  I  K R
Jk2: ta c  a c t  t t t  ggc cag ggg acc aag c t g  gag a te  aaa c t g .
Y T F G G G T K L E I K R
Jk3 : t t c  a c t  t t c  ggc c c t  ggg acc aaa g t g  ga t a te  aaa c g t .
F T F G P G T K V D I K R
Jk4: c tc  a c t  t t c  ggc gga ggg acc aag g t g  gag a te  aaa c g t .
L T F G G G T K V E  I  K R
(A)
JH3: g e t  t t t  g a t  g t c  tg g  ggc caa ggg aca a tg  g tc  acc g t c  t c t  t e a .
A F T V W G G G T M V T V S  S
JH4: tac  t t t  gac ta c  tgg  ggc caa gga acc c tg  g tc  acc g t c  t e c  te a .
Y F T Y W G G G T L V T V S  S
JH6: ta c  tac  g g t  a tg  gac g tc  tg g  ggg caa ggg acc acg g tc  acc g t c  t e c  tea .
Y Y G M D V W G G G T T V T V S S
(B)
Figure 4.5: J gene sequences utilised by a) the light chains and b) the
heavy chains in the Fab fragments being analysed in this study. The 
nucleotide sequence is given for each, followed by the equivalent amino 
acid sequence. All sequences taken from Kabat e ta i,  (1987).
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Analysis of the D genes (Ichihara et al., 1988) used has proven to be 
very difficult, as there is a lack of homology with known sequences. 
This would suggest either modification through somatic mutation, or 
the presence of thus-far unknown D genes. However, within the 
groups there is a remarkable conservation of length and sequence of 
the CDR3 regions, suggesting that all the members of a group use the 
same D-J combinations or that they are variants of one another. It is 
also notable that most VH use the DXP1 sequence (Figure 4.6).
Figure 4.6 shows a selection of germline D segments displaying the 
greatest homology to a representative member from each group (see 
legend, page 122). The b8 group all use the DXP1 sequence at the 
core, perhaps flanked by a large N segment. The b3 group may 
represent a fusion of the DXP1 to an inverted DK1 segment as is the 
case with s7, while all the other members of the group may be 
somatic variants of this. The b1 group do not show significant 
homology with any of the known D sequences and so are difficult to 
analyse.
b l , bl4 acggcgcgaacgaggatggaaccctagggcccttcgaggt
DIR2 cg**g*ga*c**g*****aa*cc*ag**ccc**c*agg
DIRI aacgag
DMl tggaac
DM2 ggaacc
b 2 , B2 acggcgcgaacggggatggaatcctagggccctcgtcggt
DIR2 cg**g*ga*c**g*****aa*cc*ag**ccc*
DXPl cgggga
Al gggga*ggaa
DHQ52 c*aacgggga
DIRI agggc*c*cgtcgg
DIR1/2RC ggaatcc*a*g
DN4 ctcgtc
b 2 4 acggcgcgaacgaggatggaaccctcgggcccttcgaggt
DIR2 cg**g*ga*c**g*****aa*cc**g**ccc**c*agg
AIRC accctc
DIRI/2 aacgag
DMl tggaac
DM2 ggaacc
B 3 0 gcggcgcgaacgaggatggaatcctagggcccttcgaggt
DIR2 cg**g*ga*c**g*****aa*cc*ag**ccc**c*agg
DFLI6 tggaatcc*a
IRl/2 gaatcc*ag
b 3 aaatatccgcgctactcggatatggtgactggtgttcgaaacc
DXPl ta* t **gatat * *tgactggt * *t * **aac
DXPlRC aaatatc
DXP'l tatggt
DIR1/2 ggtgttc
DLRl ggatat*gt*actggtg
DLR2 gctactc
b 5 aaatatccgcgctactttgatatgatggctggtgttcgaaacc
DXPl ta*t**gatat**tg*ctggt**t***aac
DXPlRC aaatatc
21.10 tatgat
DIR1/2 ggtgttc
DLR5 ctactt**tatg
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B 2 O aaatatccgcgctactctgatatgatggctggtgttcgaaacc
DXPl ta*t**gatat**tg*ctggt**t***aac
DXPlRC aaatatc
21.10 tatgat
DIRl/2 ggtgttc
DLR2 gctactc
DN1/DN4 gctggt
s 2 aaatatccgcgctactcggatatgatgactggtgttcgaaacc
DXPl ta*t**gatat**tgactggt**t***aac
DLRl ggatat**t*actggtg
21.10 tatgat
DLR2 gctactc
s 3 aaatatccgcgctactctgatatgatggctggtgttcgaaacc
DXPl ta*t**gatat**tg*ctggt* *t***aac
DXPlRC aaatatc
21.10 tatgat
DIRl/2 ggtgttc
DLR2 gctactc
DN1/DN4 gctggt
s 7 aaatatccgcgctattatgacatgatgagaggtgttcgaaacc
DXPl g*tatta*ga*at**tga**ggt**t***aac
DXPlRC aaatatc
22.10 tattatga
22.12 tattatga
DXP'l tattat*ac
DIRl/2 ggtgttc
b 4 ggggccatatagttgggatgattctccccaggacaattattat
DKl atatagt*g**a*gatt
DLR3 catat*gt*g*g*tgatt
DLRlRC at*c*ccccag*acaat*at**t
DXP1l/DXPl/23.7 ttattat
DIRl/2 cccagga
b 6
cagaagcccaggtatttcgatcttttgagcggtcaatatcgcagagttgccggtgc
g
DXPl gtatt*cgat*ttttga**ggt*a*tat**c
DIRl/2 ca*aagcccag
DIR2
cgcagag***ccg
121
b 8 tattgggttaaagggcgagcattacgacattttgactgcttacggcccc
DXPl g*attacga*attttgactg*tta
DA5 tattgg
DIR1/2 a*agggcg
DKl tgg*t**a**ggc*a**attac
DN4RC gg*cgagc
bl 1 agatatccgcgctactctgaaatgatgggtggtgttcgaaaacac
DXPl ta*t**ga*at**tg**tggt**t****aa
DIR1RC aga*atccgcg
DIR2RC tgggtgg*g
DKl gatat****gctac
DLRl ggtggtgt
DLR2 gcgctactc
s 8 tcgtcggttggtcacatttgggggagttgtctcaggagggaat
21.10 gt****tg*t*ac*tttgggggagtt*tct*a
Al gaggg*at
p 3 5 aacacccgagaaaacatagaagcagatggtacggcc
DNl atag*agcag*tggtac
DlRl/2 aacaccc
Figure 4.6: Analysis of known D-gene segments with greatest
homology to the CDR3 regions of the gp120 binding Fabs. The CDR3 
sequence of the Fabs are given as the predominant sequence in each 
group. All known D segments with homolgy to the predominant sequence 
are then listed. Identical bases are indicated, while stars represent 
insertions in the predominant sequence, not present in the D segment. 
Non-listing of the D segment sequence implies that the D region does riot 
extend to that area of the CDR3 sequence.
4.2.6 Light Chains.
Analysis of the light chains is made difficult by the fact that
generally, they are more diverse than the heavy chains and it seems 
that a large number of different light chains are capable of 
combining with relatively similar heavy chains. It is also apparent 
that there is a remarkable bias in germline usage since thirteen of 
the thirty three light chains are probably related to germline
Humkv325 (Meindl et al., 1990).
Group b8 display a high degree of homology, with four chains being 
almost identical and the others could be somatic variants of this. As 
the heavy chains in this group are also very similar, this would seem 
to suggest a preference for one particular heavy-light chain
combination. The light chains of group b3 are far more diverse in 
sequence exhibiting a high degree of promiscuity with their heavy 
chains. The distribution of light chains in group b1 is similar to the 
equivalent group of heavy chains suggesting that, as in group b8, 
there is a preference for particular heavy-light chain combinations. 
Finally, homology of light chains is generally greatest between 
members of the same group. However, this is not always the case. 
For instance, clones b6 and B20 from different groups show 99.5% 
homology over their entire VJ sequence.
The usage of Jk minigenes (Figure 4 .5a). is different from the heavy 
chain situation, in that not all the members of a group necessarily 
use the same J segment. However, there is a significant bias in the 
Jk usage with Jk2 occurring in 61% of sequences, Jk4 in 18%, Jk1 in 
15% and Jk3 in 6%.
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4.2.7 BIOCHEMICAL ANALYSIS.
Six clones were chosen to perform a biochemical analysis. These 
were clone numbers b3, b6, b11, b12, b13 and b14. As can be seen 
from figure 4.3, this includes a representative from each of six 
groups, excluding s8 and the V3 loop-binding Fab.
4.2.8 CD4 INHIBITION ELISAs.
Previously it has been shown by Chang-Yuil Kang et a!., that two 
major groups of neutralising anti-gp120 antibodies exist in HIV- 
infected patients, namely, those that react with either the V3 loop 
or the CD4-binding site of gp120. Once soluble Fab fragments had 
been made, one of the first tasks was to investigate the class of 
antibody to which these belong. This was done by means of a CD4 
competition ELISA where the effect of serially diluted soluble CD4 
(sCD4) on the binding of the Fabs to 11 IB gp120 was demonstrated 
(Figure 4.7). As can be seen from the data, all clones are inhibited by 
75% at a sCD4 concentration of 10-6M, while a V3 loop-binding 
fragment is only inhibited by 10% at this concentration. Direct ELISA 
also confirmed that these clones do not bind the V3 loop peptide of 
gp120. It can, therefore, be assumed that all the fragments are 
specific for epitopes that reside around the CD4-binding site of 
gp120.
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Figure 4.7: CD4 competition ELISAs for those gp120 binding clones
used in the biochemical analysis showing that these Fabs are specific for 
the CD4 binding site of gp120. Loop 2 is again included as a negative 
control and is not inhibited by sCD4 to the same extent as the other 
clones.
4.2.9 DETERMINATION OF RELATIVE AFFINITIES.
In order to ensure that none of the differences seen in the binding 
pattern of these fragments was due solely to differences in affinity, 
it was necessary to accurately determine the relative affinity of 
each. The first method used to do this was a competitive ELISA, in 
which soluble and immobilised 11 IBgpl 20 competed for purified Fab 
preparations. The relative affinity constant was taken as the
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molarity of free gp120 which inhibited binding by 50%. As can be
seen from the graph (Figure 4.8), the relative affinities for all the
clones are very similar, lying in the range of 1x107 to 1x108 M 1.
This would also seem to demonstrate the specificity of the clones,
since polyspecific antibodies tend to bind with relative affinities of 
1 0 6 M '1 and lower (Rosenburg et a i ,  1991). The 50% inhibition 
constants for sCD4 and the relative affinities of all clones are given 
in Table 4.1. However, such a methodology is appropriate only to give 
a rough measure of affinity, which meant that it was impossible say 
whether the differences in relative affinities seen by ELISA were 
real or artificial. It was, therefore, decided to measure the 
affinities of these clones using real-time biospecific interaction 
analysis (Biacore™) in order to obtain more accurate values. The 
results for clone b 12 are presented here to illustrate the type of 
data that was obtained using Biacore. The results for the other 
clones are not shown, but are very similar to b12. All results are 
given in the form of sensograms. The binding of antibody to antigen 
is measured by the machine as a shift in the angle of reflection of a 
light beam. This is converted to response units (RU) which is 
dierectly prortional to the mass of bound antibody. The response is 
given as a graph of RU versus time and this is represented as a 
sensogram.
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Figure 4.8: Antigen specificity demonstrated by competitive ELISA with
gp120. The relative affinity (Ka) for each clone is the molarity of 
competing gp120 capable of inhibiting binding by 50%. It can be seen 
that the Ka values for all these Fabs lie in the range of 108M'1.
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4.2.10 Fab BINDING TO IMMOBILISED gp120.
An example of a sensogram showing Fab b12 binding is shown in 
Figure 4.9(a). The initial report point (illustrated by an 'x' on the 
curve) represents the baseline response to a continuous flow of PBS 
over a flowcell containing immobilised gp120. The subsequent rise 
in the response is the binding of the Fab to the gp120. Report points 
are taken during this phase at 10 second intervals in order to be able 
to calculate the association constant of this Fab. Surface 
regeneration is then achieved by an injection of 10mM HCI and is 
demonstrated by the fact that there is no difference between the 
first and last report points, i.e.: there is no Fab remaining bound to 
the gp120 once the run has been completed. This procedure is 
repeated for a number of different Fab concentrations and the 
interaction curve for each is analyzed as a dR/dt versus R plot 
(where R is the level of binding, given as Response Units (RU) and t 
is time as measured in seconds). The interaction curves for b12 at 
steady state binding are represented as an overlay plot in Figure 
4.9(b). The slope value for each graph is then plotted versus antibody 
concentration, and K0n, the association constant, is obtained from 
the slope of the fitted line as shown in Figure 4.9(c).
4.2.11 CALCULATION OF THE DISSOCIATION CONSTANT, 
K 0ff
Antibody is permitted to bind to gp120 until equilibrium is reached. 
This is achieved by using a high Fab concentration, typically 
150|ig/ml, and by immobilising low amounts of gp120, in this case, 
700RU. The antibody is then dissociated from the antigen by passing
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PBS over the complex at a flowrate of 50jil/mln. It is during this 
phase that report points are taken for calculations. The high 
flowrate ensures that there is no binding-rebinding effects, which 
would interfere with the calculation of K0ff- The interaction curve 
for dissociation is then represented as a ln(Ro/Ri) versus tj-to plot 
(Rj is the response at time tj; Ro is the initial response at time to), 
as in Figure 4.9(d) and the slope of this curve is taken as the 
dissociation constant. Relative affinity is calculated as K0n/K 0ff. The 
relative affinities for a number of clones used in this study, as 
calculated by BIAcore, are shown in Table 4.2. These results are very 
reproducible, with a standard deviation from the mean of 
approximately 5%, as determined by calculating a number of these 
constants in triplicate. They also show that there is very little 
difference between the relative affinities of any of these clones, 
which indicates that any differences identified in the binding 
patterns of these Fab fragments is not due to differences in affinity. 
All Fabs examined have affinities in the range 5x107 to 1x108 M '1. 
This is an accurate corroboration of the results obtained by ELISA.
" ^ ^ ^ V A L U E
konCM-'s'1) koff(s_1) Ka (M'1)
b3 9.6*103 1.8*10"* 5.1*10?
b6 1.6*104 1.6*104 9.7*107
b l2 4.5*104 4.3*104 i . i* io 8
b l3 1.1H 04 1.4*10 4 7.9*107
T A B L E  4.2
Table 4.2: Relative affinities of the six Fabs used in the biochemical analysis 
obtained with BIAcore. The values given here are accurate to within +/-
5%.
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4.2.12 EPITOPE MAPPING.
Since these antibodies are all very similar in terms of affinity and 
inhibition by sCD4, it was sought to determine if the epitopes 
recognised by these Fabs on gp120 are all identical, or whether the 
human response we are studying involves a number of related but 
non-identical epitopes around the CD4 binding site of gp120. This 
could be important both for understanding the human response to 
HIV, and to understanding the mechanism by which the virus binds 
CD4 in vivo.
4.2.13 COMPETITION OF ANTIBODY 13 WITH Fabs.
The most obvious method to determine the epitope specificity of 
these Fabs was to perform a competition ELISA in which the 
fragments compete with each other for binding to the immobilised 
antigen. This was achieved by competing each Fab used in this study 
with whole antibody 13. The titre of this antibody, as previously 
determined by ELISA, was 1:10000, and so this dilution was used in 
all wells of the ELISA plate. The Fabs all had titres in the range 
1:4000 (25ng/ml) to 1:8000 (12.5ng/ml), and these were diluted in a 
serial dilution of 1:100 (100ng/ml) to 1:32000 (3.125ng/ml). As can 
be seen from the graph (Figure 4.10), almost all the Fabs had 
inhibited the binding of b13 by 50% at a dilution of 1:5000, which is 
approximately equal to their titres. This would indicate that their 
epitopes are sufficiently similar to that of b 13 to enable them to 
compete with it in an ELISA assay. Moreover, since all the clones 
compete with b 13 to approximately the same extent, it may be
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concluded that all the fragments bind to overlapping, but not 
necessarily identical epitopes.
3
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Figure 4.10: Competition of whole antibody 13 (Ab13) with the Fabs. The
titres of these Fabs are in the range 12.5ng/ml to 25ng/ml. It can be seen 
that b13 is inhibited by 50% by Ab13 within that range as expected. The 
other Fabs are similarly inhibited, within the error rate for this type of 
ELISA.
4.2.14 EPITOPE MAPPING WITH BIACORE.
An alternative, and more precise method for determining similarity 
of epitopes is using the BIAcore. In this situation, a polyclonal anti- 
human F(ab ' )2 is immobilised to the sensor chip and used to capture
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an initial Fab. This, in turn was used to capture gp120, and finally a 
second Fab was injected. Binding by both Fabs, as measured in 
response units (RU), indicates that their epitopes are distinct from 
one another. Conversely, a lack of binding by the second antibody 
indicates that the two Fabs share the same epitope.
The results of this experiment are shown in Table 4.3. 4.3(a) shows 
the positive and negative controls for the clones used. The positive 
controls are the RU levels obtained when the first Fab used is the 
clone as indicated and the second Fab is an anti-gp120 V3-loop Fab, 
which should not share any epitope with our clones since they are all 
CD4 inhibited. As can be seen from the table, all positive controls 
result in significant values of 99 or more, validating that the 
technique does work in the case of non-identical epitopes. The 
negative controls are the values obtained when both the first and 
second Fabs are the same in each case, as indicated. This gives the 
background values for each clone, and these values were subtracted 
from all subsequent experiments in order to give true readings.
An epitope map, Table 4.3(b), was then constructed with clones 
b3,b6,b11 ,b12,b13,and b14. It can be seen from this map that any 
combination of Fabs b3,b6,b11 and b14 results in no binding of the 
second antibody, i.e. RU=£0. This would suggest that all the clones in 
this set share an almost identical epitope. However, Fabs b12 or b13 
appear somewhat different in that they do compete with members of 
the above set but not as effectively as within the set. b12 and b13 
are also dissimilar from one another. It could be inferred from this 
that the epitopes of b12 and b13 are sufficiently dissimilar from 
those of the other four and from each other, to allow for a certain
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amount of low affinity binding when they are used in combination 
with any of the other clones.
It may, therefore be concluded, that clones b3,b6,b11 and b14 bind 
similar epitopes, with b12 and b13 showing some distinct features 
not found in the others. Interestingly, it is these two Fabs which 
have been generally shown to neutralise virus (Barbas et al., 1992), 
while the other four display little or no neutralisation capability.
3 6 11 12 13 14
POSITIVE 129 128 131 125 135 134
NEGATIVE 24 38 - 17 15 -
TABLE 4.3(a)
13 12 6 3
14 30 24 14 0
11 54 28 14 0
3 26 29 0 0
6 21 17 0
12 22 0
TABLE 4.3(b)
Table 4.3: BIAcore epitope maps for the six Fabs analysed, a): Positive and 
negative values for each of the Fabs. b): Values obtained when the 
different combinations of Fabs were used. The Fabs shown on the top 
row represent those used as the first antibody to immobilise the gp120 
initially, while those along the side, represent the secondary Fabs used 
in each case. The negative value subtracted in each run was that 
obtained for the primary Fab.
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4.2.15 gp120 KNOCKOUT ASSAYS.
In order to obtain a clearer picture of the specific details of each 
epitope, gp120 knockout assays were performed. This essentially 
involved examining the binding pattern of our Fabs with a panel of 
gp120 molecules, each of which was altered with a different, 
specific mutation (Olshevsky, et a i ,  1990). This would yield 
information as to which residues are important for the binding of 
the individual clones to gp120 and would enable us to define more 
accurately the epitopes. The results of these assays are shown in 
Figure 4.11(a-f). It had previously been demonstrated that there are 
a number of positions very important for the binding of monoclonal 
antibodies (MAb) directed against the CD4 binding site of gp120, and 
that if these residues are mutated, this inhibits the binding of these 
antibodies. These mutations include residue 257 mutated from 
Threonine to Arginine (257 T/R), 368 D/R, 370 E/R and 457 D/A 
(Olshevsky et a i ,  1990; Thali et a i,  1991). Inhibition of binding as a 
result of these mutations is a common feature of CD4 binding site 
antibodies and, as can be seen from the figure, are a common feature 
of our Fabs, showing that they are, indeed, directed against that area 
of gp120. The only two clones not inhibited by mutation 257 T/R are 
numbers b6 and b12. Fab b3 binding is not affected by mutation 
457D/R. However, 457 D/A does inhibit binding by this Fab, with a 
binding index of 0.42 (data not shown). Therefore, b3 is also specific 
for the CD4-binding site.
Some of the other major features of this study are also shown in 
Figure 4.11. Enhancement of binding as a result of mutations at the 
base of the V1/V2 loop are usually accompanied by mutation 166 R/L
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and are not uncommon with this type of antibody. This effect is seen 
in the case of clones b6,b11,b12 and b13. Fab b14, however, exhibits 
an unusual knockout effect induced by mutation 113 D/A at the base 
of the V1/V2 loop.
In one particular mutant of gp120, the V1/V2 loop (residues 119- 
205) is completely removed. It has been previously demonstrated 
that this type of change can actually enhance the binding of CD4 
site-specific antibodies to gp120, as is the case with clones b6,b11 
and b14 from our study. However, clone b12 exhibits the highly 
unusual effect of having its binding completely knocked-out by this 
mutation, suggesting that the V1/V2 loop is important for binding by 
this Fab.
Mutations at the base of the V4 loop (residues 393 to 414) are
known to affect the binding of certain MAb specific for the CD4
binding site of gp120. This usually manifests itself by enhancing 
binding by the antibody, as is demonstrated here in the case of 
clones b3 and b12. However, a more uncommon effect is apparent in 
the binding pattern of Fab b13. The binding of this clone is 
completely prevented by mutations 384 Y/E and 386 N/R, both of 
which are at the base of the V4 region. Other mutations in this area
are also capable of inhibiting binding of clones b11 and b 14,
although to a lesser extent, for example 386N/G in both cases. On 
the other hand, some of these mutations, such as 435Y/S and 
438P/R, are capable of enhancement.
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Finally, it is interesting to note that mutations in the V3 loop of 
gp120 are capable of partially inhibiting binding by a number of 
these Fabs, namely 314 G/W which inhibits binding of clones b6,b11 
and b14 and mutations in residues 308 to 310 capable of inhibiting 
clone b12.
Figure 4.11: Graphs a-f represent the knockout patterns observed for the
six clones used in this analysis. The gp120 muations are given on the Y- 
axis, while the binding indices are plotted on the X-axis. A binding index 
of 1.0 indicates no effect; below 0.5 suggests an inhibitory mutation; 
above 1.5 Implies an enhancing effect.
V1 / V2 -
BASE 
OF 
V1 /V2
BASE
OF
V4
257 T/R 
368 D/R 
370 E/R 
457 D/R 
NO V1/V2 
166 R/L 
179/180 LD/DL 
183/184 PI/SG 
113 D/A 
117 K/W 
120/121 VK/LG 
207 K/W 
256 S/Y 
NO V3 
314 G/W(V3) 
OTHERS 
386 N/G 
420 i/R 
427 W/S 
433 A/L 
435 Y/S 
438 P/R 
456 R/K 
NO V1/V2/V3
{
0 . 0 0 . 5 1 .0 1 .5 2 . 0 2 .5
4.11(a): KNOCKOUT DATA FOR Fab 3
1 4 0
BASE 
OF •
V1 /V2
V1 /V2
BASE
OF
V4
257 T/R 
368 D/R 
370 E/R 
457 D/R 
NO V1/V2 
166 R/L 
179/180 LD/DL 
183/184 PI/SG 
113 D/A 
117 K/W 
120/121 VK/LG 
207 K/W 
256 S/Y 
NO V3 
314 G/W(V3) 
OTHERS 
386 N/G 
420 l/R 
427 W/S 
433 A/L 
435 Y/S 
438 P/R 
456 R/K 
NO V1/V2/V3
{
0 . 0 0.5 1 . 0 1 .5 2 . 0
4.11(b): KNOCKOUT DATA FOR Fab 6
V1 / V2 H
BASE 
OF 
V1 / V 2
BASE
OF
V4
257 T/R 
368 D/R 
370 E/R 
457 D/R 
NO V1/V2 
166 R/L 
179/180 LD/DL 
183/184 PI/SG 
113 D/A 
117 K/W 
120/121 VK/LG 
207 K/W 
256 S/Y 
NO V3 
314 G/W(V3) 
OTHERS 
386 N/G 
420 l/R 
427 W/S 
433 A/L 
435 Y/S 
438 P/R 
456 R/K 
NO V1/V2/V3
{
0.5 1 .0 1 .5 2. 0
4.11(c): KNOCKOUT DATA FOR Fab 11
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BASE 
OF 
V1 /V2
V1 / V2 -
BASE
OF
V4
257 T/R 
368 D/R 
370 E/R 
457 D/R 
NO V1/V2 
166 R/L 
179/180 LD/DL 
183/184 PI/SG 
113 D/A 
117 K/W 
120/121 VK/LG 
207 K/W 
256 S/Y 
NO V3 
114 G/W(V3) 
OTHERS 
386 N/G 
420 l/R 
427 W/S 
433 A/L 
435 Y/S 
438 P/R 
456 R/K 
NO V1/V2/V3
r
0.5 1 . 0 2 . 5
4.11(d): KNOCKOUT DATA FOR Fab 12
V1 /V2
BASE 
OF ■ 
V1 /V2
BASE
OF
V4
257 T/R 
368 D/R 
370 E/R 
457 D/R 
NO V1/V2 
166 R/L 
179/180 LD/DL 
183/184 PI/SG 
113 D/A 
117 K/W 
120/121 VK/LG 
207 K/W 
256 S/Y 
NOV3 
314 G/W(V3) 
" OTHERS 
386 N/G 
420 l/R 
427 W/S 
433 A/L 
435 Y/S 
438 P/R 
456 R/K 
NO V1/V2/V3
{
0 . 0 0.5 1 .0 1 .5 2.0
4.11(e): KNOCKOUT DATA FOR Fab 13
1 4 2
BASE
OF ■ 
V1 /V2
V1 / V2
BASE
OF
V4
257 T/R 
368 D/R 
370 E/R 
457 D/R 
NO V1/V2 
166 R/L 
179/180 LD/DL 
183/184 PI/SG 
113 D/A 
117 K/W 
120/121 VK/LG 
207 K/W 
256 S/Y 
NO V3 
.-314G/W(V3) 
OTHERS 
386 N/G 
420 l/R 
427 W/S 
433 A/L 
435 Y/S 
438 P/R 
456 R/K 
NO V1/V2/V3
2.5
4.11(f): KNOCKOUT DATA FOR Fab 14
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4 . 3  DISCUSSION.
4.3.1 VALIDITY OF THE COMBINATORIAL LIBRARY 
APPROACH.
The phage display library system has been shown to be very 
successful in isolating a large number of diverse, high affinity, 
antigen-specific Fab fragments (Scott et. a i ,  1991; Devlin et. a!., 
1990) as can be seen from the number of Fabs generated against 
gp120/gp160 in this study. Four rounds of panning lead to an 
enrichment of 100 to 1000-fold, which is a very significant, and 
greatly increases the chances of obtaining the required clones, over 
techniques such as plaque-lift assays described by Persson et a i,  
(1991). This study has also demonstrated that the Fabs isolated here 
have high relative affinities (10s M '1) as a result of expressing the 
fragments as a fusion product with the genelll (gill) product coat 
protein. This leads to a monovalent expression of the Fabs on the 
phage surface ensuring that Fabs are selected on the basis of 
specificity and affinity during the panning process. Fusions with the 
gVI11 product result in multivalent display on the phage surface and 
this can prevent the separation of phage displaying lower affinity 
Fabs from those displaying high affinity peptides, due to the 
phenomenon of avidity ( Cwirla et a i,  1990).
However, it can be argued that the combinatorial library approach 
does not reflect the in vivo situation, for a number of reasons. Since 
the purpose of this study is to investigate the antibody response of a 
single HIV positive patient on a molecular and biochemical levels
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and to see if any conclusions can be drawn as to the nature of the 
response, it is, therefore, very important that the validity of the 
combinatorial library approach with regard to how it reflects the in  
vivo  situation is first investigated. The recombination of heavy and 
light chains in the library is, in theory, a completely random process 
and therefore, any combination should be possible (It is worth noting 
at this point that this random nature of the combinatorial system 
can be taken advantage of to produce required specificities not found 
in vivo, e.g. ca ta ly tic  an tibod ies capable of chem ica l 
transformations). In the in vivo situation it has been estimated 
that there are 108 possible antigen specificities, however, there are 
restrictions on the combinations that can occur as a result of 
phenomena such as self tolerance. This ensures that those 
combinations capable of harming 'self' do not occur.
Clonal selection (Liu et al., 1989) is also a very important part of 
the in vivo response, not present in the construction of the 
libraries. This has the consequence that certain B cells expressing 
antibody specific for antigens to which the host has already been 
exposed may be present in disproportionately high numbers and may 
bias library construction.
Third ly, antibodies in vivo are capable of undergoing affinity 
maturation (Griffiths et al., 1984) after combination of the heavy 
and light chains, whereas the library combines mature chains and no 
further maturation is possible.
The method of library construction may also introduce artifacts. 
This could include the types of primers used in PCR, or the PCR 
itself could introduce mutations. It may also be possible that low
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affinity binders will be lost through the use of the gill fusion, which 
may be important in the overall immune response.
The study of this response has lead to a number of conclusions as to 
the validity of the combinatorial approach and about the response 
i ts e l f .
Heavy Chains.
Firstly, the question must be answered, do the heavy chains in vitro 
reflect those found in vivo ? The available data suggests that they 
do, for a number of reasons:
First, several studies have failed to isolate high affinity binders 
from non-immunised libraries (Persson et al., 1991; Marks e t  
a l. ,1991, Kang et al., 1991). Therefore, since the patient being 
studied here has elevated antibody levels for gp120 in the serum and 
we are able to isolate antibodies from the library, there would seem 
to be a correlation between the two situations. Second, there are a 
number of heavy chains from high affinity Fabs that are highly 
represented in the library, suggesting that these chains were also 
represented in the in vivo situation. For example, the heavy chain 
from group b8 represents 30% of all heavy chains isolated. It is 
possible that this is just an artifact of the PCR. However, only 
primers for the VH1a (indicated by the N-terminal sequence LEQSG, 
Figure 4.3) and VH3a (N-terminal sequence LEESG) gene families 
were used to amplify the library, and the fact that there is an 
almost equal number of each family in this group would seem to 
argue against this possibility. It is still possible that this group 
arose from two genes that were disproportionately amplified, but 
the number of intraclonal variants present in other groups (e.g.: b3
1 4 6
group) would seem to suggest that this also is not the case, although 
it cannot be completely ruled out.
Third, it will be shown in further studies (chapter 5) that the 
antigen specificity of an Fab seems to be predominantly due to the 
heavy chain, as it can be shown that heavy chains from immunised 
libraries in association with unrelated light chains can bind antigen, 
while the converse is not true. Taken together with the other points, 
this is a strong indication that the heavy chains isolated from this 
library represent the in vivo situation.
Light Chains.
It is more difficult to argue a similar case for the light chains as 
antigen specificity is not associated with the presence of a 
particular light chain, and so any bias could possibly be as a result 
of the methods used to construct the library. Since the mechanisms 
of heavy and light chain combinations in relation to antigen-binding 
and antibody function are not fully understood, it is very difficult to 
speculate on the validity of the light chains present in the library. 
However, it could be argued that the light chain must play some part 
in the function of the antibody, even if it is not in the initial binding 
of the antibody to the antigen, and that the most efficient antibody 
in vivo would consist of the best heavy and light chain combination 
to effect the function of that antibody.
The function of these antibodies is to neutralise virus and it will be 
shown later (chapter 6) that very small changes in the light chain 
sequence can drastically alter the ability of a particular Fab for 
neutralisation. It will also be shown that shuffling the chains of
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Fabs within a given group can dramatically affect the neutralising 
capability of a Fab despite very few differences in sequence. 
Therefore the heavy and light chain requirements for neutralisation 
seem to be more stringent than for antigen binding. Bearing this in 
mind, and considering that a number of the library Fabs, particularly 
in the b4 group, neutralise, it is a strong case that the light chains 
found in these Fabs at least, and possibly their heavy and light chain 
combinations, are representative of those found in the in vivo
antibodies.
Heavy-Light Chain Combinations.
It is particularly interesting to note that there is a high degree of 
heavy chain promiscuity in the Fabs, i.e.: one heavy chain can pair 
with a number of light chains and retain binding to the antigen. This 
promiscuity makes it impossible to say whether the combinations of 
heavy and light chain seen here reflects the in vivo situation. 
However, the prevalence of certain heavy-light combinations 
suggest that these combinations exist in vivo or at least that the 
light chains present in these combinations are associated with 
antigen binding in vivo.
A number of approaches may be taken to study this in greater detail. 
For example, a given heavy chain could be crossed with a complete 
light chain library and panned against gp120, to see if the same 
combinations could be retrieved. This would indicate a preference 
for certain combinations in vivo. It could also be useful to compare
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the combinatoria l approach with other antibody production 
techniques (Canton & Koprowski, 1990; Gherardi & Milstein, 1992) 
such as EBV transformation and hybridoma technology, although each 
methodology is thought to reflect a slightly different aspect of the 
antibody response.
4.3.2 GENETIC ANALYSIS.
The importance of the CDR3 region of the heavy chain (HCDR3) to 
antigen binding has been demonstrated in this study. It has also been 
shown previously that this region of the antibody is probably the 
most diverse in terms of sequence, with the possib ility of 
generating 1014 different peptides at this location (Sanz, 1991). The 
mechanism by which such diversity has been generated has been 
attributed to the recombination of V, D and J germline genes (Darnell 
et al., 1986) although the details of this process have not been fully 
established (Chun et al., 1991; Alt et al., 1992).
D Segments.
However, simple recombination is not sufficient to explain the 
levels of diversity observed, and so studies on large numbers of 
immunoglobulin genes (Ichihara et al., 1988 ; Decker et al., 1991; 
Sanz, 1991) have lead to the elucidation of a number of other 
mechanisms, such as DIR D genes, inverted D gene fusions, cross­
over events and gene correction mechanisms including insertions, 
deletions and mutations. A number of these phenomena may also have 
been observed in the study of this panel of Fabs. The length and 
sequences of the HCDR3s within any given group are all remarkably
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similar, suggesting that all the members of a group are derived from 
similar D-J combinations. The D segments of the Fabs in group b3 all 
seem to be related to DXP1, and it is possible that there is a D-D 
fusion occuring here between DXP1 and inverted DK1. The 
mechanisms of how this might occur are not fully understood, as it 
would be breaking the 12-23 spacer rule (Millner et al., 1986). It is 
interesting to note that 13 nucleotides of the consensus sequence 
are homologous to a region in the D locus approximately 300bp 
downstream of the DLR1 gene, which is not flanked by the usual 
heptamers and nonamers. This may be a coincidence, or it may
represent another form of recombination as yet unknown. The 
members of the b1 group exhibit similar V-D and D-J joins, which, in 
addition to the fact that they are all the same length and similar in 
sequence, would suggest that they all use the same D-J combination. 
However, the patterns of homology observed in the VH regions 
indicate that there may be a number of different germlines present.
This may be as a result of cross-over events during PCR, although it
would require multiple, coincidental cross-overs to give the
sequences observed. There may also be a form of convergent 
evolution ocurring in vivo in an attempt to mix different germline 
VH genes with a single,- beneficial, D-J combination. However, this 
has not been described previously. The overall lack of homology of 
these D regions to previously sequenced genes would argue for the 
existence of hitherto unknown D segments or additional somatic 
mechanisms that have not yet been identified. A similar conclusion 
was reached by Sanz in his study of CDR3-specific cDNA libraries 
(Sanz, 1991).
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4.3.3 BIOCHEMICAL ANALYSIS.
We have used combinatorial libraries to isolate a number of 
antibodies specific for gp120 from a single seropositive patient.
An analysis of this panel of Fabs at a DNA level has revealed that it 
was possible to divide the genes into eight different groups, 
dependent on the sequence of the CDR3 of the heavy chain. Within 
these groups, there was a diversity of sequences representing 
distinctly different germlines. However, certain heavy chain 
sequences appeared in relatively high frequency, suggesting that 
they also appear in high frequency in the mRNA of the patient and 
are, therefore, representative of the heavy chains used in vivo. The 
light chains also show a diversity of sequences and there is a bias in 
the germline genes they represent, which also probably reflects the 
in vivo situation.
However, it was not known how this diversity of genetic sequences 
was related to the biochemical properties of the Fab proteins coded 
by these genes and so it was necessary to conduct a biochemical 
analysis of a representative cross section of that panel. Six Fabs 
were chosen for this purpose, one from each of the groups containing 
two or more Fabs. These were b3, b6, b11, b12, b13 and b14.
CD4 Inhibition.
Firstly, it was shown that all the Fabs used are competitively 
inhibited by sCD4 from binding to IIIB gp120. This categorises them 
in the class of antibodies that bind the CD4-binding site of gp120. 
This was not a surprise since the majority of antibodies found in 
patients in the latter stages of HIV infection, as this patient is, are
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known to be of this type. However, it did mean that the analysis of 
specific, epitopes for these Fabs would be more difficult due to the 
discontinuous nature of the CD4-binding site.
Relative Affinities.
The second stage was to accurately measure the affinity of each 
clone. The ELISA method suggested that all the affinities were very 
similar. However, this was not sufficiently accurate, and so the 
affinities were measured more accurately using BIAcore, which 
confirmed the fact that all affinities were in the same range of 
5x107 to 1x10s M ’ 1. The reproducibility of these values was found to 
be +/- 5%.
Epitope Mapping by Competitive ELISA.
Competitive ELISAs were performed in order to determine if the 
epitopes of all the fragments were similar. It was found that they 
were all capable of competing in an ELISA situation, suggesting that 
their epitopes were overlapping, if not identical. The genetic
analysis of this panel of antibodies had shown that they have been
encoded by distinctly different genes, yet our biochemical analysis 
had, thus far, not shown any differences. Therefore, more accurate 
methods were required to analyse this.
Epitope Mapping by BIAcore.
Epitope mapping using the BIAcore, revealed certain differences 
between the fragments. It was possible to ascertain that the 
epitopes of Fabs b3,b6,b11 and b 14 were similar enough as to not
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allow any interactions of two clones with gp120 to occur
simultaneously. However, some interaction was reproducibly 
detected between gp120 and any of the above four clones (b3,b6,b11 
and b14), when the gp120 had already been bound by either Fab b12 
or b13. This suggested that the epitopes of b 12 and b 13 were
sufficiently different from the others to allow simultaneous low 
affinity binding of two clones to gp120. These two Fabs also 
displayed some binding characteristics dissimilar from one another. 
This was the first indication that the genetic diversity had 
translated into biochemical diversity of the Fab fragments.
Knockout Assays.
It was then possible to establish, by means of knockout assays that 
the residues on gp120 capable of affecting the binding of the Fabs 
were different for each clone. All clones displayed certain knockout 
patterns typical of antibodies specific for the CD4 binding site of 
gp120, however, there were some very significant differences. Clone 
b 12 exhibited some features not usually seen in this class of 
antibody, in that a deletion of the V1/V2 loops of gp120 effectively 
knocked out the binding by this Fab, which suggests that its epitope
partially includes the V1/V2 loop. It was also inhibited by certain
mutations in the V3 loop region (308-310 deletion).
Fab b13 also showed some interesting features not commonly 
encountered in CD4 binding site antibodies. Mutations at the base of 
the V4 loop were capable of knocking out the binding of this 
fragment to gp120 suggesting that they may be directly involved in 
the binding of gp120 by b13, while mutations at the base of the
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V1/V2 loop strongly enhanced it's binding. The knockout effect seen 
at the V4 base is very uncommon and suggest that the epitope of b13 
is significantly different from the other Fabs. The other clones 
displayed interesting, though probably less significant differences 
in their binding patterns. This data corroborates the BIAcore 
evidence, in that it is Fabs b12 and b13 that are seen to be the most 
unique in both cases, which helps to establish BIAcore as a valid 
method of epitope mapping.
This result is particularly interesting in this case as it has already 
been demonstrated that b12 and b13 are the two Fabs best able to 
neutralise the virus from the panel of Fabs available to us. This 
ability to neutralise may be linked to the unusual binding patterns 
demonstrated by these Fabs. Both require residues common to most 
CD4 binders, while b12 also requires the V1/V2 loop and b13 is 
inhibited by mutations at the base of the V4 loop. This may lend 
credence to a theory that the V1/V2 loop, and perhaps the V4 loop 
fold down over the CD4 binding site, and so can be part of an epitope 
for this type of antibody.
Although any attempt to explain these results is merely speculation, 
it may be the case that the virus is capable of altering the CD4- 
binding region to escape being bound by antibody and that it is more 
limited in it's ability to change the V1/V2 and V4 loop areas. 
Therefore, any antibody with an epitope including the CD4-binding 
site and one or other loop region may be a better neutraliser, since 
the virus would find it more difficult to produce escape mutants to 
prevent binding by this antibody.
The results presented here may prove useful in determining the 
structure of gp120 which may, in turn, yield some information as to 
the mode of action of the HIV virus. It was also interesting to note 
that mutations in the V3 loop were able to affect the binding of a 
number of these Fabs (b6, b11, b12 and b14), all of which were 
determined to be CD4 site-binding antibodies. This may be a 
reflection on the folding of the gp120 molecule, bringing the V3 loop 
in close contact with the other areas involved in CD4 binding, or it 
may be that changes in the V3 loop can effect changes elsewhere in 
the molecule, by other mechanisms. Perhaps a larger panel of 
antibodies such as these would yield more information about the 
structure of gp120.
4.3.4  HIV AND THE IMMUNE SYSTEM.
We have now established that the genetic diversity of the genes 
coding these antibodies can also be translated into biochemical 
diversity, without losing the overall specificity of the antibodies. 
When the immune response is challenged with the HIV virus, it must 
make antibodies capable of neutralising the virus. One of the most 
immunodominant epitopes on HIV is the CD4 binding site of gp120, 
which the virus uses to bind to CD4+ cells and subsequently invade 
them (Rosenburg et al., 1991). Therefore, if the virus is to be 
neutralised, antibodies to this epitope must be produced. However, 
the virus is capable of altering itself in an attempt to "shake off" 
these antibodies. The immune system must, therefore, produce a 
range of antibodies capable of binding to the CD4 binding site, yet 
possessing slightly different specificities, so that the virus may be
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neutralised even after it has changed. I believe that the subtle 
diversity among our panel of Fabs- all specific for the CD4 binding 
site of gp120, and yet with slightly different epitopes- may be an 
attempt by the immune system of our patient to avoid viral escape 
mutants.
We have been able to use the combinatorial library system in
conjunction with a number of other techniques to analyse, both at a
genetic and a biochemical level, the way in which evolution of the 
immune system has adapted the immune response of one particular 
individual in an attempt to fight off a virus capable of escape
mutants. The information gained in this study, in conjunction with 
neutralisation data for these clones should prove useful in the 
design of antibodies capable of neutralising the HIV virus. This 
technique may not be limited to the particular case of the HIV virus, 
but may prove useful for effectively analysing the immune response 
of patients with a range disease states. This would allow us to
obtain a better understanding of how evolution has dealt with the 
problems of infectious agents, and this knowledge may facilitate 
use in the design of better systems to combat these diseases.
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CHAPTER 5
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5.1  INTRODUCTION
5.1.1 OVERVIEW.
Combinatorial antibody libraries have been developed as a means of 
producing a large number of diverse antibodies (Persson et a/., 
1991; Huse et a!., 1989; Marks et at., 1991) both from human and
murine sources (Caton & Koprowski, 1990). A large panel of Fab 
fragments specific for gp120has been generated by means of 
combinatorial library technology, as has been discussed in chapter 4. 
However, it has been argued that these libraries are not a true 
representation of the in vivo response (Gherardi & Milstein, 1992) 
and it was not clear whether this panel of antibodies accurately 
reflected the in vivo situation, due to a number of circumstances 
which have previously been specified (section 4.3.1). It has already 
been argued that the heavy and light chains present in the panel 
probably represent those found in vivo. However, it was more 
difficult to say whether the same was true for the combinations of 
heavy and light chains in the Fabs.
5.1.2 REPLICON-COMPATIBLE PLASMIDS.
In order to explore this more fully, a set of two replicon-compatible 
plasmids were developed by Dr. Thomas Collet (Collet et at., 1992; 
Larimer et a i,  1990) which enabled us to clone the heavy and light 
chains of these fragments seperately, one into each plasmid. The 
plasmids were designed to be compatible with the cloning system 
already in place for the library construction, and so the heavy and
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light chain genes could be transfered directly from one system to 
the other. This new binary plasmid system facilitated chain 
shuffling in order to study the extent to which one chain could 
accept a number of different complementary chains and still retain 
antigen-binding, i.e.: the phenomenon of chain promiscuity. This 
could yield information about how restricted the combinations found 
in the panel of Fabs were, and how likely these combinations were to 
exist in vivo. It would also be interesting from the point of view of 
verifying how relevant the groupings, made on the basis of heavy 
chain CDR3 sequence, were to antigen binding.
5.1.3 IMPORTANCE OF THE HEAVY CHAIN.
A pivotal assumption made in the arguments in chapter 4, was that 
the property of antigen binding for any particular Fab resided mainly 
with the heavy chain. That assumption was made on the basis of 
results in this chapter; that an Fab will only retain antigen binding 
if it contains a heavy chain from a clone that originally bound that 
antigen. However, the question remained , whether or not the same 
was true of the light chains. This problem was examined by means of 
a number of directed crosses involving heavy and light chains from 
Fabs of two different specificities, known as interantigenic crosses. 
This type of chain shuffling was particularly attractive as it lead to 
the possibility of combining two different specificities in one Fab 
which would be desireable for a number of applications such as, 
bifunctional antibodies for tumour imaging and therapy (Nolan & 
O'Kennedy, 1990), catalytic antibody production (Lerner &
Tramontane», 1988) and the development of metalloantibodies 
(Iverson et al., 1990; Iverson & Lerner, 1989).
5.1.4 APPLICATIONS OF CHAIN SHUFFLING.
The use of antibodies derived from combinatorial libraries for 
therapy would require that they have reasonably high affinities, 
preferably in the same range as that of the later immune responses. 
Although the affinities of our Fabs are quite high ( approximately 
108 M '1 ), it would be desireable to increase this value if possible. 
Methodologies which could be employed, include the introduction of 
point mutations in V genes using error-prone polymerase and the 
selection of clones with increased affinity (Hawkins et al., 1992), or 
shuffling of hypervariable regions according to methods described 
previously (Jones et al., 1986; Reichmann et al., 1988). Chain 
shuffling also provides a means to achieve this. The implications of 
this technique are that we are no longer limited to the combinations 
of heavy and light chains obtained from the libraries, irrespective of 
whether or not these are the combinations present in vivo . It was 
possible that shuffling the chains could produce new fragments with 
increased affinity over the original antibodies. This has been done 
previously by Marks et al., (1992). Heavy and light chains from 2- 
phenyloxazol-5-one (phOx)-binding clones were shuffled with light 
and heavy chain libraries from unimmunised donors, respectively, 
with the result that a new Fv fragment specific for phOx was 
produced upon shuffling, with an affinity 20 times greater than the 
original antibody.
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There are a number of other reasons why it might be useful to 
shuffle antibody chains. It is often advantageous to produce a 
number of antibodies of similar specificity but of distinct idiotypic 
composition. For example, antibodies used for viral neutralisation 
can be rendered useless through the ability of the virus to form
escape mutants (Blattner, 1991). This may be avoided by using a
mixture of antibodies with similar, but not identical, epitope 
specificity. This technique may also be used to eliminate unwanted 
cross-reactivity while maintaining the desired specificity.
Another study (Kang, et a/., 1991) shuffled the chains of a panel of
antibodies specific for nitrophenyl phosphonamidate (NPN) and found 
a very high degree of promiscuity among the chains. Therefore, the 
possibility of producing antibodies, with new specificities and 
affinities, by shuffling the chains of the panel of gp120-specific 
Fabs was also investigated.
Finally, it had been previously reported (Ward et a!., 1989) that 
single VH domains specific for hen egg lysozyme could be prepared 
with affinities only 10-fold less than the parent Fv fragments. It 
was considered interesting to test whether this was the case with 
this panel of Fabs.
5.1.5 LARGE-SCALE PRODUCTION OF SOLUBLE Fab.
The final set of results presented in this chapter deal with the 
production of one of the Fabs on a large scale, and its purification 
from the culture broth. Large-scale production of purified Fab would 
be important if these fragments were to be used for therapeutic or 
diagnostic purposes. It would also be important to have a large
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amount of purified protein for a number of techniques such as X-ray 
crystallography. A crystal structure of a gp120-antibody complex, or 
even a loop peptide-antibody complex could yield a great deal of 
information about the mechanism of action of AIDS and its 
neutralisation. However, as much as a 100mg of pure protein could 
be needed for this procedure.
A B. Braun Melsungen SG 20I fermenter was used to grow 12 litres of 
E.co li broth to an O.D.(550nm) of between 60 and 80 as described 
previously (methods section 3.4.4). This meant that the cells could 
then be separated and lysed, to release the Fab, which was 
concentrated on a cross-flow f i l t ra t ion  system. First step 
purification of the antibody was then achieved using a zinc metal 
column (Skerra et a!., 1991), since the Fab was engineered to contain 
a histidine tail at the carboxyl end of the heavy chain. The tail 
consisted of 5 histidine residues which is sufficient for metal 
binding. The results of these experiments will be presented and 
further work in this area will be suggested.
5 . 2  RESULTS
5.2.1 CONSTRUCTION OF THE BINARY PLASMID SYSTEM.
A binary plasmid system consisting of two replicon-compatible 
plasmids was constructed previously by Dr. Thomas Collet (Figure 
5.1). pTC01 was designed for cloning light chains, while pTACOIH 
was for heavy chain cloning. These vectors are based on the multiple 
cloning sites of HC2 and LC2 (Huse e ta !. ,  1989), the vectors 
originally used in combinatorial library construction. This means 
that chains can be directly transferred from one system to the other 
by restricting with enzymes Xhol and Spel for the heavy chains or 
Sacl and Xbal in the case of the light chains. The leader sequences 
and multiple cloning sites were transferred from HC2 and LC2 to 
vectors pFL281 and pFL261 (Larimer e ta !., 1990) respectively, using 
PCR. This provided a flush fusion of the leader sequences to the 
ribosome binding site (rbs) of each vector, via an internal BamHI 
site. pTACOIH was then further modified by insertion of a synthetic 
linker at the Spel site, incorporating an oligohistidine tail followed 
by the stop codon TAA (Figure 5.2). This was done to facilitate the 
purification of the Fab by metal affinity chromatography, since a 5- 
base histidine sequence will bind metal ions (Skerra et a i ,  1991). 
The tacPO represents a trp-lac hybrid promoter-operator, while the 
rbs is the consensus ribosome binding site sequence AGGAGG (as 
opposed to the LacZ rbs, AGGA, which resulted in much poorer 
expression levels). The phage f1 intergenic region was included to 
facilitate the production of ssDNA for sequencing (see introduction,
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section 1.7). Both plasmids have selection markers allowing their 
maintenance in culture: pTACOIH codes for (3-lactamase (bla) which 
confers res is tance to am pic ill in  and pTC01 codes for 
chloramphenicol acetyltransferase (cat) conferring resistance to 
chloramphenicol. Both plasmids can be maintained in culture 
simultaneously as a result of the compatible origins of replication, 
ColE1 and p15A. The ratio copy number for these two replicons has 
been estimated to be roughly 2:1, ColE1:p15A. Expression of soluble 
Fab from these palsmids is partially supressed by the addition of 
glucose and is induced by the addition of isopropyl-3-D- 
thiogalactopyranoside (IPTG) at 30°C.
Figure 5.1: Plasmid maps of the replicon compatible chain shuffling vectors. pTC01 was designed for
light chain cloning and pTACOIH for the heavy chains. Both plasmids contain a stuffer fragment between 
their respective restriction enzyme sites ready for replacement by the appropriate antibody chain. Maps 
are drawn approximately to scale.
tac promoter______________  rbs
TGI TGACAATTAATCATCGGCTCGTATAA1 G TGTGGAATTGTGAG CG GATAACAATTTCACAC AGGAGG AA 
ACS ACTGTTAATTAGTAGCCCGAGCATAn ACACACCTTAACACTCGCTATTGTTAAAGTGTC TCCTCC TT
BamHI p e lB  l e a d e r
M K Y L L P T A A A G L L L L A A Q P A M A
GGATCCATGAAATACCTATTGCCTACGGCAGCCGCTGGATTGTTATTACTCGCTGCCCAACCAGCCATGGC
CCTAGGTACTTTATGGATAACGGATGCCGTCGGCGACCTAACAATAATGAGCGACGGGTTGGTCGGTACCG
S a c I  X h o l  X b a l
E L STOP
CGAGCTCGGTCGGTCCTCGAGGGTCGGTCGGTCTCTAGAGTTAAGCGGCCGC 
GCTCGAGCCAGCCAGGAGCTCCCAGCCAGCCAGAGATCTCAATTCGCCGGCG
5 . 2 ( a )
tac promoter rba
TG' 'TGACAATTAATCATCGGCTCGTATAAT GTGTGGAATTGTGAGCGGATAACAATTTCACAC AGGAGG AA
ACj ACTGTTAATTAGTAGCCGAGCATATTA CACACCTTAACACTCGCCTATTGTTAAAGTGTC TCCTCC TT
BamHI p e lB  l e a d e r
M K Y L L P T A A A G L L L L A A Q P A M A
GGATCCATGAAATACCTATTGCCTACGGCAGCCGCTGGATTGTTATTACTCGCTGCCCAACCAGCCATGGC
C C TA G G TACTTTATCCATAACGGATGCCG TCG GCGACCTA ACAATAATGAGCGACGGGTTGGTCGGTACCG
X h o l X b a l  S p e l  ( H i s ) 5 - t a i l
Q V K L L E  T S H H H H H
CCAGGTGAAACTGCTCGAGGGTCGGTCGGTCTCTAGACGGTCGGTCGGTCACTAGTCATCATCATCATCAT 
GGTCCACTTTGACGAGCTCCCAGCCAGCCAGAGATCTGCCAGCCAGCCAGTGATCAGTAGTAGTAGTAGTA
STOP
TAAGCTA
ATTCGAT
5 . 2 ( b )
Figure 5.2: Nucleotide sequence of the multiple cloning site in a) the
light chain vector, pTC01 and b) the heavy chain vector, pTACCMH. 
Relevant restriction sites are underlined. Thefac promoter and ribosome 
binding site (rbs) are indicated by boxes (Collet et al., 1992). The amino 
acid sequence of the pleB leader is also given.
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5.2.2 Direct Cross of Heavy and Light Chains.
As was previously described (chapter 4), a large panel of gp120IIIB 
binding Fabs had been isolated from the bone marrow of a single 
asymptomatic HIV patient and these could be assigned to one of 
seven groups based on the sequence of the CDR3 region of the heavy 
chains. For the purposes of the chain shuffling experiment, twenty 
Fabs were chosen representitive of the seven gp120 binding groups 
(b1 ,b14,b24; b4,b7,b12,b21; b6;b8,b13,b18,b22,b27,B26,B8,B35,s4;
b11; b3; and s8). The V3 loop peptide binding clone, p35, was also 
chosen. The heavy and light chains of all twenty one Fabs were 
cloned separately into the binary plasmids and directed crosses 
were carried out by co-transformation of two plasmids, resulting in 
441 (21x21) shuffled fragments. The binding of these Fabs to gp120 
was then analysed by ELISA and the results are given in Table 5.1. 
Unpurified E. coli supernatants were used in all cases and a clone 
was determined to be positive if it gave a reading of 3 times above 
background level or higher. The negative control used in all 
experiments was supernatant from E. coli not expressing Fab. Clones 
are sorted according to the groupings already established. The 
diagonal from top left to bottom right represents the original 
combinations of chains and these are all positive, as expected. The 
exception here is the loop binder, p35, which does not bind gp120. 
However, binding to V3 loop was maintained in the cross containing 
the original two chains of p35.
b l l b6 b4 bl2 b7 b21 b3 bl3 b22 B26 b8 blS b27 BS B35 «4 bl bl4 b24 ■8 p35
bll + + w + + - +
b6 + + + + + - + + - + - - - - + + + - -
b4 + + + + + + + + - + -
bl2 + + + + + + + + - + -
hi + + + + + + + + V -
b21 + + + + + + + -
b3 + + - + + - +
bl3 w w + + - + + + + + + + + + - - - w -
b22 + + + + + + + + + + + + + + + +
B26 w + + + + - + + + + + + + + + +
bS + + + + + - V + + + + + + + + + - - - - -
blS + + + + + - + + + + + + + + + + + - V - -
b27 + + + + + - + + + + + + + + + +
B8 + + + + + - + + + + + + + + + +
B35 + + + + + - + + + + + + + + + + - - w - -
<4 + + + + + - + + + + + + + + + + - - - - -
bl + + + ' + + - - + M - + V - - - - + + + - -
bl4 w + + + + V - + - + - - - - + + + - -
b24 + + + + + - + - - + - - - - + + + - -
■8 w + + + + - V + + w + + + + + + - - - + -
p35 + + + + + - + w w w + w w w w + V - - - •
Table 5.1: Complete set of directed crosses between heavy and light chains 
of all selected Fabs isolated from the original library. Heavy chains are 
listed horizontally and light chains are listed vertically. The clones are 
sorted according to the groups previously discussed, with different 
groups being separated by horizontal and vertical lines. + indicates a 
positive signal of 3 times backround or greater; - denotes a negative 
signal and w stands for a weak positive.
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5.2.3 HEAVY CHAIN PROMISCUITY.
An initial observation is that within any particular group, there is 
complete promiscuity of the heavy and light chains. In other words, 
any heavy chain from a group can combine with any light chain from 
that group and retain binding to the antigen. This lends validity to 
the system of grouping on the basis of H chain CDR3 sequence, at an 
antigen binding level at least and emphasises the importance of the 
heavy chain in this role. If chains from Fabs outside the group are 
used it can lead to a general lack of promiscuity and an inability to 
retain antigen binding. For example, there are very few binders 
amongst the crosses between the groups b1-b24 and b13-s4.
The degree of promiscuity in general was surprising, in that a given 
heavy chain could recombine with a number of light chains with 
retention of binding. This ability to productively pair with a number 
of light chains varied considerably, and seemed to be strongly 
dependent on the heavy chain sequence. Five of the heavy chains, 
b11HC, b6HC, b12HC, b7HC and b8HC could productively pair with any 
other light chain in the panel studied, including that from the loop 
binder. Even the least promiscuous chain from the Fabs panned with 
gp120llIB, b14HC, still did so in 18% of it's crosses. An attempt was 
made to correlate promiscuity and amino acid sequence. However, 
sequence alignments between the least and most promiscuous heavy 
chains did not reveal any such connection (Figure 5.3). For example, 
b6HC, a very promiscous heavy chain, exhibits very little sequence 
homology with either b7HC, also very promiscuous, or b1HC, one of 
the least promiscuous chains. The same can be said from a number of 
such comparisons considered during the analysis of these crosses.
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Unlike the heavy chains, there were no light chains that would cross 
productively with all heavy chains, nor were there any that were 
distinguishable from the other light chains by unusually low 
promiscuity. The high degree of promiscuity among heavy chains, 
however, could have Important implcations for the combinatorial 
library, and how it relates to the in vivo situation.
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CLONE PR1 COR1
b6 LEESGCGLVKPGiSSLRLSCVOSGFTFS SAWMA
b l2  . .  Q . . AEVK.. . A . VKV.. QA. . YR. . NFVIH
b l l  . . Q . . . . V .................... . E ............. P N . . . T
FR2 CDR2 PR 3 CDR3 FR4
WVRQAPGRGLEWVG LIKSKADGETTDYAT PVKG RFSISRNMLEDTVYLQMDSL.RADDTAVYYCAT QKPRYFDLLSGQYRRVAGAPOV
.................O R F ..M . W.NPYNGNKEFSAKFQD
. . . . S . .  K  A S  F . .G SPH . .A . .E .
. VTFTAWSAM. A . MELR. . .S A ....................R VG. YSW. DSPQDNYYMDV
. . T  D. . . K . F . . .N G .K .E . - G . . R Y .. . SEMMG. VRKHFYMDV
(A)
LEESGCJGI.VKP02SLRI,SCVGi;GPrFS SAWMA
...................... 0 .  . R . . . V . . EA........... .YE.M
WVRQAPGRGLEWVG LIKSKADGETTDYATPVKG RFS ISRNNLEtrrVYLQMDSLRADDTAVYYCAT QKPRYFDLLSGQYRRVAGAFDV
-K  S  Q.S.SGSRTYYADSVKG
. T E F K P ..S .V K V .. K A ..G . . 0 DYASNYAJS WVRQAPGCKiLEYIG G.TPTSGSADYAOKFQG
. . T . .  . D. AKNSL. . E .T . .  . V....................R GRRLVTFGGWSGGN1
.VT..ADRFTPIL.MELR...IE...1---- R ERRERGWWPRALRGALDF
(B)
WGHGTTVTVS PAST
.  .K . . ......................
. . K ____ S . . S . . .
WGHGTTVTVSPAST
. .Q . .M  S .  . .
. . O . . R . F ............
FIGURE 5.3: Amino acid comparison of the most promiscuous heavy chain, b6HC, with other promiscuous chains, b12HC and b11HC and
the least promiscuous chains, b14HC and s8HC. Similatities are indicated by dots; differences are given. No sequence patterns 
emerge between promiscuous and non-promiscuous chains.
Most crosses using heavy chains with identical variable region 
sequences gave identical binding patterns. For example: those 
crosses involving b18HC, b27HC, B8HC, B35HC and s4HC all show 
identical binding ■ patterns. However, there are some minor 
differences between the b12HC and b4HC (both are identical in their 
VH region sequences) crosses. In addition to this, all crosses 
involving b8HC are positive, despite the fact that b8VH is identical 
in sequence to b18VH , b27VH, B8VH, B26VfH and s4VH. This may be 
due to differences in expression levels in the cell, or it could be 
attributed to sequence differences in the constant regions of these 
chains. This can not be confirmed as these regions were not 
sequenced. Also, it is not known if differences in the constant
regions alone are capable of affecting antigen binding properties to
this extent. Having said this, it should be noted that maintenance of 
amino acid differences in constant region alleles by selective 
pressure, (Schreier et al., 1981) would seem to suggest that the 
sequence of these regions is critical for optimal antibody function.
5.2.4 AFFINITY MATURATION.
The question was then addressed as to whether or not the chain
shuffling process could produce Fabs of altered affinity, and so
could be used as a means of affinity maturation within a predefined 
set of antibodies. The affinities of a number of selected clones were 
measured by competitive ELISA, using gp120 as the competing 
antigen. A number of series of clones were selected with the same 
heavy chain and different light chains. The results for two of these 
series, b12HC and b13HC, are shown in Figures 5.4(a) and (b). No
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significant differences were detected between the clones in any 
series tested (5 other sets were also tested, with the same result, 
data not shown), leading us to believe that, within this panel of 
antibodies, it was not possible to improve on affinity by chain 
shuffling.
It Is also interesting to note that no single chain by itself, either 
heavy or light, could bind antigen, as detected by ELISA which may 
suggest that the phenomenon of domain antibodies (dAbs) does not 
exist in the context of this set of gp120 binding Fab fragments.
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H12L1
H12L3
H12L6
H12L11
H12L12
H12LB35
H12Ls8
H12Lp35
H13L4
H13L12
H13L13
H13L14
H13LB35
H13Ls4
H13Ls8
H13Lp35
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5.2.5 INTERANTIGENIC CROSSES OF HEAVY AND LIGHT  
CHAINS.
To determine if the promiscuity observed within this library of 
clones could be extended to other high affinity binders derived from 
a non-related library, an Fab fragment specific for tetanus toxoid 
(Persson et ai, 1991 ),P3-13, was chosen for a new set of crosses. 
The P3-13 heavy chain was crossed with all light chains from the 
gp120 library, and conversely, the heavy chains were all crossed 
with the P3-13 light chain. All crosses were then assayed for 
binding to both tetanus toxoid antigen and gp120 (Table 5.2).
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Clone
P3-13HC with all light chains P3-13LC with all heavy chains
TT antigen IHB gpl20 TT antigen m B g p l2 0
b l - - - -
b3 - - - 6.3x10
b4 2.5x10 - - -
b6 - • - 2.5x10
b7 • • - -
b8 - - - -
b l l - - - 3.2x10
b l2 6.3x10 - - -
bl3 - - * -
bl4 w - - w
bl8 - - -
b21 3.2x10 - -
b22 - - -
b24 • - -
b27 - - -
B8 - - -
B26 - - -
B35 - • -
s4 * - -
s8 ■ - -
p35 ■ • - -
P3-13 6.3x10
'
- -
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It can be seen from the table that the degree of promiscuity is far 
less than previously observed within the set of gp120 binders, as 
expected, since the two chains are obtained by panning with 
completely different antigens. There are, however, a number of 
crosses that still exhibited some antigen binding. P3-13HC crossed 
with light chains from b4, b12 and b21 bound tetanus toxoid (TT) and 
similarly, heavy chains from b3, b6 and b11 crossed with the P3-13 
light chain bound gp120. Fab b14 gave weak binding when crossed 
with P3-13 in both cases, but this was too weak to be used in any 
further analyses. Therefore, it is apparent that a Fab will only bind 
the antigen if the heavy chain of that Fab originally came from an 
antibody specific for that antigen. The converse is not the case: light 
chains do not possess the ability to confer antigen binding on an 
antibody. This is confirmed by the fact that none of the P3-13LC 
crosses bound TT and none of the gp120-bindingLC crosses bound 
gp120. It is also supported by X-ray crystallography data showing 
that it is only the heavy chain that provides the surface topography 
and steric complementarity for antigen binding in the active site of 
the antibody. Therefore, "the combination of the heavy chain with 
any light chain that allows the formation of the combining site 
without creating unfavorable steric or electrostatic interactions 
should preserve a significant proportion of the antibody specificity" 
(Sastry et al., 1989).
The ability of a heavy chain to recombine with an unrelated light 
chain does not seem to be totally related to the promiscuity 
displayed by that heavy chain within a set of related clones. This is 
demonstrated by the fact that b3HC crosses productively with P3-
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13LC and yet, within the gp120 crosses, it displays a lower rate of 
promiscuity (81%) than any of the clones b4HC (88%), b12HC (100%) 
or b7HC (100%), none of which cross productively with P3-13LC. 
This may be related to the fact that all three of the above chains 
originate from the same sequence group and are incompatible with 
P3-13. In addition to this, the three light chains giving rise to 
productive crosses with the P3-13HC all originate from the same 
group (b4LC, b12LC and b21LC). Therefore, it seems likely that the 
compatibility of a combination of heavy and light chains is highly 
sequence dependent and that a promiscuous sequence within a group 
of related clones may not be suitable to recombine with chains 
outside that group.
5 .2 .6  AFFINITIES OF INTERANTIGENIC CROSSES.
The affinities of this set of clones was also analysed (Figure 5.5(a) 
and (b)). Although the affinities of the interantigenic crosses were 
quite sim ilar to each other, there was a significant difference 
between these values and the affinities of the Fabs containing the 
original combination of heavy and light chain. The replacement of the 
P3-13LC in the P3-13 Fab with another unrelated light chain, 
lowered the affinity of the fragment by a factor of 10-100 times 
(from 6.3x108 to 6.3x106 M '1). Similarly, the affinity of the gp120 
fragments was lowered by a factor of approximately 10 times.
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A similar cross was attempted with a fluorescein-specific mouse 
light chain (Sastry et al., 1989; Iverson et a!., 1990). Three mutant 
variants of this light chain incorporating histidine residues at 6 
different locations (see chapter 7) were each combined with all of 
the gp120 heavy chains and binding of gp120 was tested by ELISA. 
The only heavy chain that showed a productive cross with these light 
chains was b6HC. The affinities of the 3 crosses ranged from 1 to 
6 x10 7 M '1 (Figure 5.6), which is 8 to 50 fold lower than the affinity 
of the original b6 Fab (5x108 M-1). The level of expression of these 
Fabs in the cells was very low, however, making it extremely 
difficult to produce enough Fab for purification, and so further 
studies with these clones were discontinued in favour of another 
line of research (see chapter 7).
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Figure 5.6: Affinities of the b6HC with the three fluorescein-specific light
chains (Q2, C2 and QC2). All have affinities of the order of 107 M-1. 
However, expression levels were too low to continue the analysis of 
these clones.
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5 .2 .7  La rge  Sca le P ro d u c tio n  o f S o lu b le  Fab by
F e rm e n ta t io n .
A minimal medium was chosen for fermentation purposes, for a 
number of reasons. Firstly, all the components of such a medium are 
added individually, and so it is completely defined. This ensures that 
the operator has complete control over all components of the
medium and can alter each one to suit the requirements of any
particular fermentation run. Secondly, commercially available media 
often contain ingredients which may interfere with purification 
protocols, especially when large volumes are concerned. Thirdly, a 
mimimal medium is cheaper to produce. This is of critical
importance when volumes of 10 to 100 litres of medium are used in 
each run. The medium used has been previously been described in the 
methods section (Section 3.4.4; Dreyfus et a!., 1992). A number of
carbon sources were assayed for support of bacterial growth and 
compatibility with expression of the soluble Fab. The compounds 
chosen were glucose, lactose, sodium citrate, succinic acid and 
maltose. A 2.5%(w/v) of each of the above was added to 500ml 
samples of minimal medium and Fab b13 was grown overnight at 
37°C. The O. D. of the cultures were measured the next day. Glucose 
supported the highest levels of growth, resulting in O.D.(550nm) 
values of 10.0. Succinate and citrate gave C).D.(550nm) values 
between 6.0 and 8.0, while lactose and maltose proved to be 
unsiutable for obtaining high yields of cells. Therefore, glucose was 
chosen as the carbon source. However, as was mentioned earlier, 
glucose inhibits the expression of Fab from the plasmids, so the 
levels of glucose that would support adequate growth, while
1 82
permitting induction of Fab expression had to be investigated. 10ml 
cultures of b13 were grown for 10 hours at 37°C in the presence of 
varying concentrations of glucose. 5ml of these cultures were 
allowed to continue growth overnight while 5ml were removed and 
transferred to 30°C where they were induced with 1mM IPTG 
overnight (Figure 5.7). Glucose levels below 0.025%(w/v) did not 
support growth and a high level of cell lysis was obvious in these 
cultures. Levels above 0.2%(w/v) inhibited expression of Fab as 
determined by ELISA, presumably due to the presence of residual 
glucose at the time of induction. On the basis of this result, 2%(w/v) 
glucose was used in all subsequent fermenter runs during the cell 
growth phase and the level was then allowed to drop to below 
0.2%(w/v) before induction. It was also necessary to add an 
alternative carbon source at this stage or cell lysis would occur. 
Therefore it was decided to add 1%(w/v) sodium citrate at induction.
b CELL GROWTH (O.D.) 
♦ FAB (ELISA O.D.)
' o . o  0 .5  1.0 1 .5  2 .0  2 .5
GLUCOSE CONC. (%)
Figure 5.7: Graph showing the effects of glucose levels on growth and
protein expression. Glucose levels above 1.0%(w/v) resulted in maximal 
cell density, while levels above 0.2%(wN) caused a significant reduction 
in the expression of protein. A certain minimum level of protein is always 
expressed as glucose does not completely supress the tac promoter.
Twelve litre fermentation runs were carried out as described in the 
methods section 3.4.4. An example of such a run with b13 is given in 
Table 5.3. When the culture had reached an 0,D.(550nm) of 60.0, it 
was decided to allow the glucose levels to fall below 0.2% and then 
induce Fab expression. The rate of cell growth slowed down over the 
next 75mins such that there was an increase of only 4 O.D. units by 
the time the glucose levels had dropped to 0. Glucose levels were
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measured by means of a glucometer commerically available for 
diabetes patients. The culture was then induced with IPTG and1% 
(w/v) citrate was also added to maintain cellular integrity. The 
addition of base increased until induction in order to neutralise 
acidic products being produced by the growing cells. After induction, 
there was a certain amount of cell lysis, releasing basic cellular 
components which were neutalised with the addition of acid.
O . D . ( 5 5 0 ) G L U C O S E O X Y G E N
A N T I F O A M
( S E C O N D S )
pH
A C ID
(S E C )
B A S E
2 1 :3 0 0 .33 H I G H 100% I 7.0 0 0
8 :30 2 9 .0 LO W 64% 49 7.0
A D D E D  2% G L U C O S E
9 :20 3 3 .0 H IG H 6 3 .4 % 53 7.0
1 0 :0 0 4 8 .5 H I G H 6 3 .4 % 54 7.0 25 1912
1 0 :3 0 51 .5 H IG H 6 1 .6 % 57 7.0 25 1993
A D D E D  1 %  G L U C O S E .  B O O S T E D  T H E  O X Y G E N
1 1 :0 0 54 .5 H IG H 64% U 7.0 25 2054
1 1 :3 0 (0 .0 H I G H 6 1 .4 % n 7.0 25 2138
1 2 :0 0 61.8 0.5% 6 1 .3 % 81 7.0 25 2257
1 2 :1 5 62.1 0 .3 8 % 6 2 .5 % 84 7.0 25 2329
12 :3 0 62.5 0 .2 5 % 6 0 .5 % 90 6.9 30 2428
12 :4 5 64 .0 LO W 6 6 .4  % 90 6.9 32 2507
I N D U C E D  W I T H  l m M  I P T G  A N D  1% C I T R A T E
15 :4 5 69.3 LO W 8 7 .7 % 228 7.0 52 2507
1 8 :4 5 IS LO W 9 1 .6 % 228 7.0 62 2507
Table 5.3: Table of readings taken during the fermenter operation. The 
times each reading was taken is listed in the left hand column. 30ml 
samples were taken at each time point for measurement of cell density by 
0,D.(550nm). The glucose level of each sample was measured using a 
glucometer. All other parameters were measured directly from the 
fermenter control panel.
The factor most limiting to maximal cell growth was the dissolved 
oxygen content in the fermenter. Oxygen levels were maintained at 
approximately 60% of maximum while the cells were growing. This 
increased to 90% after induction as the cells were not now growing 
as rapidly and so, did not utilise the oxygen as quickly. The entire 
supply of oxygen in the vessel would be used in 40 seconds if the 
supply was stopped (Figure 5.8). This meant that the maximal oxygen 
flow had to be maintained in order to achieve sufficiently high cell 
numbers.
SECONDS
Figure 5.8: Graph showing the depletion of oxygen in the fermenter
vessel over time, when the external oxygen supply is temporarily cut off.
5. 2 .8  DOWNSTREAM PROCESSING.
Subsequent processing of the fermenter contents are shown in figure 
5.9. The cells and supernatant from the broth were separated before 
processing. The supernatant was filtered and concentrated, while 
the cells were broken, first by periplasmic lysis (mixing at 4°C for 
1 hour in the presence of PMSF) and then by means of a French 
Pressure Cell. The fermenter supernatant and lysed cell fractions 
were both analysed by ELISA for Fab content (fractions 1, 2, 3 and 
4). It was found that the French Pressure Cell released most Fab 
from the cells as determined by ELISA (Table 5.4). Sonication was 
also an efficient technique, however, this became impractical at 
high volumes.
FRACTION 0-D.(550nM)
FILTRATE 1 
1LITRE 0.538
FILTRATE 2 
1.5LITRES 0.594
CONC.
FILTRATES 0.900
PERIPLASMIC 
LYSATE 3 
(200ml)
0.810
FRENCH PRESS 
LYSATE 4 
(300ml)
0.994
COLUMN
FLOWTHROUGH 0.469
Table 5.4: ELISA analysis of samples taken a different stages of the 
downstream processing procedure. Numbers given are the 0,D.(405nm) 
values. Filtrates 1 and 2 represent the supernatant of the fermentation 
broth and can be seen to contain Fab, which is retained upon 
concentration (row 3). The cell pellet was lysed, first by periplasmic lysis 
and then using a french press. It is evident from the O.D.(405nm) that the 
french press is more effective at releasing Fab. Finally, the metal column 
flowthrough also contains Fab, demonstrating that the column was 
overloaded.
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All four fractions were combined and purified on the metal column. 
The fractions were eluted using a histidine/imidazole gradient and 
tested by ELISA. The Fab peak (Figure 5.10) was found to be eluted 
between 17% and' 33% buffer B (Buffer B contained 100mM histidine 
and 0.5M imidazole).
% Buffer B in G radient
Figure 5.10: Elution of Fab from the metal column as measured by
performing an ELISA on each fraction. The elution was carried out in an 
imidazole/histidine gradient with 2 buffers: A was a phosphate buffer 
(50mM sodium phosphate; 1M NaCI, pH7.0) and B was the eluting buffer 
(50mM sodium phosphate; 1M NaCI; 100mM histidine; 0.5M imidazole, 
pH6.0). The Fab eluted at approximately 25mM histidine and 125mM 
imidazole.
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These fractions were combined to give a final volume of 300ml 
containing 1 mg/ml protein as determined by O.D. at 280nm. A sample 
of this was examined by SDS gel electrophoresis and was found to 
contain a band at 50kDa (corresponding to the size of an Fab 
fragment) representing approximately 30% of the overall protein 
content. It is likely, therefore, that this sample contained 
approximately 100mg of Fab protein at 30% purity. Further 
purification of a small fraction of this sample was carried out on a 
goat anti-human F(ab')2 column by Diane Schoedler (Scripps Research 
Institute, La Jolla CA), resulting in 100% purified Fab (data not 
shown). However, purification of the entire sample was not 
performed due to the limited capacity of these columns.
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Figure 5.9: Downstream processing of the fermenter contents after
completion of the run. The supernatants were concentrated on a 10000
*
molecular weight cut-off membrane using the Pellicon filtration 
apparatus. The cell supernatants were then further concentrated on a 
similar membrane using a 250ml Amicon positive pressure filtration 
apparatus. All concentrates, labeled 1,2,3 and 4, were combined and 
purified by metal affinity chromatography.
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5 .3  DISCUSSION
5.3.1 BINARY PLASMID SYSTEM.
The binary plasmid system presented here, in conjunction with chain 
shuffling, is another approach aimed at extending the range of 
poss ib il i t ies  already exp lo ited with com b ina to r ia l lib rary 
technology, and so extend antibody diversity beyond that found in 
nature. This type of binary system has been proven before as a means 
of identifying the relative contribution of two subunits of an enzyme 
to the active site (Larimer et al., 1987). The overriding feature of
these plasmids is the ability to create large numbers of directed
crosses between characterised light and heavy chains without the 
need for recloning individual chains for each cross after the initial
vector construction. In other words, each chain need only be cloned
once, after which, any number of crosses can be achieved with that
chain. The viability of these plasmids for the expression of a
heterodimer protein has been proven by the ability to regain antigen 
binding with comparable levels of expression and affinity, when 
heavy and light chains corresponding to those in the original Fab are 
recombined. This was the case for all of the Fabs analysed (diagonal 
of Table 5.1).
5 .3 .2  HEAVY CHAINS AND ANTIGEN-BINDING.
Antibody structure has been a topic of investigation for over thirty 
years, and the presence of two distinct subunits was first 
discovered in the early sixties (Small et al., 1963; Utsumi and
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Karush, 1964). Since then, a great deal of progress has been made in 
the study of antibody structure (Chothia et at., 1989; Alt et a!., 
1992) and production (Kohler and Milstein, 1975; Huse eta!., 1989). 
However, one issue, very important for the construction of most 
antibody fragments (including catalytic antibodies), that has not 
been satisfactorily resolved, has been the relative contributions of 
the heavy and light chains to antigen-binding and the mechanisms by 
which these chains combine to produce a functional antibody. It has 
long been thought that the heavy chain contributes more to this 
function as single heavy chains in isolation have been shown to 
retain part of the antibody activity (Jaton et a i, 1968) albeit with 
an affinity of 10 to 100-fold less than the complete antibody. Light 
chains do not seem to possess this ability (Utsumi and Karush, 
1964). However, the loss in affinity exhibited by single heavy chains 
can be restored to a certain extent by recombining these chains with 
a nonspecific light chain. Since then, it has been demonstrated that 
the majority of electrostatic and steric interactions in the antigen 
binding site come from the heavy chain (Sastry et a i,  1989), 
indicating that it is more important for antigen binding. This group 
went on to postulate that the combination of a heavy chain with any 
light chain which did not disrupt the interactions in the binding 
pocket, would preserve the specificity of the heavy chain.
This binary plasmid system provided the means to study these 
issues more closely. It was apparent that there was a wide diversity 
in the degree of promiscuity among the heavy chains, ranging from 
18% to 100%, depending on the heavy chain, while the same 
differences were not observed among the light chains. Antigen
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binding by a particular clone, therefore, seemed to be very strongly 
dependent on the sequence of its heavy chain. This supports the data 
previously published. The degree of promiscuity of a heavy chain can 
be more specifically attributed to the CDR3 sequence, since, when 
all the Fabs were arranged according to this sequence, crosses 
within a group were always productive, while this was not
necessarily the case outside of a group. Therefore, in order to 
preserve a significant portion of antibody specificity, it seems that 
the light chain must be compatible with the CDR3 of the heavy chain. 
This cannot explain the variations in promiscuity completely, 
however, as b13HC and b8HC are *ar more promiscuous than other
members in the same group, although they are identical in the
sequence of all 3 CDR regions. Another, as yet unknown factor must
also be important here.
5 . 3 .3  HEAVY AND LIGHT CHAIN PAIRING.
The heavy chains are not constrained to pairing with light chains of 
the same specificity, as demonstrated by the P3-13 crosses, 
although the limitations do seem to be greater when unrelated light 
chains are used. The method of library construction ensures that 
binders are selected from a very large pool of antibodies and 
probably only those with the best combinations of chains and, so, the 
highest affinity for antigen are selected, which could be a factor in 
the high degree of promiscuity observed in the gp120 crosses. It may 
be possible that if a library of gp120-specific heavy chains were 
combined with a library of TT-specific light chains, for example, 
that a similar number of equally promiscuous Fabs would be
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generated. However, if the combinatorial library really reflects the 
in vivo situation, it is likely that clonal selection and affinity 
maturation (Griffiths et a i,  1984; Liu et al., 1989) have ensured a 
level of promiscuity that would only be displayed in crosses 
between related chains. In other words, the chains represented in a 
panned library have already undergone a natural selection process 
making them more suitable for combination with related chains than 
with chains of a completely different specificity. This is supported 
by the fact that all the gp120 crosses maintained their affinities, 
while the interantigenic crosses all displayed affinities less than 
those of the original Fabs. The lack of knowlege on the exact 
mechanisms of chain combination make it very difficult to speculate 
on this. A more extensive data bank of antibody structures and more 
work with the libraries is needed to clarify the matter.
It can be concluded that heavy chains can combine productively with 
a number of light chains, presumably when unfavourable interactions 
in the binding pocket are not created. This seems to depend on the 
heavy chain sequence, and more particularly on the CDR3 sequence, 
although other factors must also be important here. Unrelated chains 
can be sucessfully combined, suggesting that two specificities may 
be incorporated into a single Fab. This could be important for the 
production of Fabs with beneficial activities, such as catalytic 
antibodies.
5 .3 .4  LIGHT CHAINS IN ANTIBODY FUNCTION.
What role, then, does the light chain have in the antibody, if as was 
suggested, any light chain will do as long as it does not interfere
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with binding in the active site of the antibody? Perhaps the light 
chain is present merely to stabilise the heavy chain, since 
otherwise, large hydrophobic areas would be exposed to the surface 
and that, depending on sequence, certain light chains can achieve 
this more effectively than others, for a particular heavy chain. 
However, this study has confined itself to an analysis of the antigen 
binding properties of the Fabs, in which the light chains do seem to 
have a limited role to play. No attempt has been made to study the 
other functions of these Fabs, particularly the ability to neutralise 
virus (this will be done in chapter 6). It is possible that light chains 
are a more important for this function. This would imply that chain 
combination, in vivo at least, is not quite as random as ensuring 
that the specificity of the heavy chain is not impaired, but that a 
particular combination of chains are selected for that possess the 
capability to bind antigen and carry out the other functions of the 
antibody. Clonal selection would then be a process that selected for 
functionally active binders, rather than clones secreting antibody 
that just bound antigen.
5 .3 .5  THE LIBRARY Fabs AND THE IN VIVO RESPONSE.
A number of conclusions can be drawn from these results as to how 
the in vitro combinatorial library reflects the in vivo response. 
Firstly: the importance of the heavy chain in antigen binding has 
been demonstrated, supporting the arguments made in chapter 4. 
Secondly: it is apparent from diagrams 5.4 and 5.5 that the affinities 
of the gp120 crosses are all comparable to the original Fabs while 
those of the interantigenic crosses are as much as 100-fold lower.
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This indicates that all the chains from the gp120 crosses represent 
a closed set, which might be explained by the fact that they all 
possessed the same specificity in vivo. If is was the case, as 
described above, that clonal selection in vivo was on the basis of 
both antibody specificity and functionality, then it would be 
reasonable to expect that both the specific heavy and light chain 
DNA would be highly represented in the bone marrow of our HIV 
positive patient, and accordingly, in the final library. It would be 
necessary to perform more interantigenic crosses with other Fabs of 
varying specificities to verify or contradict this theory.
The promiscuity of the heavy chains obviously makes it more 
difficult to determine if the combinations of chains observed in the 
libraries are present in vivo or not. Assuming that the chains taken 
separately are those found in vivo then there is some restriction on 
the possible combinations that can occur, even in vivo as 
demonstrated by the fact that chains will not always combine with 
others outside of their own group. For example, b21HC will only pair 
with chains in its own group and b22LC. It is probable, therefore 
that b21HC does combine in vivo with one of the light chains found 
in its own group or with a very similar light chain. Since the original 
b21 Fab is also a good neutraliser (Barbas et al., 1992) it could be 
argued that this is the in vivo combination (however, it must be 
mentioned that the assays for neutralisation are, necessarily, in 
v itro  assays and may not be totally representitve of the true 
situation). It is impossible to argue this for the more promiscuous 
heavy chains, unless they are found to neutralise in combination 
with one particular light chain. Group b1 (Table 5.1) is a group whose
1 98
heavy chains in general do not combine well with light chains from 
outside the group. This group probably represents a set of in vivo 
antibodies, although the exact combinations are difficult to predict 
since there is complete promiscuity within the set. On the other 
hand, it is interesting to note that the pattern of sequence diversity 
in this group is similar for both the heavy and light chains, 
indicating that these represent prefered combinations. However, due 
to the complete promiscuity within this group and the similarity in
affinities, it is difficult to draw conclusions from this study. An
examination of viral neutralisation patterns for all the crosses in
this group may distinguish certain heavy-light chain combinations 
and yield some further information about the in vivo situation.
In conclusion, the evidence is compelling that the chains isolated in 
the combinatorial library reflect those found in gp120-specific 
antibodies in vivo. The equivalent statement is more difficult to 
make for the combinations of heavy and light chains found, although 
it may be possible to limit the number of feasible combinations to 
certain groups. This varies for each Fab depending on the degree of 
promiscuity of it's heavy chain, and the ability of the Fab to
neutralise the HIV virus..
5 .3 .6  Large Scale P roduction  of Fab by Ferm entation.
The binary plasmids had been designed to incorporate a histidine tail 
into each Fab, so as to facilitate the purification of large 
quantities of antibody. Therefore, it was decided to test this system 
by growing large volumes of cultures using fermentation. It has been
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shown that, by using the correct media components and optimising 
the fermentation conditions, it is possible to grow E. coli to a high 
density and to maintain the binary plasmids in the culture during 
growth. It is also possible to express recombinant protein, in this 
case Fab, from these plasmids and to extract this from the culture 
broth. Further optimisation of the medium conditions and possibly 
the reactor conditions should give rise to higher cell densities and 
therefore better yields of protein.
Downstream processing of the cell pellets proved to be 
comparatively easy, as the volumes tended to be small and, as a 
result, easy to handle. The supernatant, in contrast, was more 
difficult to process due to the larger volumes involved, which made 
filtration very difficult. This could be solved by using larger filters 
than were available to us. However, since approximately 60% of the 
Fab protein was extracted from the cell pellet, it was decided in 
further runs to discard the supernatant and concentrate solely on the 
pellet.
Purification of the Fab by metal affinity chromatography was quite 
sucessful, giving a product of about 30% purity. This is significant 
for a first step purification procedure. A similar procedure has been 
previously described (Skerra et al., 1991) for the purification of Fv 
fragments, with similar results to those presented here. It may be 
possible to increase the efficiency of this technique by altering the 
imidazole gradient to elute the Fab more specifically, or the use of a 
different metal on the column such as copper or nickel, may give 
higher yields. The column we used was 0.5 litres in volume and it 
can be seen from the flowthrough that its capacity was overloaded
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by the amount of protein we applied (Figure 5.4). It would be 
possible to increase the yield of protein by either using a larger
column or splitting the purification into a number of samples.
Further pu r if ica tion  of th is  sample by im m u no -a ff in ity
chromatography proved to be very sucessful. However, this technique 
is very expensive and has a very low capacity in comparison to the 
amounts of protein being used. It may be advisable to try other 
methods of purification such as ammonium precipitation and ion
exchange chromatography.
These results are preliminary and are open to a certain amount of 
optimisation to maximise the yields achievable. However, it was 
clearly demonstrated that it is possible to produce large amounts of 
pure recombinant protein from the binary plasmid system by means 
of fermentation. This could be an invaluable technique in 
circumstances where large quantities of protein are needed, such as 
X-ray crystallography or clinical trials.
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CHAPTER 6
6.1 INTRODUCTION
6.1.1 OVERVIEW.
The HIV virus invades CD4-positive T lymphocytes by binding to the 
CD4 surface antigen via the viral surface glycoprotein, gp120 
(Sattentau et al., 1986; Rosenberg and Fauci, 1991). The mechanisms 
following this event remain to be conclusively established. However, 
it is thought that gp120-shedding ensues, followed by fusion of the 
viral and cell membranes and internalisation of the viral RNA into 
the cell (Moore et al., 1993). This is followed by the synthesis of 
viral DNA and integration into the cell genome (Haseltine, 1991). 
Whatever the mechanisms of cell invasion, it is the binding of gp120 
to CD4 that remains the most important step for initiating the 
fusion process and, so, inhibition of this reaction is likely to lead to 
neutralisation of the virus.
6 .1 .2  USE OF SOLUBLE CD4 (sCD4).
The most obvious candidate molecule for use as an inhibitory agent 
in this way would be soluble CD4 itself (sCD4). This form of CD4, 
produced in Chinese hamster ovary cells (CHO) consists of the first 
two N-terminal domains of CD4 only. However, it has been shown 
previously (Landau et al., 1988) that the interaction with gp120 
occurs with these 2 domains. Therefore, sCD4 is a suitable candidate 
for neutralisation studies. The concentration of sCD4 used in 
neutralisation was found to be of primary importance, as low sCD4 
concentrations could actually lead to an enhancement of the viral
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infectivity. It is thought that sCD4 can induce conformational 
changes in gp 120, mimicking the changes induced in the viral 
envelope by cell surface CD4. The sCD4-activated virions can then 
bind to cells and invade with higher levels of infection. Increased 
doses of sCD4 leads to gp120 shedding, and complete, irreversible 
neutralisation of the virus (Moore et at., 1993). This process is 
highly temperature dependant and also relies on a least 50% of the 
total virion surface gp120 molecules being bound by the sCD4. The 
physical state of the virus is also crucial, with older viral isolates 
undergoing more gp120 shedding and are therefore more difficult to 
neutralise (McKeating et al., 1991; Layne et al., 1992).
6 .1 .3  ANTIBODIES AS NEUTRALISING AGENTS.
A more practical approach for therapeutic purposes is the study of 
the humoral responses elicited in HIV-infected individuals. These 
patients develop antibody responses against viral proteins, some 
antibodies of which are specific for neutralising epitopes on gp120. 
As was previously discussed, there are two major groups of these 
neutralising antibodies: those specific for the V3 loop and those 
specific for the CD4-binding site of gp120 (Chamat et al., 1992). A 
number of studies hav.e been carried out on the V3 specific 
responses and particularly on the effect that this type of antibody 
has on the V3 loop (Gorny et al., 1991). This loop is defined by a 
disulphide linkage between amino acids 296 to 309 and 331 to 343, 
depending on the viral strain. There is a significant degree of 
residue conservation, particularly with the central motif, GPGRAF 
(Nara et al., 1991b). Antibodies to this region tend to be viral
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stra in -specif ic  and of high titre in the serum, afford ing 
neutralisation of the virus by interfering with some event 
subsequent to the binding of CD4. This was initially thought to be 
the route to finding a quick and effective therapy for AIDS. However, 
this optimism declined after it was learned that the V3 loop was 
more complex than a linear peptide epitope. It was quickly 
established that the gp120 molecule was capable of changing in 
conformation to give rise to neutralisation escape mutants (NEM), 
and that these could occur with the minimum of change in the 
primary amino acid sequence (Haseltine, 1991). These mutants would 
be functionally close enough to the parental strain, but sufficiently 
different in the presentation of antibody binding sites as to avoid 
being bound by these antibodies. It was also found that single point 
mutations in sequence are magnified through global rearrangements 
in the 3 dimensional structure and so, a minimum change in the 
primary sequence could lead to loss of recognition by an antibody. 
This finding lead to the formulation of theories such as Original 
Antigen Sin (OAS) whereby a slightly altered gp120 molecule could 
elicit antibodies to the unaltered form, rather than it's present 
conformation and so escape neutralisation (Nara et al., 1988).
It was soon realised that the V3 loop could not account for the broad 
virus neutralising activity detected in the sera of many infected 
patients, particularly those in the later stages of infection (Ho et 
al., 1991b; Kang et al., 1991). A new set of antibodies was 
discovered that could cross-react with a number of viral strains, 
which was not typical of the V3 set. Also, monoclonal antibodies 
raised by immunisation with 111 Bgp 120 could not compete with
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known V3 loop binders and so possessed a different specificity (Ho 
et al., 1991b). They were found to bind a conformationally sensitive 
epitope and inhibited binding of CD4 to gp120. The CD4 binding site 
has been defined in more detail through the use of these antibodies, 
as discussed in chapter 4 (Olshevsky et al., 1990; Ho et al., 1991; 
Thali et al., 1991; McKeating et al., 1992).
A number of attempts have been made to produce antibodies of
either group (V3 or CD4) capable of neutralising HIV (Palker et al., 
1988; Ho et al., 1991b). In order to be of practical therapeutic use, 
the antibody must be designed such that it can evade the escape 
mutants and so, effectively neutralise the virus even after it has 
altered its coat proteins. Alternatively, a cocktail of antibodies
must be produced with similar but not identical epitopes such that 
there will always be an antibody capable of binding gp120, despite 
any changes made by the virus. The isolation of a panel of Fab 
fragments specific for the CD4 binding site of gp120 has recently 
been described by Barbas et al., (1992). Although all of these Fabs 
were able to inhibit the binding of gp120 to sCD4, only a few were 
shown to neutralise the virus in vitro. This would suggest that
either the process of neutralisation is more complicated than the 
simple blocking of receptor binding, or that the epitope specificity 
of these fragments is more subtle, as is discussed in chapter 4. The 
lack of neutralising activity in a small proportion of these Fabs 
could be explained by the fact that they were isolated with
recombinant, soluble gp120 as opposed to virion-bound gp120. 
However, this could not account for all the weak or non-neutralisers 
found. Whatever the explanation, these Fabs provided an ideal
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opportunity for the study of neutralisation as it relates to antibody 
structure in more detail.
6 . 1 .4  LIGHT CHAINS IN ANTIBODY FUNCTION.
It has already been shown that antibody specificity can be attributed 
more to the heavy chain than the light chain within this group of 
Fabs. The high degree of promiscuity of the heavy chains, with 
regard to antigen specificity, has also been demonstrated, and it has 
been conjectured that heavy chain specificity would be retained in 
combination with any light chain that did not antagonise the
thermodynamic or steric interactions in the binding pocket.
It has been postulated that the selection of the light chain in vivo is 
not as random as ensuring that the binding pocket remains viable, 
but that there may be a positive selection for a light chain that, in 
combination with a given heavy chain, can effect the desired 
function of the antibody. Since the antigen specificity seems to be 
associated with the heavy chain, the light chain must carry some 
other function with it.
The work in this chapter will set out to establish that the light
chain, within the set of Fab fragments studied, has critical 
importance for neutralisation of the virus. As an extension of the 
directed crosses carried out in chapter 5, the neutralisation ability 
of a selected number of those crosses will be examined. One 
particular group from those crosses (the b4 group) yielded a large 
number of neutralisers and there was complete promiscuity within 
the group. These crosses will be analysed in further detail. This 
study will aim to establish whether the promiscuity seen for
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antigen binding is translated into neutralising capabilty, or whether 
a particular heavy and light chain combination is required for this 
function.
It has also been previously established that each neutralising Fab is 
capable of acting on a different set of viral isolates. The question as 
to whether the isolate specificity is carried with the light chain 
will be addressed. If it were the case that only Fabs with a 
particular light chain were able to neutralise a given set of HIV 
isolates, this would be compelling evidence that this function was 
allied with the light chain. The precise epitope of a number of these 
mutants was also examined by gp120 knockout assays.
Finally, this study will serve as a comparison of a number of in vitro 
assays available for testing neutralisation of HIV. It is not clear 
whether all assays currently available give comparable results in 
relation to one another and so this study will examine this question.
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6 .2  RESULTS
6.2.1 SELECTION OF Fabs.
One group in particular from the original panel of antibodies yielded 
a high proportion of neutralising antibodies, namely b4, b7, b12 and 
b21. It was shown previously (Barbas et al., 1992) that the b4 and 
b 12 displayed high levels of neutralisation in both the p24 and 
syncytial assays, giving rise to titres in the range 1:80 to 1:128 in 
the p24 and syncitial assays respectively. The Fabs b7 and b21 also 
neutralised, but at lower levels, typical titres being 1:20 to 1:32. 
Since these 4 clones exhibited a range of neutralisation titres, they 
provided suitable candidates for further analysis. The chain 
shuffling experiment presented in chapter 5 revealed complete 
promiscuity within this group of Fabs, i.e.: any directed cross 
between 2 given chains within this group yielded a productive 
combination in terms of antigen binding. However, in order to 
perform a detailed analysis, a limited number of these crosses had 
to be chosen. Fab b12 was the original Fab found to neutralise the 
virus and it was also determined to have the most unique specificity 
(chapter 4) which probably contributed to its high neutralisation 
titre. It was, therefore, decided to use the four crosses involving the 
heavy chain from b 12 for analysis of the neutralisation patterns. 
This included Fabs H12L4, H12L7, H12L12 (i.e.: b12) and H12L21.
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6 .2 .2  RELATIVE A FF IN IT IE S  AND CD4 IN H IB IT IO N  
CONSTANTS.
Neutralisation titres could be very sensitive to small differences in 
affinity and so two Fabs with slightly different affinities could 
demonstrate significantly different titres. Therefore, in order to 
determine that any effects observed during neutralisation were not 
merely an artifact due to affinity, it was necessary to establish 
whether or not the affinities of all the Fabs being used were 
sufficiently similar so as not to be a factor in the neutralisation 
patterns. This was first measured by competitive ELISA as described 
previously (Methods, 3.1.5). Figure 6.1 shows the relative affinites 
of the original 4 Fabs, b4, b7, b12 and b21. Assuming that .the 
affinity is the concentration of competing gp120 resulting in 50% 
inhibition of binding, it can be seen that the values for all these 
Fabs are in the range 5x107 to 1x108M-1.
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Figure 6.1 Relative affinities of the original 4 Fabs from group b4 as 
determined by competitive ELISA. The affinity value for each clone is that 
concentration of gp120 leading to 50% inhibition of binding.
Figure 6.2 demonstrates that the 4 crosses indicated above also 
yield values in the same range and that their affinities are very 
similar to one another.
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Figure 6.2 Relative affinities of the shuffled Fabs as determined by 
competitive ELISA. H12L18 was included as a Fab that was known to 
possess no neutralising ability.
More accurate measurements of affinity for all the Fabs were 
obtained using real time biospecific interaction analysis as 
described in chapter 4. The values obtained are shown in Table 6.1 
and are accurate to +/- 5%. The affinities of the four Fabs b4, b7, 
b 12 and b21 are confirmed to be in the range 7.25x107 to 1x108, 
thereby showing that they are sufficiently close as to not be a 
factor in the neutralisation titres. The affinities of the four crosses 
show a higher degree of simialrity with a much narrower range of 
values between 9.6x107 and 1.05x108. This is probably to be 
expected since they share a common heavy chain. The affinity of a
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negative control for the neutralisation assays, H12L18, is also 
given.
^•s^V alue
Kon (M’1 s '1) K 0ff (s'1) Ka (M'1)
b4 1.56x104 1.74x10 4 8.97x107
b7 2.35x10 4 3.24x10 4 7.25x107
bl2 4.53xl04 4.31x10 4 1.05x108
b21 3.02x104 3.61x10 4 8.38xl07
H12L4 3.62x104 3.56X10"4 1.02x108
H12L7 1.78xl04 1.86x10 4 9.6x107
H12L18 6.78x103 1.43x10 4 4.73x107
H12L21 1.20x10 4 1.15x10 4 1.04x108
Table 6.1 Affinities of all clones as determined using real-time biospecific 
interaction analysis (BIAcore). Both the 'on' and 'off' rates are given for 
each clone and the affinity (Ka) is defined as kon/koff in units of M'1. These 
results confirm the ELISA data insofar as the affinities are sufficiently 
similar not to have any significant effect on the neutralisation titres.
2 1 3
The 'off' rates of all the Fabs are very similar, while the 'on' rates 
are also quite similar except for that of H12L18 which is an average 
of 5 times lower than the others.
The specificity of these Fabs was determined by competition ELISA 
using sCD4 as the competing antigen. The results given in Figures 6.3 
and 6.4 indicate that all the Fabs used in this analysis are inhibited 
by CD4 and are, therefore, specific for the CD4 binding site of gp120.
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Figure 6.3 CD4 inhibition curves for the original clones as determined by 
ELISA, using souble CD4 (sCD4) as the competing antigen. The 
inhibition constant for each clone is that concentration of sCD4 leading to 
50% inhibition of binding. All these constants were found to be in the 
range 1 x107 to 1x108M'1. The loop 2 data is given as a negative control.
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Figure 6.4 CD4 inhibition curves for the shuffled Fabs as determined
by competitive ELISA with sCD4 as the competing antigen. The 
constants for these Fabs all lie in the range 1x106 to 5x107M'1.
6 .2 .3  NEUTRALISATION ASSAYS.
The shuffled Fabs H12L4, H12L7, H12L12, H12L18 and H12L21 were 
assayed for neutralisation in both the p24 assay and the syncytial 
assay. The results of the syncytial assay are given in Figure 6.5.
The method measures the number of syncytia formed in the presence 
of an MN viral strain and the Fab, in relation to the number formed 
when there is no antibody present, and the result is given as a 
percentage reduction in the number of syncytia formed at that
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H12L12
— I— H12L18
H12L21
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concentration of Fab, i.e.: the percentage neutralisation. It is evident 
from the graph that H12L4 and H12L12 are very good neutralisers 
with 50% neutralisation occuring at approxim ate ly 1 jig/m l. 
However, H12L7 requires a concentration of 15mg/ml to attain the 
same level of neutralisation while H12L21 neutralises by 50% at 
40jj.g/ml. Therefore, substitution of the light chain in b12 for LC21 
leads to a 40-fold reduction in the neutralisation titre.
1 1 0  1 0 0
Fab C o n ce n tra tio n  (p.g/ml)
Figure 6.5 Neutralisation titres for the shuffled Fabs as determined using the 
syncytial formation assay. The titre for a given clone is defined as the Fab 
concentration resulting in 50% neutralisation. H12L18 is included as a 
negative control and shows no signs of neutralisation except at very high 
concentration.
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A similar result was noted when a neutralisation assay measuring 
the levels of p24 production was employed (Table 6.2). This assay 
measures the highest dilution of Fab (twofold serially diluted) that 
still gives rise to 80% neutralisation of the virus, as detected by 
p24 production. As can be seen from the figures, H12L4 and H12L12 
both neutralise by 80% at maximum dilutions of 1:40 (approx. 
2.5|ig/ml), whereas H12L7 and H12L21 do not show any significant 
signs of neutralisation of either the IIIB or MN strains of virus at 
any of the dilutions tested in this assay. It must, therefore be 
concluded that H12L4 and H12L12 are far stronger neutralises than 
the other two. H12L18 was used in both assays as a negative control.
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MN IHB
H12L4 40 40
H12L7 - -
H12L12 40 40
H12L18 - -
H12L21 - -
Table 6.2 Neutralisation data for shuffled clones as determined using the 
p24 production assay. The assays were carried out with the MN and the 
IIIB strains of the HIV virus. The numbers indicate the maximum dilution 
for each Fab which will permit 80% neutralisation of the virus. Only 
H12L4 and H12L12 neutralise either strain at any of the dilutions tested 
in this assay.
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6 .2 .4  SEQUENCE COMPARISONS.
The data so far seemed to indicate that Fabs with the same heavy 
chains but different light chains could exhibit varied neutralisation 
patterns, ranging from strong neutralisation to very weak titres. 
Since it was only the light chains that were different between these 
Fabs, a comparison of these chains was performed to establish how 
this was reflected in the amino acid sequences (Figure 6.6). LC12 
was used as the predominant chain since it was clear that this was
associated with neutralisation. The sequences of LC7 and LC21 are
given with similarities to the predominant sequences indicated by 
dots and the differences are given as the single letter amino acid 
codes. It can be seen that LC7 differs from that of LC12 by eight 
residues, while LC21 only differs by four. This is remarkable that a 
difference of only four amino acids between two Fabs can lead to a
reduction of as much as forty-fold in the neutralisation titre. The
residues observed to be different between LC12 and LC21were: an 
aspartate at position fifteen in LC21 was glutamate in LC12 
(15D/E), 26N/S, 33A/R and 77L/V. Three of these changes are 
relatively conservative in both size of the residue side chains and in 
charge. The only one that introduces a charge difference is 33A/R, 
where the uncharged alanine in LC21 is replaced by a positively 
charged arginine in LC12.
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Comparison of the Light Chain Sequences of Cones b7, b12 and b21
C lo n ii FR1 CDR1 FR2 CDR2 FR3 CDR3
t»l 2 ELTQAPGTLS USPG ERATFSC RSSHS1RSRRVR WYQHKPCQAPRLV 111 GVSNRAS GISORFSGSGSGTDFTl.TITRVEPEDFAI.YYC QVYGASSYT
b21   D............N ____..A ................................ ......... ......... L............... ......
t.7    T .............................T .................................... V .G .............................................................................................................................V . . .  .Q.  . S . R . .
1.1  S ...........................................................................A ........................................................ ......................................................................................................
Figure 6.6 Comparison of the light chain sequences of clones b4,b7,b12 and b21. The predominant sequence 
is that of b12 since this light chain was derived from a strongly neutralising Fab. The other 3 chains are given as 
a series of dots to indicate similarity to the predominant sequence, while differences are shown using the single 
letter amino acid code.
FR-1
FCQGTKl.ERKR
6 .2 .5  NEUTRALISATION WITH VARIOUS VIRAL ISOLATES.
It had been noted previously (unpublished data) that a given Fab was 
capable of neutralising a given set of viral isolates and that this set
of isolates was different for each Fab even though all the isolates
were of the same viral strain (in the case, MN). It was postulated 
that if the neutralisation ability of a particular Fab was associated 
with the light chain, then, shuffling of the chains should give rise to 
a situation where all the Fabs with the same light chain would
neutralise a similar set of isolates. To test this, the Fabs b7 and 
b12 were shuffled to give the four possible combinations (H7L7, 
H7L12, H12L7 and H12L12). These were then tested for
neutralisation of six different isolates of the MN virus using the p24 
assay. The results of this experiment are given in Table 6.3. Firstly, 
it is evident that the shuffled Fabs neutralise fewer isolates than 
the original Fab containing the same heavy chain. This is expected 
since these shuffled Fabs do not consist of the original combination 
of chains and this has already been shown to drastically affect the 
neutralisation titre. Fab b12 (H12L12) can neutralise all six of the 
isolates while b7 can only neutralise four of them. Also, b12 can 
neutralise isolates 2815, 1702 and 1033 more strongly than b7. 
Therefore, b7 is a weaker neutraliser of fewer isolates. When LC12 
is combined with HC7, the resulting combination can neutralise five 
isolates, including 4501 which was not neutralised by b7 before. 
Furthermore, the titres for 1702 and 1033, previously neutralised by 
b7, have increased, especially in the case of 1702. None of the titres 
have decreased from those exhibited by b7. Combining LC7 with HC12 
leads to a loss of activity in all cases except that of 1702.
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Therefore, the trend seems to be that the presence of LC12 confers 
strong neutralisation activity, while LC7 is associated with weaker, 
and in many cases, a complete loss of neutralising activity. This 
would appear to concur with results obtained previously in this 
study.
N s F a b
IsolateV ^ H12L12 H7L12
H7L7 H12L7
2815 80 40 40 -
812 40 - - -
2951 20 40 40 -
1702 80 160 20 20
1033 40 40 20 -
4501 40 20 - -
Table 6.3 Neutralisation data for the four Fabs indicated, on different isolates 
of the MN strain of virus, as determined using the p24 production assay. 
The isolates originated from a varied group of HIV-infected patients as 
described in the text. The numbers indicate the maximum Fab dilution at 
which 80% neutralisation of the virus occurred.
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6. 2 .6  KNOCKOUT ASSAYS.
An epitope analysis was performed on Fabs H12L12, H12L21 and b21
in order to determine the influence that the light chain was having 
on the overall epitope specificity of the Fab (Figures 6.7(a), (b), (c), 
(d) and (e)). Firstly it can be seen that all the Fabs exhibit certain 
features characteristic of CD4 binding Fabs, for example the 
inhibitory mutations 368D/R, 370E/R and 457D/R. Binding by H12L12 
is enhanced by 207K/W, 252R/W,475W/S, 491 l/F and a number of 
mutations around residue 430 in the fourth constant region. There 
are a number of inhibitory mutations at the base of the V4 loop as
well as 308-310 and 298R/G in the V3 loop. It is also inhibited by
loss of the loops V1,V2,and V3 and displays the highly unusual 
effect of being inhibited by a loss of V1/V2 loop (see chapter 4). Fab 
b21, on the other hand, is not affected by the V1/V2 mutation and is 
enhanced by mutation 477D/V rather than knocked out as is the case 
with b12. 384Y/E completely inhibits binding by b21 while the 
effect is not so pronounced for b12. 45W/S knocks out b12 and does 
not affect b21 and 475W/S does not enhance b21. The b12 enhancing 
mutations around residue 430 do not affect b21 which is also not 
inhibited by 298R/G.
The map for the shuffled Fab displays most of the characteristics of 
b12 including the inhibitory mutations due to the loss of V1/V2, 
308-310 and 384Y/E and maintains the enhancing mutations at 
491K/L, 207K/W, 252R/W, 475W/S and a single enhancing mutation 
at 429K/L. Therefore, the overall pattern of binding is reasonably 
conserved between the 2 Fabs b12 and H12L21, which may not be so 
surprising since both use the same heavy chain which is responsible
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for specificity. However, there are a few mutations in H12L21 which 
seem to be more characteristic of b21 than of b12. These include the 
enhancing mutation at 477D/V which actually knocked out binding by 
b12. 298R/G no longer exerts an inhibitory effect which is
characteristic of b21. Similarly, there is no knockout effect at 
45W/S. The pattern of inhibitory mutations at the base of V4 loop 
has altered somewhat, although the b12 mutations 380G/F and 
384Y/E had been conserved. The three enhancing mutations in the 
fourth constant region around residue 430 have been reduced to a 
single effect, 429K/L, which may be a type of compromise, since 
b21 did not exhibit any of these effects.
Combination of HC12 and LC7 reveals the same type of trends in 
binding patterns. Many of the characteristics of b12 are maintained 
including the inhibitory mutations 368D/R, 370E/R, 384Y/E, 457D/A 
and 308-310. It is interesting to note that the knockout mutation
477D/V is conserved in H12L7 and not in H12L21 and that this 
mutation was found to be inhibitory in one other clone studied (b 11 - 
see chapter 4). Moreover, the enhancing mutations 207K/W, 252R/W, 
421 K/L and 475M/S are also conserved. However, combination with 
LC7 introduces a number of differences. Firstly, there is a new 
sensitivity to mutations in the C2 region (250-270) and secondly, 
the Fab no longer seems to be sensitive to a loss of the V1/V2 loop, 
which was one of the original distinguishing characteristics of b12. 
Therefore, both shuffled Fabs maintain the central characteristics 
of the b12 binding pattern, with a number of changes, depending on 
the light chain being used. These changes seem to be sufficient to
radically affect the neutralisation titre of a given Fab.
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Figure 6.7 (a): Data for H12L12
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Figure 6.7 (b): Data for H12L21
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Figure 6.7 (c): Data for H21L21
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Figure 6.7 (d): Data for H12L7
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Figure 6.8 Knockout assays of the shuffled Fabs, given on a different graph 
for each clone. The various mutations considered are indicated on the 
vertical axis, while the binding index is marked on the horizontal axis. 
Each bar represents the binding index for that particular mutation. An 
index of 1 implies no effect on binding; less than 0.5 indicates an 
inhibitory mutation and greater than 1.5 denotes an enhancing mutation. 
All mutations are grouped according to their position along the 
secondary structure of the gp120 molecule, except for 368D/R, 370E/R 
and 457D/A which are shown together since they are typically inhibitory 
for this class of antibody.
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6 .3  DISCUSSION
6.3.1 ANTIBODY FUNCTION.
It has previously been established that the specificity of a Fab is 
associated primarily with its heavy chain and that it is possible to 
use a variety of light chains while maintaining specificity. However, 
it is difficult to believe that the light chain is chosen at random, 
dependent merely on its ability not to interfere with the
interactions in the binding pocket, and so the experiments in this 
chapter sought to define the role of the light chain more clearly.
An antibody does not just serve to bind antigen, it must effect a 
particular function once it has bound the antigen, depending on what 
that particular antigen is. In this case, the antibodies must first 
bind gp120 on the viral surface and then effect its neutralisation.
The studies so far had only looked at antigen binding and so this
series of experiments sought to bring this one step further and 
investigate the neutralising ability of these Fabs, and perhaps
attribute this activity, in part at least, to the light chains.
6 .3 .2  THE b4 GROUP OF Fabs.
The collection of Fabs chosen all came from one particular group (as 
defined in chapter 4) due to the high proportion of Fabs in this group 
capable of neutralising virus in vitro. The Fabs b4 and b 12 were 
known to be 2 of the best neutralisers isolated to date, while the 
remaining 2 members, b7 and b21, also neutralised, although to a 
lesser extent. The crosses chosen all incorporated the HC12 due to
2 2 8
the obvious ability of b 12 to neutralise and the unique epitope 
specificity displayed by this Fab.
6 .3 .3  AFFIN IT IE S .
The initial task was to accurately measure the affinities of these 
Fabs in order to ensure that this was not giving rise to artifacts in 
the neutralisation data. All affinities were found to be sufficiently 
similar in both ELISA assay and on the BIAcore. It is interesting to 
note that the affinities of the HC12 crosses all lay within a very 
narrow range, even compared to the original Fabs, further supporting 
the theory that the binding of the Fab to antigen, in terms of 
specificity and affinity, are due mainly to the heavy chain. H12L18, a 
non-neutralising Fab, displayed an "on-rate" significantly lower than 
that of the other Fabs, which may be a contributory factor to its 
inability to neutralise.
6 .3 .4  NEUTRALISATION PATTERNS.
Once it had been established that the affinities of all the Fabs were 
similar, and that the were all inhibited by sCD4, the neutralisation 
assays could be performed. This revealed that H12L4 and H12L12 
were significantly better at neutralising, in two assays, than the 
Fabs H12L7 and H12L21, by factors of 15 and 40, respectively. This 
in itself is compelling evidence that the light chain, in combination 
with the heavy chain, is important to the neutralisation titre of the 
Fab, since these Fabs only differ in the light chains used. They did 
not differ in their heavy chains. A sequence analysis of the light 
chains revealed that there were very few differences between
2 2 9
chains, particularly between the neutralising LC12 and the poor 
neutraliser, LC21, where there were only four amino acid 
differences, two in the framework regions and two in the CDR1. 
Three of these changes were very conservative in both the size of 
the residue side groups and the charge they carried. The only non- 
conservative change was between the positively charged arginine 
with a large 5 carbon side chain (LC12) and the uncharged alanine 
consisting of a methyl group as a side chain (LC21), 33A/R. This is a 
very significant change especially since it resides in the CDR1 
region and so is directly involved with the antigen binding site of 
the Fab. However, the importance of this change in relation to 
neutralisation titre, was not clear since an analysis of b4 and b12 
showed that their heavy chains were identical and their light chains 
differed by 2 amino acids. The first was 5S/A in FR1 and the second 
was 33A/R in the CDR1, yet both of these Fabs neutralise very 
efficiently. Therefore, this difference, in isolation, may not be as 
important as it first seemed. It is apparent, however, that a small 
number of changes in the amino acid sequence of the light chain can 
radically affect the neutralisation titre of the Fab, supporting the 
idea that the light chain used is extremely important for this 
function. The criteria for neutralisation seems to be far more 
stringent than for antigen binding, for which there is 100% 
promiscuity within this group.
6 .3 .5  VIRAL ISOLATES.
Although it has been established that, for this set of Fabs, the light 
chain is critical in the context of the heavy chain combination, the
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relative importance of the light chain compared to that of the heavy 
chain has not yet been analysed. In other words, is the light chain 
important only in combination with a particular heavy chain, or can 
it confer neutralisation ability on an antibody in the same way as 
the heavy chain can sometimes carry antigen specific ity to 
interantigenic crosses?
A number of MN HIV isolates were employed to investigate this 
possibility. Thses isolates were all taken from male and female, 
homosexual and heterosexual patients that had become infected with 
the MN strain of the HIV virus. Five of the patients were European 
while the sixth was Ugandan and all were at various stages of the 
disease. The Fabs chosen for this study were b7 and b12 and the two 
shuffled combinations of these.
Initially it was noted that b12 neutralised more isolates with higher 
titres than b7, as expected. The shuffled Fab, H7L12 was able to 
neutralise one more isolate than b7 and the titres of two others had 
increased. This would suggest that LC12 had conferred an increased 
ability to neutralise on its Fab. This effect can be seen more clearly 
in the case of H12L7, which was only capable of neutralising a 
single isolate, that with the highest titre for b12. So HC12 with its 
own light chain was able to neutralise all isolates while it could 
only weakly neutralise one in combination with LC7. This evidence is 
a strong indication that the neutralising ability is more closely 
associated with the light chain, for this group of Fabs.
However, H7L12 was not able to neutralise all the isolates as was 
the case with b12 and, similarly, H12L7 could not neutralise the 
four isolates indicated for b7. Therefore, neutralisation is not
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totally related to the light chain. The heavy chain has some role to 
play also and the extent to which this occurs probably depends on 
the sequence of the heavy chain.
It may be that the role of the heavy chain is derived from its ability 
to bind the antigen in combination with a given light chain in such a 
way that the light chain can then act to effect neutralisation. If this 
was the case, a light chain capable of neutralisation would always 
be required and the role of the heavy chain would be due mainly to 
the combination of chains than to specific properties encoded within 
its own sequence. However, this is merely conjecture and it is 
possible that the heavy chain has a more important role to play in 
neutra lisation.
Having said that, the evidence does suggest that the light chain is 
more important in the heavy-light combination in terms of 
neutralisation than is the heavy chain.
Finally, it is interesting to note that most Fabs are not capable of 
neutralising all the isolates despite the fact that they are all of the 
same viral strain, the only difference being that they were all 
isolated from different patients. This serves to illustrate the 
complexity of the virus-antibody neutralisation reaction, in that it 
is not a simple case of binding the correct antibody to the virus to 
achieve neutralisation, but that there is a complex series of events 
taking place involving an interplay between the antibody and virus 
which may or may not lead to neutralisation. This must be borne in 
mind when investigating this interaction and it will require many 
more studies before it will be fully understood. One can only 
speculate on the mechanisms based on the results from single
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studies such as the one presented here. Nevertheless, these 
experiments can yield vital information which may help in the final 
understanding of this phenomenon.
6 .3 .6  LIGHT CHAIN AND EPITOPE SPECIFICITY.
The next question to be addressed was: what exact effect was the 
light chain exerting on the antibody-gp120 interaction in order to 
facilitate the neutralisation of the virus? There must be a reason 
why one light chain in combination with HC12 leads to efficient 
neutralisation while another does not. It was thought that some 
useful information might be derived from examining the epitope 
specificity of a number of crosses, all involving the HC12, in more 
detail. This was done using the knockout assay described in chapter 
4. The 3 Fabs investigated were H12L7, H12L12 and H12L21 since 
they all displayed different neutralisation titres. H12L12 (b 12) 
showed many of the features common to all antibodies of this type, 
plus a number of characteristics specific to that antibody including 
the unusual V1/V2 inhibition effect which was seen to distinguish it 
from other Fabs in the panel. H12L21 displayed a very similar 
pattern of binding with the major differences being a lack of 
inhibition by mutation 45W/S, the loss of two enhancing mutations 
in C4 and perhaps the most significant change being an enhancement 
by 477D/V rather than the knockout effect seen with H12L12. The 
differences observed between H12L12 and H12L21 were seen to be 
characteristic of the Fab b21 and were, therefore, probably 
attributable to the LC21 present in Fab H12L21. Therefore, it seems 
that by switching the light chain in the Fab, the central
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characteristics of the epitope are conserved with a small number of 
changes occurring around this, possibly as a result of the new light 
chain. This might not be particularly surprising since, if the epitope 
specificity resides mainly in the heavy chain as postulated, then the 
epitopes of these two shuffled Fabs, both having the same heavy 
chain, should remain essentially the same.
A similar result can be observed in the case of H12L7. The main 
characteristics of the H12L12 epitope are conserved, with a number 
of changes occurring around this. There are more changes for this 
Fab than was seen with H12L21, possibly because LC7 exhibits twice 
the number of differences that LC21 does from LC12 and six of the 
LC7 differences are in the CDR regions, compared to two for LC21. 
The presence of LC7 increases the susceptibility of the C2 region 
and also is no longer affected by the loss of the V1/V2 loop.
It could be postulated from these results that the heavy chain is
initially responsible for binding of the Fab to gp120, which explains 
the conservation of the central epitope in all of the shuffled Fabs. 
The light chain may then be responsible for the 'fine-tuning' of this 
binding, hence the differences in epitopes observed around the 
central binding site. Perhaps it is the ability of the light chain to
'fine-tune' the binding in this way that defines whether the Fab is
capable of neutralising the virus or not. This would help to explain 
why a particular light chain was needed for neutralisation to occur 
and also why the chains are not nearly so promicuous in relation to 
neutralisation as they are when only antigen binding is considered. 
The Fab will bind the antigen as long as the correct heavy chain is 
present and the light chain is not obstructing the binding site.
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However, neutralisation is a far more precise phenomenon possibly 
requiring that the heavy chain binds the antigen in the correct 
orientation so as to allow the light chain to 'fine-tune' the binding 
and effect the neutralisation. This may explain why the combination 
of heavy and light chain is also important in this process and why 
LC7 could not confer full neutralising ability in combination with 
HC12 when tested against the MN viral isolates.
On a more detailed level, it can be seen that there are very few
differences between the binding patterns of H12L12 and H12L21 and 
yet the neutralisation titres differ by as much as 40-fold. The major 
difference is mutation 477D/V which knocks out binding by H12L12 
and enhances binding of H12L21. This suggests that the presence of 
light chain 21 has altered the epitope in this area and that this may 
be contributing to the enormous difference in titres. It is also 
interesting to note that this mutation inhibits binding of both 
H12L12 and H12L7 and that H12L7 displays a higher neutralisation
titre than H12L21. However, the other changes in binding pattern
induced by LC7 make the effect of this mutation unclear. H12L7 is no 
longer inhibited by the loss of the V1/V2 loop as b 12 was, which
may be a factor in its weaker neutralisation titre. Whether the
increased sensitivity in the C2 region augments or counteracts this 
effect is unknown. Further study of this area will be required to
fully understand the mechanisms taking place here.
Finally, the high degree of sensitivity in the heavy and light chain 
combinations for neutralisation would support the theory that those 
Fabs isolated from the library capable of neutralising the virus, are, 
in fact, the in vivo combinations.
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In conclusion, the promiscuity demonstrated with antigen binding 
does not translate to neutralisation, suggesting that this is a more 
precise phenomenon. The light chain has been shown to have primary 
importance in the neutralisation activity of this group of Fabs, 
although the combination with the heavy chain also has some role to 
play in this event. These experiments have lead to a theory on the 
mode of neutralisation of HIV by this group of Fabs, however, many 
more studies will have to be carried out before this event is fully 
understood. This type of approach could prove useful in the analysis 
of this and, perhaps, many other antibody-mediated viral processes.
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CHAPTER 7
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7.1  INTRODUCTION.
7 .1 .1  OVERVIEW.
It should be clear at this stage that there are a number of highly 
sophisticated techniques available, such as phage-display libraries 
and recombinant DNA methodologies, which permit the dissection of 
the antibody response, and its analysis on a very detailed scale. 
However, this technology was limited unless it can be applied at a 
practical level. The area of viral neutralisation using antibodies, 
which was one such application, has been previously discussed in 
chapter 5. Another development, which takes advantage of the 
diversity and specificity of the humoral response, was that of 
catalytic antibodies (Lerner and Tramontano, 1988; Schultz et al., 
1990). These are molecules capable of carrying out chemical 
transformations by making use of a catalytically active group in the 
antigen-binding site. The applications of this class of protein have 
been previously discussed in the introduction, section 1.11. Since 
antibodies with catalytic properties do not usually exist in nature, 
it was often necessary to use protein engineering or molecular 
biology techniques to introduce such groups into the molecule.
7 .1 .2  METAL-MEDIATED CATALYSIS.
Metalloantibodies have been mentioned as a means of achieving 
hydrolytic reactions, particularly the cleavage of a peptide bond. The 
study of these catalysts stems from knowledge about existing 
metalloenzymes such as carboxypeptidase. This consists of a B-
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pleated sheet containing eight 3-strands surrounded by a number of 
helices, folded in such a way as to bring residues His69, Glu72 and 
His196 in proximity to one another. These three residues bind zinc in 
a tetrahedral structure in the active site. The zinc then catalyses 
proteolytic cleavage polarising the carbonyl oxygen of its substrate 
(Lehninger, 1982; Branden and Tooze, 1991). Zinc was also a critical 
component of a similar enzyme carbonic anhydrase which catalyses 
the hydration of CO2 to H2CO3.
7 .1 .3  METAL-BINDING SITES IN ANTIBODIES.
An antibody variable region consists of nine antiparallel 3 stands in 
two sheets of four and five strands arranged in a barrel, joined by 
loops. There are three major loops forming the CDR regions with 
CDRs 2 and 3 joining adjacent strands and CDR1 joining two strands 
across the barrel structure. This structure was compared to those of
a number of metalloenzymes in order to find any structurally
conserved areas and so identify possible zinc binding sites in the 
antibody (Roberts et at., 1990). A high degree of similarity was 
found between the active site of carbonic anhydrase B and the area 
around residues 34, 89 and 91 of the light chain variable region of
the antibody. It was, therefore, chosen to mutate these residues to
histidines (to bind metal) in a mouse fluorescien-specific FAb as a 
model system, for a number of reasons: first, the 3-D structure of 
the binding site was known; second, this chain had already been 
cloned and third, there were a number of proximal tryptophan 
residues, so the metal could be detected by fluorescence quenching. 
The use of three histidines would ensure that three zinc
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coordination sites would be bound, leaving the fourth free to 
activate a water molecule. It was found that these mutations would 
place the zinc in the center, at the bottom of the binding pocket, 
which would be ideally positioned for hydrolysis to occur. The 
results from this group indicated that the antibody bound both metal 
and fluorescein simultaneously and so acted as a noncatalytic model 
for this type of system. Furthermore, it was established in a 
separate study, that zinc was the most efficient metal cofactor for 
this type of catalysis. However, this engineered light chain had not 
been proven in a catalytic system.
7 .1 .4  THEORY OF Fab CONSTRUCTION.
It has already been demonstrated, in chapter 5, that it was possible 
to combine heavy and light chains of different specificities and 
retain binding to the heavy chain-specific antigen. Therefore, it 
should be possible to combine the functions of 2 different chains to 
produce an advantageous antibody. The purpose of the work presented 
in this chapter was to combine the gp 120-specificity of the heavy 
chains discussed in chapter 5, with the hydrolytic capabilities of 
the metallo-light chains designed previously, in an attempt to 
produce an Fab fragment, capable of cleaving gp120 on the HIV viral 
surface. This would validate the metal-based system designed above 
in a relevant, catalytic situation. It would also be highly beneficial 
with the obvious consequences that it may yield an antibody with 
equal or even improved ability to neutralise HIV over any previously 
observed.
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Two methods for achieving this were attempted: Directed crosses 
with the gp120 heavy chains from chapter 5, and a cross involving 
the metallo-light chain and an entire gp120-specific heavy chain 
library. The results of both experiments will be discussed. Three 
different light chains were used in this study: the first was 
designed as shown above with histidines incorporated at positions 
34, 89 and 91, named LCQ. This chain also had Tyr36 mutated to a 
Leu as the tyrosine would have interfered with metal binding. The 
second chain incorporated histidines at an alternative zinc binding 
site involving positions 49,50 and 53, named LCC. The third chain, 
LCQC, had all seven of the above changes. Western blot techniques 
involving radioactive zinc, and novel ELISA assays were developed to 
demonstrate binding of the antibody to metal. The neutralisation 
capabilities of the resulting antibodies were also tested both with 
and without zinc to determine if this was having an effect.
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7.1 RESULTS.
7 .1 .1  LIGHT CHAIN.
The sequence of the light chain is given in Figure 7.1 with the 
mutations indicated. The position of the five missing residues are 
also shown, although this was corrected during the overlap PCR (see 
methods section 3.6.2). The domain swapping worked perfectly, 
giving a chain with the mutated mouse variable region and the 
constant region from the human gp120 specific chain, LC22. This 
was confirmed by sequencing.
7 .2 .2  CROSSES WITH gp120-SPECIFIC HEAVY CHAINS.
Initially, the three light chains (LCQ, LCC, LCQC) were cloned into 
the binary plasmid vector, pTC01 in order to perform directed 
crosses with all the heavy chains previously cloned into the 
complementary vector, pTACOIH (see chapter 5). Productive crosses 
were selected for, based on their ability to bind gp120 on direct 
ELISA assays. Only HC6 was found to bind productively with all three 
light chains. No other heavy chain gave a positive result on ELISA. 
The relative affinities of -these three crosses were determined to be 
in the range 1x107 -6x107M*1 (Table 7.1) which is in the range found 
for the interantigenic crosses presented in chapter 5.
However, the level of expression of these clones was very low, 
making it difficult to use them for further experiments. In addition 
to this, only one heavy chain had crossed productively, and so, in
2 4 2
order to maximise the chances of success, an alternative route was 
decided upon.
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FR1 0
GAG CTC GTT ATG ACT CAG ACA CCA CTA TCA CTT CCT GTT AGT 
E L V M T Q T P L S L P V S 9
CDR1
CTA GGT GAT CAA GCC TCC ATC TCT TGC AGA TCT AGT CAG AGC 
L G D Q A S I S C R S S Q S 2 3
FR2 (Y)
CTT GTA CAC AGT AAT GGA AAC ACC TAT TTA CAT TGG TTA CTG 
L V H S N G N T Y L H W L L 3 7
(R) CDR2
CAG AAG CCA GGC CAG TCT CCA AAG GTC CTG ATC CAC CAT GTT 
Q K P G Q S  P K V L  I  H H V 51
FR3 ( Y)  (K)
TCC CAT CGA TTT TCT GGG GTC CCA GAC AGG TTC AGT GGC AGT
S H R F S G V P D R F S G S  65 
(N)
GGA TCA GGG ACA GAT TTC ACA CTC AAG ATC AGC AGA GTG GAG 
G S G T D F T L K I  S R V E 7.9
CDR3
GCT GAG GAT CTG GGA GTT TAT TTC TGC CAT CCA CAT ACA CAT 
A E D L G V Y F C H Q H T H  93 
FR4 ( S)  ( S)
GTT CCG TGG ACG TTC GGT GGA GGC ACC AAA CGG GCT GAT GCT 
V P W T F G G G T K R A D A  107
GCA CCA ACT GTA TCC
A P T V S 112
Figure 1: Nucleotide and amino acid sequence of fluorescein-specific light 
chain mutated to bind metal. All seven mutations are included in this 
sequence (LCQC) shown by the underlined residues. The residue before 
it was mutated is given in brackets for each. The residues L,E,I,K and R 
are missing between R104 and A105. This was corrected during overlap 
PCR.(Numbering according to Roberts, 1990).
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CROSS AFFINITY (IVT1 )
H6LQ 1.99*107
H6LC 5.00*107
H6LQC 6.30*107
TABLE 7.1: Affinities of crosses between gp120-specific heavy chain 6 and 
the metallolight chains as determined by competition ELISA.
7 .2 .3  CROSSES WITH THE HEAVY CHAIN LIBRARY.
It was decided to cross the light chains with an entire library of
heavy chains to try and isolate the maximum number of productive 
pairings possible. The heavy chain source chosen was the library 
used originally to isolate the gp120 binders (chapter 4) at a stage 
before the light chains had been inserted into the vector. It,
therefore consisted of a library of pComb3 vector containing heavy 
chains with nothing yet inserted into the light chain site. This
library was then cut with the appropriate enzymes (Xba I and Sac I) 
and split into three portions. One of the three metallolight chain 
inserts were then inserted into each portion and the three new
libraries were cloned back into E. coli . They were then subjected to 
four rounds of panning against gp120 in four groups: the three
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libraries and a further, equal mixture of the phage obtained from 
each of these. The results of the pannings are given in Table 7.2.
PANNING 1 PANNING 2 PANNING 3 PANNING 4
LCQ 1.46*106 3.00*106 4.2*105 5.00*105
LCC 1.09*106 5.40*106 2.64*105 1.30*106
LCQC 1.49*106 2.80*106 9.00*105 l.oono6
MIXTURE 1.12*106 4.15*106 2.40*106 7.00* 106
Table 7.2. Panning results of the metal library. The figures given are the 
output titres of phage (particles/ml) after each round of panning.The titres 
for the four rounds of panning of the 4 libraries (as explained in the text) 
are shown. It is notable that there is no increase in phage titre over the 
four rounds of panning for any of the libraries tested.
Normally, a 100 to 1000-fold increase in phage titres would be 
expected from the first to the fourth rounds of panning. However, as 
can be seen from the table, this was not the observed result in this 
case. No overall trend towards increasing titres can be seen, with 
the fourth round titre being approximately equal to the first. The 
reasons for this will be examined in the discussion.
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This failure to increase the titre would mean that there was little 
or no enrichment for the required gp120 binding clones and so the 
frequency at which they would occur in the overall population would 
be extremely low. A method capable of screening a far larger number 
of clones was, therefore required.
A technique was developed to grow the clones and express the Fab 
protein entirely in 96-well plates, thus allowing 96 cultures to be 
screened at a time. The supernatants from these plates could be 
transferred directly to gp120-coated plates for the ELISA. 
Approximately 1000 colonies from the third and fourth pannings of 
each library were screened in this way, giving rise to the detection 
of 17 clones that specifically bound gp120 (an O.D. of 3 times above 
the negative control). There was a bias in the clones derived from 
each of the light chain libraries (9 from LCQC, 6 from LCC and 1 
from LCQ), with only one being isolated from the mixed panning and 
this used the light chain LCQ. They were divided approximately 
equally between the third and fourth pannings: 8 from panning 3 and 
9 from panning 4. All 17 clones were sequenced for both heavy and 
light chains (Figure 7.2). The clones are labeled according to their 
light chain, the panning they were derived from and their position on 
the ELISA palte during screeining. Thus, C3F11 uses light chain LCC, 
was derived from the third panning and was isolated from well F11. 
None of these sequences are identical to those isolated from the 
original gp120-panned library discussed in chapter 4. Moreover, none 
of these CDR3 sequences were sufficiently similar to those from the 
previously isolated clones to be included in any of the seven groups
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defined for those Fabs. Therefore, this was a completely new set of 
gp120 binding Fabs.
It was thought to be necessary to carry out all further studies with 
purified Fab fragments and so all of the above clones were expressed 
as described previously and the Fab was purified. HPLC analysis of 
these preparations using a size exclusion column, under the 
direction of Robert O'Connor, DCU, showed them to be 100% pure 
with no aggregates or breakdown products (Figure 7.3)
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HEAVY CHAIN SEQUENCES OF THE METALLOANTIBODIES
CLONE FH1 <2UR1 IFR2 <wDR2 FR3 CDR3 FR4
C 3F 11 LEESGGGLVQPGGSLRLSCVASGFPFS NYWLH WVRQAPGKGLVWVA RIHSDGSRTAYADSVQG RFTISRDTAKTTLYLQMNSLRAEDSAVYYCAK A ED IW W A TTTFD Y WGQGILVTVSSASTKGPS
Q 4F11 LEESGGGLVKPGGSLRISCW SGFSFS DAWMS WVRQAPGKGLEWVG RIKSESEGGTIDYCAPVKG RFSISRDDSTATLYLQMNSLRSEDTAVyYCTT SPGRFSHRNY WGQGTLVSVSSTSTKGPS
C3G1 LEESGGGWHPGRSLTLPCAASGFSLS GYAMK WVRQAPGKGLEWLS V ISG SG  DETDYA DSVK D RFTISRDWSKNTLFLQMSSLRVDDSAIYYCVT SDRPVLRFLQWFPMDV WGKGTTVTVSSASTKGPS
QC3G7 LEESGGGLKKAGGSLRVSCEASGYTFT DYHIH WVRQAPGRGLEWMG WISPDSGGTKYAKSFQD WVTISRDTSISTVYMELSRLRSDDTAIYYCAR THYDILTGVTGAEYFPH WGQGTLVTVSSASTKGPS
Q C3F9 LEQSGEEVKKPGESLKMSCETSGYSFS AYWIG WVRQMPGKGLEWLG IIN PG D SEVIY K SSFQG Q VTISA DKSISTAY LQWSS L KAS DTAMYYCAR LDSWGTYL5GFDH WGQGTLVTVSSASTKGPS
QC3G10 LEESGGDLVQTGRSLRLSCAASGFSFD DYVMN WVRLVPGKGLEWVS SINWSGLNLDYADSVKG RFTISRDNAKNSLYLQMDSLRPEDSAFYFCAR PKDYGAYQPFDL WGRGTRVTVSSASTKGPS
C 3F6 LEQSGAEMRKPGESLKISCKGSGYSFS NYWVG WVRQMPGKGLEYMG 11Y PG DSDTRYS PSSQG QVTISVDKSINAAY LQWRSLRAS DTAMYYCAR HRAAAGGHFDY WG PGTLVTVSS PS TKG PS
C4A5 L.EESGRNLVRPGGSLRLSCAASGFTFS YYTMH WLRQAPGKGLEWVA L IS S  DGHRTDYADSVKG RFTISRDNSKNTLFLQVASVRFEDTAVYSCAR DLGLPGSWYFDL WGRGTLVTVSSASTKGPS
QC4ES LEESGAEVKKPGESLRISCKGSGYRFT SYWIG WVRQMPGKGLEWMG 11Y PGDSDTRYSPSFQG QVTISA DKSISTA Y LQWSS LKA S DTAMYYCAR HRAIQ PTQ IDI WGQGTMVTVSSA S TKG PS
QC4H2 LEESGGGWQPGRSLRLSCAVS LVNFN TYAMH WVRQAPGKGPEWVA FISHDGKTESYADSVRG RFSVSRDNSKNMLYLHMDRLGAEDTAVYYCAK DFKDLVCDFWGGVYRHFDF WGHGTLVTVSSASTKGPS
QC4A8 LEESGGGWQPGRSLRLSCAASGFIFG RFAIH WVRQAPGKGLEWVA LISY  DESNKFYADSVKG RFTISRDNYQYTSWLQMNGLKADDTAVYYCAR EHFDWSRTS DY SYYMDV WGKGTTVTVSSASTKGPS
C4A1 I.EESGGGW QPGRSLRLSCAASGFTFS RYGFH WVRQ A PG KG L EW V A WSHDGYNEFYADSVKG RFTVSRDDSKNTLYLQMNSLRAEDTAVYYCTR WRRHYDFWRQYRLLDF WGQGTLVLVSSASTKGPS
QC4C2 LEQSGGGLVQPGGSLRLSCWSGFTFS SYDMN WVRQAF'GKGLEWVS HVSNTGNTIYYSDSVKG RFTISRDNAKNS LY LQMNS LRADDTAVY YCAR RRQSSGWFRGWYFDL WGRGTLVTVSSASTKGPS
QC4D2 L EQSGGGLVTPGGSLRLSCEASGFIFS DFYMN WIRQAPGKGLEWVA YISSSGNIIYYGDSVKG RFIVSRDNAKKSVY LQMSDLGTE DTAVY YCAS SSPEYNYRSGYYRWFDP WGQGTPVTVSSASTKGPS
Q 4F11 LEQSGGDLVQPGGSLRLSCVASGFTFG DYAMH WVRQAPGKGLEWVS GITWNGNS1GYVDSVKG RFTIFRDNAKNSLYLQMDSLRVEDTAFYYCAK DKLYNSRYYGDWYFDL WGRGTLVTVSSASTEGPS
C 3F 10 LEQSGAEVK K PG ESLKISCKGSGYRFT SYWIG WVRQMPGKGLEWMA rMYPGDSHTIYSPSFQG Q ITIS A D T S IS T A Y  LQWSSLKAS DTAMYYCVR LSSPTVAHEPPLGY WGQGILVTVSSASTKGPS
QC3G6 LEESGAEVKRPGASVKLSCKASVYTST TYDIN WVRQ]ACQCLQWMG WMN PNNGVASY A RKFEG RWMTRNJ STATAYMELRSLRPEDTGIYFCSR GQKRSSSGLGS WGQGTQVTVSSAS TKG PS
Figure 7.2. Variable heavy chain sequences of the 17 clones found to bind gp120 when tested by direct ELISA. The clone names 
are given on the left and are explained in the text. None of these sequences were found to be similar to those previously isolated 
from the same library. Furthermore, these heavy chains cannot be organised into any of the sequence groups described in chapter 
4.
Time (minutes)
Figure 7.3. HPLC analysis of purified clone C4A5 as an example of the 
results from the purification procedure. The Fab can be seen to be 100% 
pure with no aggregates or breakdown products. All Fabs gave a similar 
profile.
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7.2.4 RELATIVE AFFINITIES AND CD4 COMPETITION ELISAs.
The relative affin ities of these clones were measured by 
competition ELISA, using gp120 as the competing antigen (Table 7.3). 
All the clones displayed affinities in the range 1x107 to 5x107M -1 
which was slightly lower than the values obtained for other gp120 
binders, possibly as a result of the fact that these are hybrid 
antibodies containing chains of 2 different specificities.
CLONE AFFINITY(M'1)
CLONE AFFINTY(M-1) CLONE
AFFINITY
(M'1)
C4F11 1.0 QC4D2 1.0 C3F11 2.0
QC3G6 2.0 C4A1 2.0 QC3G7 1.0
C3G1 2.5 QC3G10 3.0 QC4E5 7.0
C4AS 1.0 QC4A8 1.5 QC4H2 5.0
C3F6 8.0 QC3F9 2.0 MQ4F11 1.0
C4A1 1.5 C3F10 6.0
Table 7.3. Affinities of all gp120-binding clones isolated from the metal 
library. All values given are multiplied by a factor of 10-7.
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The epitope specificity of a number of these clones were then 
determined by means of sCD4 competition ELISAs (Figure 7.4). It can 
be seen from the graph that all the clones are inhibited by sCD4 to a 
similar extent as a previously analysed antibody, H12L21, and 
therefore, it can be concluded that they are specific for the CD4 
binding site of gp120. This was corroborated by the result that none 
of these Fabs bound toa V3 loop peptide on direct ELISA, showing 
that they are not specific for the V3 loop.
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Figure 7.4. CD4 inhibition curves of a selection of Fabs isolated from 
the library. H21L21 was used as a positive control since this was known 
to bind to the CD4-binding site of gp120. All clones, including the positive 
control resulted in CD4 inhibition constants of approximately 10'7M.
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7 .2 .5  Z in c -b in d in g  assays.
The next stage was to determine whether the Fabs bound zinc. 
Previously the presence of metal binding had been detected by 
fluorescence quenching. However, this was a relatively indirect 
assay and can be difficult to obtain reproducible, accurate results 
with. Therefore, two alternative methods for detection of zinc 
binding were chosen.
The first was a Western blotting technique (Schiff et a!., 1988) 
which involved running the antibodies on an SDS-gel, transferring 
them to PVDF membrane and probing this membrane with Zn65. A 
band at 50kDa would indicate binding of the metal by the antibody. A 
gp120-binding Fab not engineered to bind zinc was used as a
negative control. This technique met with limited success: none of 
the negative control antibodies ever came up positive which showed 
there was no cross-reactivity ocurring. However, only 2 of the 17 
antibodies displayed any binding by this technique, although these 
consistently yielded the same positive result (Figure 7.5), while all 
the others remained consistently negative. This result would seem 
to suggest that only 2 Fabs, QC3G6 and C4A5, were capable of 
binding both gp120 and zinc. However, it was possible that the Fabs 
were only being weakly expressed in culture, and that this technique 
was not sensitive enough to detect the metal-binding. Also, a
western blot was a purely qualitative assay and did not allow any 
quantitation of the binding response. Furthermore, Zn65 is a very
strong radioisotope with a relatively long half- life which made it
comparatively difficult to work with.
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1 2 3 4 5 6
200 KDa
97.4 KDa
69.0 KDa
46.0 KDa
30.0 KDa
21.5 KDa
Figure 7.5 W estern  b lot o f Z inc-b ind ing  assays. A  band at 50K D a  ind ica tes  
the  presence o f Fab, as detected w ih Z n 65„ Such a band w ou ld  suggest 
tha t the  an tibody in tha t lane was capab le  o f b ind ing m eta l. The  s izes of 
he m o lecu la r w e igh t m arkers are ind ica ted  to the  left o f the gel. 5ug of 
purified  Fab w as run in each lane, as ind ica ted  be low  and the b lo t was 
probed  w ith  rad io ac tive  m eta l as d e sc rib e d  in sec tion  3 .6 .4  o f th e  
m ethods. The a rrow  indicates the  position o f the Fab.
Lane 1: M olecu lar w e igh t m arkers.
Lane 2: H 12L12
Lane 3: Q4F11
Lane 4: Q C3G6
Lane 5: C 4A5
Lane 6: C4A1
Lane 7: C3G1
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Therefore, it was decided to develop an ELISA technique to detect 
metal binding. The main problem with this approach was to find a 
way of immobilising the Zn to the surface of a plate in such a way as 
to make it accessible to binding by the Fab. It was decided to adopt 
an adaptation of the technique used by J. Rosenblum, Scripps, 
employing amidated plates (Costar), or alternatively, Covalink 
plates (Nunc), both of which permit the covalent immobilisation of 
molecules to the plate via a surface amine group (Rasmussen, 1990). 
A linker molecule was immobilised in this way, followed by a 
chelator which could bind Zn, thus immobilising it to the plate 
(Figure 7.6).
Chelator
*, Conjugated 
Antibody
' Zn T~~ '"'^Fab
Linker
I  Amidated ELISA Plate
Figure 7.6. Representation of the direct ELISA used to test for metal-
binding. Commercially available amidated plates were used to 
immobilise a linker molecule (BS3, Pierce). This could then capture a 
metal chelator (Iminodiacetic acid, Sigma) which could then bind the 
metal ion. This provided a surface for the direct ELISA. Bound Fab could 
be detected using a secondary, conjugated antibody (see methods, 
3.6.4).
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The linker molecule ensured that the Zn would be immobilised a 
sufficient distance from the surface to make it accessible to the 
Fab. The Fabs could then be tested by direct ELISA, with this plate, 
for Zn binding. When this was done, six of the seventeen fragments 
were found to bind at significantly higher levels than backround 
(Figure 7.7). These were Q4F11, C3G1, C3F6, C4A5, C4A1 and QC3G6. 
It is interesting to note that The two clones resulting in the highest 
signal were QC3G6 and C4A5, which were the two clones that were 
found to be positive with the western blot technique. It seems 
likely, therefore, that the western blot was only sensitive enough to 
detect binding by these two clones and none of the others. All 
subsequent studies were carried out on these six positive clones 
only.
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Figure 7.7. Binding of metalloantibodies to zinc as examined by direct 
metal-binding ELISA. 6 clones resulted in O.D. values of three times 
backround or higher.
7 .2 .6  Z inc b ind ing constan ts .
It was necessary to measure the strength of binding of the Fabs to 
Zn, and so competitive ELISAs were performed using Zn as the 
competing molecule (Figure 7.8). It can be seen from the diagram 
that the Fabs were inhibited by 50% at Zn concentrations between 
300(j,M and 2mM.
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Figure 7.8. Zinc inhibition constants for metal binders. The inhibition 
constant is defined as that concentration of zinc resulting in 50% 
inhibition of Fab-binding. It can be seen that the constants for the metal 
binders lie in the range of 300[iM to 2mM. The positive control used was 
H21L21, produced in the binary plasmid system, which had an 
associated constant of 200[iM.
This was five to twenty times higher than values obtained 
previously with these light chains by fluorescence quenching 
techn iques (Iverson et al., 1990) which means that a higher 
concentration of Zn was required with these Fabs to reach metal
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saturation of the binding site. It should be noted, however, that 
those studies used the complete mouse anti-fluorescein Fab, while 
the Fabs in this study are composed of chains with 2 different 
specificities. A separate study on metal antibodies (Iverson and 
Lerner, 1989) concluded that the Zn concentration exhibiting the 
highest efficiency was 1.5mM, which is well within the range found 
for these antibodies. Finally, H21L21 was used as a positive control 
in this experiment as it was produced in the binary plasmid system 
and so contains a Hiss tail at the carboxyl end of the heavy chain 
which was designed to bind metal ions (Regan and Clarke, 1990). It 
can be seen that the inhibition constant for this is the stongest of 
all the Fabs tested, at a concentration of 200(iM. None of the 
negative control Fabs displayed any binding to Zn in this assay.
It was still not known if the metal was being localised to the 
binding site of these antibodies, or if the effect seen in ELISA was 
attributable to non-specific mechanisms. A further competition 
ELISA was designed to clarify this point. The Fabs were first bound 
to gp120 immobilised on a plate and this was allowed to compete 
with serially diluted Zn in solution. Any competition for binding 
would indicate that the binding sites for gp120 and metal were 
adjacent to one another*on the Fab molecule, as Zn is very small 
compared to the gp120 molecule. The results can be seen in Figure 
7.9. Binding by all Fabs was reduced by 50% at zinc concentrations in 
the range 300|iM to 2mM, except C3G1 which was slightly higher. 
This correlates very closely with the data obtained from the 
previous Zn competition ELISAs. C3G1 displays the weakest binding 
in both cases; C3F6 and Q4F11 exhibit the strongest binding, while
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C4A5, QC3G6 and C4A1 give values in the middle of the range. As all 
of these Fabs were inhibited from binding to gp120 by Zn at 
concentrations equivalent to their Zn binding constants, it would 
strongly indicate that the binding sites for gp120 and Zn are in close 
proximity on the antibody. Furthermore, two negative control Fabs, 
H21L21 which contained the Hiss tail and H12L12 which did not, 
were not competed by Zn to the same extent as the metal binders, 
suggesting that the observed inhibition was a specific reaction.
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Figure 7.9. Zn-gp120 competitive ELISAs. The Zn was able to compete 
with the Fab-gp120 binding interaction in the case of the metalloantibodies, with 
50% inhibition constants similar to those observed in the Zn inhibition ELISAs 
(Figure 7.8). Neither of the two negative controls were inhibited to the same 
extent.
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7 .2 .7  ZINC-gp120 BIFUNCTIONAL ELISAs.
An attempt was made to establish whether the Fabs could bind both 
the metal and the gp120 simultaneously. This was achieved by means 
of a bifunctional ELISA described in the methods section 3.6.4. The 
Fabs were first bound to immobilised Zn and then gp120 was 
introduced in the hope that it would ALSO be bound by the Fab. The 
gp120 could then be detected by means of a series of secondary 
antibodies. It was not possible to bind the Fab to gp120 first and 
then introduce Zn, as there was no way to detect the Zn in an ELISA 
assay. No gp120 was detected in any of these assays, although Fab 
could be shown to be present suggesting that the Fab was being 
prevented from binding to gp120 possibly as a result of steric 
inhibition due to the nature of the assay. It is probable that the 
antigen binding site of the Fab is hidden when it binds the 
immobilised Zn to the extent where it can no longer bind gp120.
7 .2 .8 . gp120-CLEAVING ASSAYS.
Fab was incubated, in solution, with gp120 and zinc overnight at 
37°C. The reaction was then run on a reducing SDS-polyacrylamide 
gel and transferred to a PVDF membrane where it was probed with a 
se co n d a ry , g p 12 0 -s p e c if ic ,  a n t ibo dy  la b e le d  w ith  a 
chemiluminescent substance. This could then be detected with X-ray 
film. The objective was to determine if the Fab, in conjunction with 
metal, was capable of cleaving the gp120 molecule. Negative 
controls used were unrelated Fabs, zinc alone, unpurified metal 
binding Fabs and metal binding Fabs in the absence of Zn. No 
difference was observed between the negative and positive controls
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(Figure 7.10), indicating that the Fab-Zn combination was not 
capable of cleaving soluble gp120 under the reaction conditions 
described.
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Figure 7.10 Western blot of gp120-cleaving assays. gp120 is observed 
as three bands between the sizes of 110KDa and 125KDa due to 
differences in glycosylation patterns as a result of producing the protein 
in the Chinese hamster ovary system. No difference can be seen between 
any of the lanes, suggesting that the antibodies do not cleave gp120 
under these conditions. Zn was added to a concentration of 1 mM in all 
cases; 0.2ug gp120 were used and 0.5ug of antibody was added to each
tube as indicated:
Lane 1: gp120
Lane 2: gpi20
Lane 3: gpi20
Lane 4: gpi20
Lane 5: gpi20
Lane 6: gpi20
Lane 7:
oCMQ
.
C
D
1  + QC3G6 (purified) + Zn. 
1  + QC3G6 (cell supernatant) + Zn.
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7 .2 .9 .  NEUTRALISATION ASSAYS.
All of the Fabs were tested for neutralisation of HIV in vitro, in the 
p24 production assay of Björling and Norrby, both in the presence 
and absence of 1mM Zinc. The results of these assays are given in 
Figure 7.11. Preliminary evidence suggested that these Fabs were 
good neutralisers even in the absence of metal, although further 
experiments need to be carried out before this can be confirmed. 
However, it has been established that there was a very significant 
increase in neutralisation titres for all six Fabs when zinc was 
added to a concentration of 1mM. A metal concentration of 10fiM did 
not have any effect on titre, demonstrating that this is a 
concentration-dependent effect (data not shown). This effect was 
not seen in the case of antibodies not designed to bind metal. 
Therefore, it would seem that the metal binding Fabs bound Zn and 
that this was having a critical effect on the ability of these Fabs to 
neutralise the virus.
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Figure 7.11. Neutralisation titres of metalloantibodies with and without 
zinc. The titres are given as the maximum dilution of antibody resulting in 
80% neutralisation of the virus. The set of data presented above 
indicates higher titres, in all cases, when the metal is added, indicating 
that the zinc is having a profound affect on the ability of the Fabs to 
neutralise virus.
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7 .3  DISCUSSION.
7 .3 .1  FAB CONSTRUCTION.
The work presented in this chapter was an attempt to incorporate 
antigen specificity and catalytic activity into a single Fab fragment. 
The antigen chosen was gp120 since there were many Fabs of such 
spcificity available and this represented a relevant target with the 
possiblity of neutralising the HIV virus. The catalytic activity 
decided upon was that of peptide cleavage by a metal cofactor such 
as zinc. The coordinated ion, when positioned close to an amide bond 
of the protein, polarizes the carbonyl bond for attack by hydroxide 
provided by an adjacent water molecule. Zn ions can also increase 
the nucleophilic ity of the water molecule especially in the 
relatively non-aqueous environment of the antigen biding pocket 
(Figure 7.11).
Figure 7.11. Mode of 
action of Zinc in peptide 
cleavage. The Zn polarises 
the carbonyl bond, making 
it susceptible to attack 
by water, thus cleaving 
the peptide bond.
BINDING SITE
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7 .3 .2  DIRECTED CROSSES.
Initially, directed crosses were attempted with the heavy chains 
previously isolated from a gp120-panned library. The only chain to 
result in a productive cross was HCb6. This was also one of the 
chains capable of crossing productively with the tetanus toxiod- 
specific light chain. Therefore, HC6 must have a sequence which 
makes it amenable to crossing with non-related chains. Perhaps the 
same was true for the other two members of it's group, b20 and s6, 
however, these clones were never tested in the binary plasmid 
system.
The metallolight chains were made up of the constant region from 
clone b22. The original b22LC was able to productively pair with 16 
out of 21 of the original gp120 binding heavy chains, making it the 
most promiscuous of the light chains. However, swapping the 
variable region for this mouse fluorescein-specific variable region 
seems to have suffic iently interfered with the steric and 
electrostatic interactions in the binding site as to not allow the 
combination of these light chains with the heavy chains. This 
demonstrates the importance of the variable region in that it was 
not sufficient for combination just to match the constant regions, 
and corroborates the findings of Sastry et a i, (1989). The affinities 
of the HC6-metallolight crosses were found to be in the range 2 to 
6x10 7M-1 which was an order of magnitude lower than the affinity of 
the original b6 Fab (5x108M-1). This was consistant with previous 
results that interantigenic crosses tend to have affinities an order 
of magnitude lower than crosses between chains of the same 
specificity (chapter 5).
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7 .3 .3  CROSS WITH HEAVY CHAIN LIBRARY.
A cross was then carried out with a library of heavy chains. This 
was the same library that had been panned against gp120 previously 
and used to isolate the gp120 binders (Barbas et a i, 1992,1993). In 
that case, panning had lead to a 1000-fold increase in phage titre 
after four rounds. However, when panning was performed on this 
crossed library, there was no significant increase observed, 
although screening of a large number of clones from this library did 
reveal gp120 binders with affinities between 1x107 and 1x108M-1. 
The lack of amplification was further demonstrated by the fact that 
an equal number of clones were isolated from the third and fourth 
rounds, showing there was no increase from one round to the next. 
The question must, therefore, be asked why these relatively high 
affinity binders were not amplified in the panning process. The fact 
that these clones bind gp120 would indicate that the heavy chains 
involved originally derived from gp 120-specific antibodies, yet none 
of these heavy chains were amplified from the original library 
either as can be seen from their sequences (Figure 7.2). The geneIII 
fusion was designed to permit the isolation of high affinity binders 
from a library, probably to the detrement of lower affinity Fabs. The 
geneVI 11 system was designed for the generation of low affinity 
Fabs. Perhaps the affinities of these crossed Fabs were too low to 
be amplified in the genelll system being used here. However, this 
was unlikely as their affinities are comparable to Fabs previously 
isolated from this type of library (Persson et a i, 1991) and are not 
in the lower range of affinities (11x04 to 1x105M ‘ 1) that it was 
possible to isolate from the geneVI 11 system (Gram et a i, 1 992).
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Nonetheless, it might be interesting to transfer this library to the 
geneVIII system and repeat the panning.
An alternative explanation might be that the RNA coding for these 
chains exists at such a low frequency in the overall population that 
it was not amplified during the panning process. Perhaps this was a 
characteristic of the gene 111 fusion combinatorial library system. If 
it was the case, that there was a threshold level for RNA, below 
which, the sequence will not be amplified, then this has obvious 
implications for the study of an immune response using this system. 
It would mean that these heavy chains, which are obviously gp120 
specific, were not amplified in the original library and so, the 
analysis of the immune response, although accurate, omits this 
minor part of the response and so may not be entirely complete. The 
importance of this facet of the response was not known. This 
inability to amplify rare sequences would also affect the 
construction of naiive libraries, since it is probable that the 
sequence of interest in this type of library would be present at a 
very low frequency. This phenomenon mat not apply to the geneVIII 
fusion since the inreased levels of expression of Fab on the phage 
surface may, in itself, act as a form of amplification, allowing the 
isolation of low frequency sequences. The isolation of specific Fabs 
from a naiive library was achieved using this system (Gram et al., 
1992), although this was only a single instance and may not be 
representitive of the system in general.
In any case, screening of a larger number of clones has facilitated 
the isolation of a number of gp120 binding Fabs previously 
unidentified. There was a significant bias towards clones using the
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light chains LCC(6) and LCQC(9) with only 2 fabs using LCQ. This may 
reflect on the structures of these chains in relation to their ability 
to combine with other heavy chains without disrupting the antigen 
binding site. Perhaps the additional histidine residues in the C 
mutation alter the light chain structure so as to make combination 
with other chain easier, or the Q mutation could have the converse 
effect. Whatever the case, it seems that LCC and LCQC are able to 
combine more easily than LCQ.
All subsequent studies were carried out with 100% purified Fab 
samples to ensure that no anomalous effects were occurring. ELISA 
results confirmed that these Fabs were of the CD4-binding site 
class of antibodies with affinities of 1x107 to 8x107M*1. This puts 
them in the same category as previously isolated Fabs.
7 .3 .4  METAL-BINDING ANALYSIS.
The zinc-binding characteristics of these antibodies were found to 
be similar to Fabs studied by other groups (Iverson and Lerner, 1989; 
Iverson et a!., 1990). Their results indicated that the metal binding 
site their light chain (LCQ) would be fully occupied at a zinc 
concentration of 100|iM. The binding constants in this study of 
300fiM to 2mM differ from their value by a factor of 3 to 20. In fact, 
the best value of 300jiM was observed for clone Q4F11 which was 
the only clone using the same light chain as in the Iverson study. 
However, it may not be that surprising that the binding constants in 
this experiment are worse than those previously noted, since Iverson 
et al. used an Fab containing the original combination of heavy and 
light chain, whereas the two chains making up the Fabs in this study
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originate from different sources. It has already been demonstrated 
that interantigenic crosses result in affinities at least one order of 
magnitude lower than the original Fabs. Therfore, it was reasonable 
to assume that mixing of chains in this case could lead to structural 
changes which would reduce the affinity of the light chain for metal 
ions by a similar factor of magnitude. Another study by Iverson e t 
a!., on a set of antibodies that used a metal-trien complex as a 
cofactor for peptide cleavage, showed that the most efficient 
concentration of Zn to use was 1.5mM, which falls inside the 
concentration range found to be optimal for our antibodies. It should 
be concluded, therefore that these Fabs bind zinc with an affinity 
similar to that displayed by other antibodies.
Zinc-gp120 competition ELISAs were carried out in order to 
determine more precisely the location of the zinc-binding site in 
relation to the antigen binding site on the Fab. The Fab was allowed 
to bind immobilised gp120 first, and this was competed with zinc. 
Due to the small size of the zinc ion relative to the gp120 molecule, 
the only way the zinc would be able to dislodge the Fab would be if 
the binding sites for metal and gp120 were adjacent to one another. 
Otherwise the zinc could bind without disrupting the antibody- 
antigen interaction. It was found that the zinc could compete 
successfully with gp120 for Fab binding at concentration levels 
comparable to the zinc binding constants determined for each Fab in 
the absence of gp120. This did not occur in the case of Fabs that 
could not bind metal or with Fabs that bound metal via a histidine 
tail at the other end of the antibody molecule. This finding, coupled 
with the close correlation between the two ELISA assays, would
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seem to indicate that the two binding sites on these Fabs are indeed 
proximal, and that the Fabs are binding zinc as they were designed to 
do, i.e.: at the engineered sites in the antigen binding pocket.
7 .3 .5  SIMULTANEOUS BINDING OF gp120 AND METAL.
Attempts to establish whether the Fabs could bind both metal and 
gp120 simultaneously necessitated that the Fab was first bound to 
zinc which was immobilised to a plate via a linker. It was probably 
the presence of the linker that prevented the subsequent binding by 
gp120 and so it could not be shown that both could bind the Fab 
simultaneously. This was quite a complex problem as it was very 
difficult to detect the presence of the zinc ion if the antibody was 
also bound to the large glycoprotein, gp120. One possible solution 
might be to separate the Fab on an SDS gel and transfer it to a PVDF 
membrane. This could then be probed first by Zn65 and developed 
under X-ray film. Then, without stripping the blot, it could be probed 
with gp120 followed by incubation with an anti gp120 antibody 
labeled with a chemiluminescent marker which could be detected in 
a matter of seconds with an X-ray film. The bound zinc would not 
interfere with this exposure since it was of such high energy that X- 
ray film needs to be exposed in the presence of an intensifying 
screen at -80°C overnight to detect its presence. The blot could be 
¡mediately exposed with a new film to ensure the continued 
presence of the zinc. The detection of a correctly sized band at all 
three stages of exposure would be a strong indication of 
simultaneous binding of both the metal and the gp120.
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7 .3 .6  PEPTIDE BOND CLEAVAGE.
The function of these Fabs was to cleave gp120 using zinc as a 
catalytic cofactor. This activity was tested for by first allowing the 
antibody to bind to the zinc and then adding soluble gp120 for an 
overnight incubation at 37°C. Detection of fragments cleaved from 
the gp120 was then carried out by western blot analysis.
No differences in the number or sizes of gp120 bands were observed 
between any of the positive or negative control samples used in this 
assay. There are a number of possibilities which may explain this. 
First, simultaneous binding of gp120 and zinc may not occur, with 
the binding of the zinc preventing gp120 binding. This, however, was 
unlikely, as a number of other studies have incorporated metals in 
the active sites of antibodies while maintaining antigen binding 
capability (Pollacks? at., 1988; Iverson and Lerner, 1989; Iverson et 
al., 1990; Nakayama and Schultz, 1991). Also, these Fabs have been 
shown to bind gp120, so their structure was not such that they are 
prevented from doing so. Second, it may be possible that the gp120 
was not oriented in the correct way, upon binding by the antibody, to 
bring it sufficiently close to the zinc to initiate the hydrolytic 
reactions. The carbonyl group of an amide bond must be located 
proximal to the ion in order that it can be polarised, leading to 
cleavage of the amide bond. If this situation does not exist in the 
complex, then no such cleavage will occur. Therefore, it was 
possible that the antibody can bind both the zinc and the gp120 
without hydrolysing the protein. A more detailed study of this 
possiblity would require 3-D crystal structures for the binding sites 
of the antibodies. It would seem rather unusual, however, in the
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light of previous studies, that this situation should exist in all six 
of the Fabs studied. The third possibility would be that the reaction 
conditions for this cleavage are not suitable for the reaction to 
occur. This would include the structure of the gp120 used. It was 
possible that soluble gp120 produced in a recombinant system, and 
v ir ion  surface-bound gp120, are su ff ic ien t ly  d if fe ren t in 
glycosylation and backbone structure, such that the soluble gp120 
would not be oriented in the antigen binding site correctly, but the 
virion gp120 could be oriented to permit cleavage to occur. The 
findings from a previous study showed that the surface-bound and 
soluble forms of gp120 from the SF2 strain of virus were 
sufficiently different that antibodies bound to the surface-bound 
form and not the soluble (McKeating et al., 1991; Ivey-Hoyle, 1991). 
John Moore et al., (1991), also concluded that "studies with soluble 
env , glycoproteins may not mimic precisely macromoleculear 
interactions taking place on the virion surface". Since there are no 
crystal structures available for gp120 (due to the high degree of 
glycosylation), and the exact structure was not known, it was very 
difficult to predict if this could be the case. It would be necessary 
to test these antibodies with live virus particles, and the easiest 
way of doing this would be to study the affect of the Fabs on viral 
neutralisation, since assays already exist for testing this.
7 .3 .7  NEUTRALISATION.
When these Fabs were tested for neutralising activity, it was found 
that the addition of zinc increased the neutralisation titres of all 
these antibodies to significantly higher values than those observed
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for the same Fabs in the absence of metal. This would indicate that 
these antibodies, in conjunction with the zinc, are exhibiting some 
form of activity which was permitting the neutralisation of the 
virus. It was likely that this was due to the catalytic activity of the 
zinc, leading to the hydrolysis of a peptide bond in gp120, thus 
preventing invasion of the cells by the virus. It would require more 
experiments with the live virus to confirm that this was the case.
In conclusion, this study demonstrated that it was possible to 
produce Fabs that are capable of binding both gp120 and zinc and the 
metal was capable of raising the level of neutralising activity 
demonstrated by these Fabs.
This has important implications for AIDS research in that it raises 
neutralising antibody titres and it may provide a more broad-based 
antibody system for combating this disease, not relying completely 
on the ability of the antibody to inhibit the gp120-CD4 interaction. 
It is also one of the first practical applications of catalytic 
antibody technology.
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CONCLUSIONS
8 .0  CONCLUSIONS
The humoral response of a single individual, when challenged by the 
human immunodeficiency virus, was isolated and cloned by means of 
combinatorial phage-display technology. A examintion of the 
isolated Fab fragments was carried out at a genetic and a 
biochemical level. It was established that a large diversity of 
antibodies were produced by the immune system of this individual in 
response to the viral infection. This was observed in the large 
variation in sequence of these antibodies. Further analysis of these 
led to the postulation that a number of possible mechanisms may 
have given rise to such a diversity. This included somatic mutations, 
convergent evolution at the gene rearrangement level and diversity 
segment rearrangements. An analysis of the antibodies at a 
biochemical level revealed that, although they were very similar in 
specificity and affinity, there were some subtle differences in the 
epitopes recognised by the antibodies. Such a phenomenon could be 
interpreted as an attempt by the immune system to produce as many 
antibodies specific for the same epitope with minute differences, to 
counteract the possibility- of escape mutants.
A binary plasmid system was developed that permited the cloning of 
each heavy and light chain separately. This opened up the possibility 
of chain shuffling, which was carried out on a large selection of the 
Fabs isolated in the original study. A number of characteristics were 
observed from this, including the ability of heavy chains to pair with
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many light chain and retain antigen-binding. Interantigenic crosses 
lead to the conclusion that the heavy chain was of primary 
importance in antigen-binding and that a variety of light chains 
could be used so long as they did not adversely affect the 
interactions occuring in the binding-site.
The validity of using combinatorial libraries for studying the in vivo 
antibody response was addressed throughout the investigations. It 
was argued that the isolated heavy chains were probably an accurate 
reflection of the in vivo situation, due to their prominance in 
antigen-binding. The array of light chains isolated and the 
assortment of heavy-light chains, in combination with the binary 
plasmid findings, suggested that the light chains represented in the 
library were also probably found in anti-gp120 antibodies in vivo.
Further studies on the ability of the shuffled Fabs to neutralise 
virus in vitro strengthened these arguments and also suggested that 
the light chain sequence was more important for neutralisation than 
for antigen-binding, within this set of antibodies. The combination 
of chains was also found to be crucial in this aspect of antibody 
function, meaning that 'a  Fab would only neutralise virus if it 
consisted of the correct pairing of heavy and light chains. The lack 
of chain promiscuity displayed at this level and the fact that many 
of the original antibodies were found to possess neutralising ability, 
was further evidence that the library Fabs were an accurate 
representation of the equivalent in vivo antibodies.
278
The neutralisation studies also highlighted the complexity of the 
antibody-virus interaction as demonstrated by the inability of a 
given Fab to neutralise different isolates of the same viral strain. 
This emphasises the fact that there is much yet to learn about this 
reaction and it is more complicated than initially thought.
Finally, the interantigenic crosses performed earlier, demonstrated 
the possibility of combining two different functions within a single 
Fab. The gp120-specificity of the heavy chains was combined with 
light chains capable of binding metal in the hope of producing 
antibodies capable of metal-mediated peptide bond cleavage of
gp120. This would yield Fabs with enhanced neutralising ability and 
would be one of the first practical applications of the field of
catalytic antibodies. Six Fabs were produced that bound both gp120 
and metal. The neutralisation titres of all of these were found to 
increase significantly with the addition of metal. This suggested 
that they were, indeed, capable of cleaving viral gp120.
This work has lead to a number of observations about the ability of
the immune reponse to adapt to viral challenge, and has shed some 
light on the antibody-vicus interaction. The relative contributions 
of the heavy and light chains within this set of antibodies has been 
examined and it is hoped that these studies will aid future research 
on the relationship between antibody structue and function. Finally a 
contribution has been made both to the fields of catalytic antibodies 
and AIDS research in the production of metalloantibodies capable of 
neutralising HIV.
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